

Odontoprev S.A.

**Quarterly information (ITR) at
June 30, 2019**

(A free translation of the original in Portuguese)

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 06/30/2019 - ODONTOPREV S.A.

Company financial information/capital breakdown

Number of shares (units)	Current period
From paid-in capital	06/30/2019
Common	531,294,732
Preferred	-
Total	531,294,732
Treasury shares	
Common	1,844,214
Preferred	-
Total	1,844,214

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 06/30/2019 - ODONTOPREV S.A.

Company financial information/cash distributions

Event	Approval	Type of distribution	Payment date	Share type	Earnings per share (R\$/share)
Board of Directors Meeting	08/01/2019	Dividends	09/04/2019	Common	0.05243
Board of Directors Meeting	03/18/2019	Interest on capital	05/03/2019	Common	0.03323
Board of Directors Meeting	05/02/2019	Dividends	05/16/2019	Common	0.09529
Board of Directors Meeting	06/17/2019	Interest on capital	07/03/2019	Common	0.02989
Ordinary & Extraordinary General Meeting	04/01/2019	Dividends	05/03/2019	Common	0.04149
Ordinary & Extraordinary General Meeting	04/01/2019	Dividends	05/03/2019	Common	0.01081

Company financial information/balance sheet - assets

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Current quarter 06/30/2019	Prior year 12/31/2018
1	Total assets	1,635,291	1,571,572
1.01	Current assets	655,387	625,663
1.01.01	Cash and cash equivalents	24,277	16,597
1.01.02	Financial instruments	420,593	422,508
1.01.02.01	Financial instruments measured at fair value	420,593	422,508
1.01.02.01.03	Financial investments guarantee of technical provisions	126,131	115,490
1.01.02.01.04	Financial investments for trading portfolio	294,462	307,018
1.01.03	Trade receivables	157,548	142,313
1.01.03.01	Customers	153,274	135,594
1.01.03.01.01	Dental care receivables	190,389	174,848
1.01.03.01.02	(-) Allowance for doubtful accounts	(49,014)	(49,181)
1.01.03.01.03	Participation of beneficiaries in indemnifying events/claims	3,670	2,452
1.01.03.01.05	Dental care operators	8,229	7,475
1.01.03.02	Sundry receivables	4,274	6,719
1.01.03.02.01	Advances to suppliers	1,975	343
1.01.03.02.02	Advances to employees	523	5,101
1.01.03.02.03	Other receivables	1,776	1,275
1.01.06	Taxes recoverable	27,720	20,134
1.01.06.01	Current taxes recoverable	27,720	20,134
1.01.06.01.01	Tax and social security credits	27,720	20,134
1.01.07	Prepaid expenses	25,249	24,111
1.01.07.01	Deferred acquisition costs	22,810	22,280
1.01.07.20	Other	2,439	1,831
1.02	Non-current assets	979,904	945,909
1.02.01	Long-term receivables	154,085	127,778
1.02.01.03	Financial investments measured at amortized cost	15,577	15,227
1.02.01.03.01	Securities held to maturity	15,577	15,227
1.02.01.07	Deferred taxes	38,842	41,271
1.02.01.07.01	Deferred income tax and social contribution	38,842	41,271
1.02.01.10	Other non-current assets	99,666	71,280
1.02.01.10.03	Judicial deposits	13,772	3,745
1.02.01.10.04	Other receivables	19,089	1,721
1.02.01.10.05	Securities and credits receivable	100	79
1.02.01.10.06	Tax and social security credits	66,705	65,735
1.02.02	Investments	51,237	262,893
1.02.02.01	Equity interests	51,237	262,893
1.02.02.01.02	Interests in Subsidiaries	45,316	259,428
1.02.02.01.03	Interests in Joint Ventures	5,921	3,465
1.02.03	Property, plant and equipment	32,833	11,174
1.02.03.01	Property, plant and equipment in use	32,826	11,167
1.02.03.01.01	Property, plant and equipment for own use	9,681	9,802
1.02.03.01.02	Other fixed assets	1,573	1,365
1.02.03.01.03	Right of use (IFRS 16)	21,572	-
1.02.03.03	Fixed assets in progress	7	7
1.02.03.03.01	Fixed assets in progress	7	7
1.02.04	Intangible assets	741,749	544,064
1.02.04.01	Intangible assets	741,749	544,064
1.02.04.01.02	Goodwill on acquisition of investments	638,669	492,876
1.02.04.01.03	System development, software licenses and other	103,080	51,188

Company financial information/balance sheet - liabilities and equity

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Current quarter 06/30/2019	Prior year 12/31/2018
2	Total liabilities and equity	1,635,291	1,571,572
2.01	Current liabilities	445,851	478,278
2.01.01	Social security and labor charges	26,603	24,857
2.01.01.01	Social charges	3,936	3,366
2.01.01.01.01	Charges payable	3,936	3,366
2.01.01.02	Labor charges	22,667	21,491
2.01.01.02.01	Salaries, vacation pay and fees	22,667	21,491
2.01.02	Suppliers	16,779	14,539
2.01.02.01	Domestic suppliers	16,779	14,539
2.01.02.01.01	Commissions payable	6,512	6,386
2.01.02.01.02	Suppliers of goods and services	9,332	7,241
2.01.02.01.03	Other debits of dental care operation	244	238
2.01.02.01.04	Consideration/premiums to be repaid	313	674
2.01.02.01.05	Lease liability (IFRS 16)	378	-
2.01.03	Tax liabilities	24,087	28,058
2.01.03.01	Federal tax liabilities	15,621	18,715
2.01.03.01.01	Income tax and social contribution payable	3,292	7,648
2.01.03.01.02	Other federal tax liabilities	12,329	11,067
2.01.03.03	Municipal tax liabilities	8,466	9,343
2.01.05	Other liabilities	67,939	134,792
2.01.05.02	Other	67,939	134,792
2.01.05.02.01	Dividends and interest on capital payable	13,474	71,451
2.01.05.02.02	Minimum mandatory dividend payable	-	5,741
2.01.05.02.04	Advances from customers	984	937
2.01.05.02.05	Sundry payables	43,509	46,691
2.01.05.02.08	Investment payable	3,500	3,500
2.01.05.02.09	Contingent consideration	6,472	6,472
2.01.06	Provisions	310,443	276,032
2.01.06.02	Other provisions	310,443	276,032
2.01.06.02.04	Unsettled claims	49,381	38,352
2.01.06.02.05	IBNR - incurred but not reported claims	83,594	82,403
2.01.06.02.06	Unearned premiums	177,468	155,277
2.02	Non-current liabilities	123,142	65,838
2.02.02	Other liabilities	81,805	42,497
2.02.02.02	Other	81,805	42,497
2.02.02.02.03	Other liabilities	18,054	1,071
2.02.02.02.04	Fees payable	1,068	1,068
2.02.02.02.05	Put option in Subsidiary	27,238	26,358
2.02.02.02.06	Investment payable	14,000	14,000
2.02.02.02.07	Lease liability (IFRS 16)	21,445	-
2.02.04	Provisions	41,337	23,341
2.02.04.01	Contingent liabilities (tax, social security, labor and civil)	33,817	23,341
2.02.04.02	Other provisions	7,520	-
2.02.04.02.04	Financing of taxes and contributions	3,455	-
2.02.04.02.05	Sundry debts	4,065	-
2.03	Equity	1,066,298	1,027,456
2.03.01	Capital	607,869	506,557
2.03.02	Capital reserves	6,712	9,206
2.03.04	Earnings reserves	376,045	511,693
2.03.04.01	Legal reserve	-	101,312
2.03.04.07	Tax incentive reserve	129	129
2.03.04.08	Additional dividend proposed	-	22,018
2.03.04.09	Treasury shares	(29,330)	(17,012)
2.03.04.10	Statutory reserve of regulatory capital	202,623	202,623
2.03.04.11	Investment and expansion reserve	202,623	202,623
2.03.05	Retained earnings	75,672	-

Company financial information/statement of income

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Current quarter from 04/01/2019 to 06/30/2019	Current period from 01/01/2019 to 06/30/2019	Prior quarter from 04/01/2018 to 06/30/2018	Prior period from 01/01/2018 to 06/30/2018
3.01	Gross sales and/or services revenue	438,914	883,928	368,764	732,872
3.01.01	Net premiums with dental care plan	457,437	911,659	387,449	773,861
3.01.04	Taxes on dental care plan operations	(18,523)	(27,731)	(18,685)	(40,989)
3.02	Cost of sales and/or services rendered	(212,423)	(380,597)	(180,259)	(323,220)
3.02.01	Indemnifiable claims, net	(196,558)	(368,058)	(167,464)	(313,376)
3.02.03	Dental materials	(4,270)	(8,411)	(3,373)	(6,540)
3.02.04	Other operating costs	(1,407)	(3,062)	355	(4,908)
3.02.05	Variation of IBNR	(10,228)	(1,106)	(9,777)	1,604
3.03	Gross income	226,491	503,331	188,505	409,652
3.04	Operating revenues/expenses	(144,052)	(285,907)	(109,216)	(219,124)
3.04.01	Selling expenses	(50,229)	(101,200)	(38,084)	(79,773)
3.04.01.01	Selling expenses	(50,229)	(101,200)	(38,084)	(79,773)
3.04.02	General and administrative expenses	(70,423)	(134,552)	(56,526)	(106,838)
3.04.04	Other operating revenues	627	1,321	575	1,006
3.04.04.01	Other operating revenue from dental care	88	202	62	161
3.04.04.02	Revenue from dental care not related to company's plans	539	1,119	513	845
3.04.05	Other operating expenses	(27,051)	(55,743)	(17,546)	(36,959)
3.04.05.01	Stock option plan	(712)	(1,697)	(2,523)	(5,116)
3.04.05.02	Allowance for doubtful accounts	(19,929)	(39,570)	(13,057)	(26,326)
3.04.05.03	Profit sharing	(3,422)	(7,120)	(1,966)	(5,517)
3.04.05.04	Long-term incitement program	(2,988)	(7,356)	-	-
3.04.06	Earnings of equity method	3,024	4,267	2,365	3,440
3.05	Income before financial results and taxes	82,439	217,424	79,289	190,528
3.06	Financial results, net	5,646	10,606	6,620	13,500
3.06.01	Financial income	8,504	16,168	8,340	17,102
3.06.02	Financial expenses	(2,858)	(5,562)	(1,720)	(3,602)
3.07	Income before income taxes	88,085	228,030	85,909	204,028
3.08	Income tax and social contribution	(25,811)	(68,326)	(25,565)	(61,718)
3.08.01	Current	(25,680)	(64,668)	(27,549)	(61,618)
3.08.02	Deferred	(131)	(3,658)	1,984	(100)
3.09	Net income for the period from continuing operations	62,274	159,704	60,344	142,310
3.11	Income for the period	62,274	159,704	60,344	142,310
3.99	Earnings per share - (Reais/share)				
3.99.01	Basic earnings per share				
3.99.01.01	Common	0.11740	0.30108	0.11430	0.26929
3.99.02	Diluted earnings per share				
3.99.02.01	Common	0.11674	0.29938	0.11305	0.26634

Company financial information/statement of comprehensive income

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Current quarter from 04/01/2019 to 06/30/2019	Current period from 01/01/2019 to 06/30/2019	Prior quarter from 04/01/2018 to 06/30/2018	Prior period from 01/01/2018 to 06/30/2018
4.01	Income for the period	62,274	159,704	60,344	142,310
4.03	Comprehensive income for the period	62,274	159,704	60,344	142,310

Company financial information/statement of cash flows - indirect method

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Current period from 01/01/2019 to 06/30/2019	Prior period from 01/01/2018 to 06/30/2018
6.01	Net cash provided by operating activities	186,166	86,802
6.01.01	Cash from operations	298,901	254,173
6.01.01.01	Income for the period	159,704	142,310
6.01.01.02	Depreciation and amortization	9,479	3,966
6.01.01.03	Monetary variations, net	(148)	(637)
6.01.01.05	Contingent liabilities (tax, social security, labor and civil)	(288)	5,973
6.01.01.07	Earnings of equity method	(4,267)	(3,440)
6.01.01.08	Allowance for doubtful accounts	39,570	26,326
6.01.01.09	Stock option plan	1,697	5,116
6.01.01.10	Variation of IBNR	1,106	(1,604)
6.01.01.11	Income tax and social contribution	68,326	61,718
6.01.01.12	Unearned premiums	22,191	14,362
6.01.01.13	Right of use amortization (IFRS 16)	1,356	-
6.01.02	Changes in assets and liabilities	(112,735)	(167,371)
6.01.02.01	Financial instruments measured at fair value	1,915	(39,097)
6.01.02.02	Dental care receivables and operators	(57,250)	(29,514)
6.01.02.03	Taxes recoverable, other receivables and prepaid expenses	(6,279)	(1,018)
6.01.02.05	Long-term receivables (Non-current assets)	(9,600)	3,826
6.01.02.06	Unsettled claims	11,029	3,835
6.01.02.09	Tax liabilities (taxes and contributions payable)	385	6,916
6.01.02.10	Labor charges, suppliers, advances from customers and sundry payables	(8)	(19,241)
6.01.02.11	Non-current liabilities	16,630	(1,494)
6.01.02.13	Income tax and social contribution paid	(70,253)	(92,559)
6.01.02.14	Social charges	570	(133)
6.01.02.15	Commissions payable	126	1,108
6.02	Net cash used in investing activities	7,960	(4,569)
6.02.01	Purchases of property, plant and equipment	(1,384)	(471)
6.02.02	System development, software licenses and other	(9,108)	(8,973)
6.02.05	Write-off of incorporated investments	14,187	-
6.02.07	Dividends received from Subsidiaries	4,615	5,641
6.02.08	Advance for future capital increase and capital increase in Investee	-	(436)
6.02.11	Securities held to maturity	(350)	(330)
6.03	Net cash used in financing activities	(186,446)	(79,049)
6.03.01	Dividends and interest on capital paid	(169,759)	(30,011)
6.03.02	Repurchase of shares - in treasury	(22,627)	(70,497)
6.03.04	Receipt of stock options granted	7,045	21,459
6.03.05	Lease liability (IFRS 16)	(1,105)	-
6.05	Increase (decrease) in cash and cash equivalents	7,680	3,184
6.05.01	Cash and cash equivalents at the beginning of the period	16,597	16,112
6.05.02	Cash and cash equivalents at the end of the period	24,277	19,296

Company financial information/statement of changes in equity - 01/01/2019 to 06/30/2019

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Capital	Capital reserves, options granted and treasury shares	Revenue reserves	Retained earnings	Total equity
5.01	Opening balance	506,557	(7,806)	528,705	-	1,027,456
5.03	Adjusted opening balance	506,557	(7,806)	528,705	-	1,027,456
5.04	Equity transactions with owners	101,312	(14,812)	(123,330)	(84,032)	(120,862)
5.04.01	Capital increase	101,312	-	(101,312)	-	-
5.04.03	Stock options granted	-	1,697	-	-	1,697
5.04.04	Treasury shares acquired	-	(22,627)	-	-	(22,627)
5.04.05	Treasury shares sold	-	7,045	-	-	7,045
5.04.06	Dividends	-	-	(22,018)	(50,565)	(72,583)
5.04.07	Interest on capital	-	-	-	(33,467)	(33,467)
5.04.19	Put option in Subsidiary	-	(927)	-	-	(927)
5.05	Total comprehensive income for the period	-	-	-	159,704	159,704
5.05.01	Income for the period	-	-	-	159,704	159,704
5.07	Closing balance	607,869	(22,618)	405,375	75,672	1,066,298

Company financial information/statement of changes in equity - 01/01/2018 to 06/30/2018

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Capital	Capital reserves, options granted and treasury shares	Revenue reserves	Retained earnings	Total equity
5.01	Opening balance	506,557	21,432	395,253	-	923,242
5.03	Adjusted opening balance	506,557	21,432	395,253	-	923,242
5.04	Equity transactions with owners	-	(48,669)	-	(29,427)	(78,096)
5.04.03	Stock options granted	-	5,116	-	-	5,116
5.04.04	Treasury shares acquired	-	(70,497)	-	-	(70,497)
5.04.05	Treasury shares sold	-	21,459	-	-	21,459
5.04.07	Interest on capital	-	-	-	(29,427)	(29,427)
5.04.19	Put option in Subsidiary	-	(4,747)	-	-	(4,747)
5.05	Total comprehensive income for the period	-	-	-	142,310	142,310
5.05.01	Income for the period	-	-	-	142,310	142,310
5.07	Closing balance	506,557	(27,237)	395,253	112,883	987,456

Company financial information/statement of value added

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Current period from 01/01/2019 to 06/30/2019	Prior period from 01/01/2018 to 06/30/2018
7.01	Revenue	872,089	747,535
7.01.01	Net premiums with dental care plan	911,659	773,861
7.01.04	Provision for/reversal of allowance for doubtful accounts	(39,570)	(26,326)
7.02	Inputs acquired from third parties	(543,957)	(450,683)
7.02.01	Cost of sales and services	(368,058)	(313,376)
7.02.02	Materials, energy, outsourced services and other	(10,249)	(9,564)
7.02.04	Other	(165,650)	(127,743)
7.02.04.01	Other operating revenues	1,131	(1,436)
7.02.04.02	Selling expenses	(100,840)	(79,137)
7.02.04.03	General and administrative expenses	(64,835)	(48,774)
7.02.04.04	Variation of IBNR	(1,106)	1,604
7.03	Gross value added	328,132	296,852
7.04	Retentions	(10,835)	(3,966)
7.04.01	Depreciation, amortization and depletion	(9,479)	(3,966)
7.04.02	Others	(1,356)	-
7.04.02.01	Right of use amortization (IFRS 16)	(1,356)	-
7.05	Net value added generated by the entity	317,297	292,886
7.06	Value added received through transfer	20,435	20,542
7.06.01	Earnings of equity method	4,267	3,440
7.06.02	Financial income	16,168	17,102
7.07	Total value added to distribute	337,732	313,428
7.08	Distribution of value added	337,732	313,428
7.08.01	Personnel	57,253	43,368
7.08.01.01	Direct compensation	44,253	32,128
7.08.01.02	Benefits	10,275	8,639
7.08.01.03	Severance Indemnity Fund for Employees (FGTS)	2,725	2,601
7.08.02	Taxes and contributions	112,713	116,242
7.08.02.01	Federal	110,876	96,850
7.08.02.02	State	21	24
7.08.02.03	Municipal	1,816	19,368
7.08.03	Remuneration of third-party capital	6,365	6,392
7.08.03.02	Rentals	803	2,790
7.08.03.03	Other	5,562	3,602
7.08.03.03.01	Financial expenses	5,562	3,602
7.08.04	Remuneration of own capital	159,704	142,310
7.08.04.01	Interest on capital	33,467	29,427
7.08.04.02	Dividends	50,565	-
7.08.04.03	Retained earnings	75,672	112,883
7.08.05	Other	1,697	5,116
7.08.05.01	Stock option plan	1,697	5,116

Consolidated financial information/balance sheet - assets

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Current quarter 06/30/2019	Prior year 12/31/2018
1	Total assets	1,695,501	1,647,584
1.01	Current assets	710,902	702,255
1.01.01	Cash and cash equivalents	25,926	21,142
1.01.02	Financial instruments	433,784	460,394
1.01.02.01	Financial instruments measured at fair value	433,784	460,394
1.01.02.01.03	Financial investments guarantee of technical provisions	126,985	121,838
1.01.02.01.04	Financial investments for trading portfolio	306,799	338,556
1.01.03	Trade receivables	188,908	166,843
1.01.03.01	Customers	175,696	154,697
1.01.03.01.01	Dental care receivables	190,666	178,608
1.01.03.01.02	(-) Allowance for doubtful accounts	(49,217)	(51,211)
1.01.03.01.03	Participation of beneficiaries in indemnifying events/claims	3,670	3,339
1.01.03.01.05	Dental care operators	9,073	8,327
1.01.03.01.06	Other healthcare plan receivables	21,504	15,634
1.01.03.02	Sundry receivables	13,212	12,146
1.01.03.02.01	Advances to suppliers	3,417	587
1.01.03.02.02	Advances to employees	719	6,132
1.01.03.02.03	Other receivables	9,076	5,427
1.01.04	Inventories	3,345	3,112
1.01.06	Taxes recoverable	33,387	26,036
1.01.06.01	Current taxes recoverable	33,387	26,036
1.01.06.01.01	Tax and social security credits	33,387	26,036
1.01.07	Prepaid expenses	25,552	24,728
1.01.07.01	Deferred acquisition costs	22,810	22,280
1.01.07.20	Other	2,742	2,448
1.02	Non-current assets	984,599	945,329
1.02.01	Long-term receivables	160,258	160,593
1.02.01.03	Financial investments measured at amortized cost	15,577	15,227
1.02.01.03.01	Securities held to maturity	15,577	15,227
1.02.01.07	Deferred taxes	41,253	44,742
1.02.01.07.01	Deferred income tax and social contribution	41,253	44,742
1.02.01.10	Other non-current assets	103,428	100,624
1.02.01.10.03	Judicial deposits	16,211	14,245
1.02.01.10.04	Other receivables	20,412	20,544
1.02.01.10.05	Securities and credits receivable	100	100
1.02.01.10.06	Tax and social security credits	66,705	65,735
1.02.02	Investments	10,720	8,054
1.02.02.01	Equity interests	10,720	8,054
1.02.02.01.01	Interests in Associates	197	514
1.02.02.01.04	Interests in Joint Ventures	10,523	7,540
1.02.03	Property, plant and equipment	59,203	24,314
1.02.03.01	Property, plant and equipment in use	58,450	23,561
1.02.03.01.01	Property, plant and equipment for own use	19,531	19,969
1.02.03.01.02	Other fixed assets	2,786	3,592
1.02.03.01.03	Right of use (IFRS 16)	36,133	-
1.02.03.03	Fixed assets in progress	753	753
1.02.03.03.01	Fixed assets in progress	753	753
1.02.04	Intangible assets	754,418	752,368
1.02.04.01	Intangible assets	754,418	752,368
1.02.04.01.02	Goodwill on acquisition of investments	647,390	647,390
1.02.04.01.03	System development, software licenses and other	107,028	104,978

Consolidated financial information/balance sheet - liabilities and equity

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Current quarter 06/30/2019	Prior year 12/31/2018
2	Total liabilities and equity	1,695,501	1,647,584
2.01	Current liabilities	482,174	517,085
2.01.01	Social security and labor charges	34,988	33,897
2.01.01.01	Social charges	5,153	5,068
2.01.01.01.01	Charges payable	5,153	5,068
2.01.01.02	Labor charges	29,835	28,829
2.01.01.02.01	Salaries, vacation pay and fees	29,835	28,829
2.01.02	Suppliers	23,624	19,181
2.01.02.01	Domestic suppliers	23,624	19,181
2.01.02.01.01	Commissions payable	7,204	7,025
2.01.02.01.02	Suppliers of goods and services	13,968	11,244
2.01.02.01.03	Other debits of dental care operation	244	238
2.01.02.01.04	Consideration/premiums to be repaid	313	674
2.01.02.01.05	Lease liability (IFRS 16)	1,895	-
2.01.03	Tax liabilities	28,797	34,512
2.01.03.01	Federal tax liabilities	19,786	24,792
2.01.03.01.01	Income tax and social contribution payable	3,580	9,140
2.01.03.01.02	Other federal tax liabilities	16,206	15,652
2.01.03.02	State tax liabilities	166	51
2.01.03.03	Municipal tax liabilities	8,845	9,669
2.01.05	Other liabilities	70,168	135,637
2.01.05.02	Other	70,168	135,637
2.01.05.02.01	Dividends and interest on capital payable	13,474	71,451
2.01.05.02.02	Minimum mandatory dividend payable	-	5,741
2.01.05.02.04	Advances from customers	1,446	972
2.01.05.02.05	Sundry payables	45,276	47,447
2.01.05.02.07	Advance receipt of dental care insurance	-	54
2.01.05.02.08	Investment payable	3,500	3,500
2.01.05.02.09	Contingent consideration	6,472	6,472
2.01.06	Provisions	324,597	293,858
2.01.06.02	Other provisions	324,597	293,858
2.01.06.02.04	Unsettled claims	49,534	39,568
2.01.06.02.05	IBNR - incurred but not reported claims	84,147	83,073
2.01.06.02.06	Unearned premiums	177,542	159,878
2.01.06.02.07	Provision for claims and insurance (other provisions)	13,374	11,339
2.02	Non-current liabilities	141,862	98,811
2.02.02	Other liabilities	98,185	62,361
2.02.02.02	Other	98,185	62,361
2.02.02.02.03	Other liabilities	19,377	19,894
2.02.02.02.04	Fees payable	1,068	1,068
2.02.02.02.05	Put option in Subsidiary	28,326	27,399
2.02.02.02.06	Investment payable	14,000	14,000
2.02.02.02.07	Lease liability (IFRS 16)	35,414	-
2.02.04	Provisions	43,677	36,450
2.02.04.01	Contingent liabilities (tax, social security, labor and civil)	35,733	32,563
2.02.04.02	Other provisions	7,944	3,887
2.02.04.02.04	Financing of taxes and contributions	3,455	3,887
2.02.04.02.05	Sundry debts	4,489	-
2.03	Equity	1,071,465	1,031,688
2.03.01	Capital	607,869	506,557
2.03.02	Capital reserves	6,712	9,206
2.03.04	Earnings reserves	376,045	511,693
2.03.04.01	Legal reserve	-	101,312
2.03.04.07	Tax incentive reserve	129	129
2.03.04.08	Additional dividend proposed	-	22,018
2.03.04.09	Treasury shares	(29,330)	(17,012)
2.03.04.10	Statutory reserve of regulatory capital	202,623	202,623
2.03.04.11	Investment and expansion reserve	202,623	202,623
2.03.05	Retained earnings	75,672	-
2.03.09	Non-controlling shareholders	5,167	4,232

Consolidated financial information/statement of income

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Current quarter from 04/01/2019 to 06/30/2019	Current period from 01/01/2019 to 06/30/2019	Prior quarter from 04/01/2018 to 06/30/2018	Prior period from 01/01/2018 to 06/30/2018
3.01	Gross sales and/or services revenue	447,438	901,107	375,258	745,647
3.01.01	Net premiums with dental care plan	460,428	917,674	390,427	779,818
3.01.02	Sales of goods and services	4,259	8,320	3,290	6,910
3.01.04	Taxes on dental care plan operations	(18,696)	(28,089)	(18,855)	(41,330)
3.01.05	Taxes on sales of goods and services	(3,553)	(6,560)	(2,380)	(4,705)
3.01.06	Insurance	5,000	9,762	2,776	4,954
3.02	Cost of sales and/or services rendered	(212,590)	(381,311)	(180,472)	(324,410)
3.02.01	Indemnifiable claims, net	(196,155)	(367,008)	(166,319)	(311,650)
3.02.02	Social charges on services	37	34	(4)	(7)
3.02.03	Dental materials	(2,091)	(4,146)	(1,764)	(3,623)
3.02.04	Other operating costs	(3,851)	(7,921)	(2,250)	(9,992)
3.02.05	Variation of IBNR	(10,276)	(1,074)	(9,803)	1,633
3.02.06	Claims	(633)	(1,207)	(441)	(804)
3.02.07	Claims reserves	379	11	109	33
3.03	Gross income	234,848	519,796	194,786	421,237
3.04	Operating revenues/expenses	(151,154)	(300,091)	(115,457)	(230,131)
3.04.01	Selling expenses	(50,775)	(102,221)	(38,133)	(79,960)
3.04.01.01	Selling expenses	(50,775)	(102,221)	(38,133)	(79,960)
3.04.02	General and administrative expenses	(73,509)	(142,877)	(61,363)	(115,948)
3.04.04	Other operating revenues	727	1,497	651	1,145
3.04.04.01	Other operating revenue from dental care	179	375	138	300
3.04.04.02	Revenue from dental care not related to company's plans	548	1,122	513	845
3.04.05	Other operating expenses	(28,217)	(58,836)	(17,532)	(37,639)
3.04.05.01	Stock option plan	(712)	(1,697)	(2,523)	(5,116)
3.04.05.02	Allowance for doubtful accounts	(19,890)	(39,616)	(12,927)	(26,237)
3.04.05.03	Profit sharing	(4,408)	(9,379)	(2,082)	(6,286)
3.04.05.04	Long-term incitement program	(3,207)	(8,144)	-	-
3.04.06	Earnings of equity method	620	2,346	920	2,271
3.05	Income before financial results and taxes	83,694	219,705	79,329	191,106
3.06	Financial results, net	5,589	10,445	6,795	13,927
3.06.01	Financial income	8,844	16,856	8,586	17,612
3.06.02	Financial expenses	(3,255)	(6,411)	(1,791)	(3,685)
3.07	Income before income taxes	89,283	230,150	86,124	205,033
3.08	Income tax and social contribution	(26,417)	(69,601)	(25,633)	(62,707)
3.08.01	Current	(26,734)	(66,112)	(27,891)	(61,989)
3.08.02	Deferred	317	(3,489)	2,258	(718)
3.09	Net income for the period from continuing operations	62,866	160,549	60,491	142,326
3.11	Income for the period	62,866	160,549	60,491	142,326
3.11.01	Assigned to controlling shareholders	62,274	159,704	60,344	142,310
3.11.02	Assigned to non-controlling shareholders	592	845	147	16
3.99	Earnings per share - (Reais/share)				
3.99.01	Basic earnings per share				
3.99.01.01	Common	0.11740	0.30108	0.11430	0.26929
3.99.02	Diluted earnings per share				
3.99.02.01	Common	0.11674	0.29938	0.11305	0.26634

Consolidated financial information/statement of comprehensive income

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Current quarter from 04/01/2019 to 06/30/2019	Current period from 01/01/2019 to 06/30/2019	Prior quarter from 04/01/2018 to 06/30/2018	Prior period from 01/01/2018 to 06/30/2018
4.01	Net income for the period	62,866	160,549	60,491	142,326
4.02	Other comprehensive income	100	1,232	(705)	(1,780)
4.02.01	Cumulative translation adjustment	100	1,232	(705)	(1,780)
4.03	Comprehensive income for the period	62,966	161,781	59,786	140,546
4.03.01	Assigned to controlling shareholders	62,374	160,936	59,639	140,530
4.03.02	Assigned to non-controlling shareholders	592	845	147	16

Consolidated financial information/statement of cash flows - indirect method

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Current period from 01/01/2019 to 06/30/2019	Prior period from 01/01/2018 to 06/30/2018
6.01	Net cash provided by operating activities	203,068	94,173
6.01.01	Cash from operations	300,801	257,352
6.01.01.01	Income for the period	160,549	142,326
6.01.01.02	Depreciation and amortization	10,164	4,722
6.01.01.03	Monetary variations, net	(181)	(713)
6.01.01.05	Contingent liabilities (tax, social security, labor and civil)	205	6,441
6.01.01.06	Gain on disposal of property, plant and equipment and investments	175	66
6.01.01.07	Earnings of equity method	(2,346)	(2,271)
6.01.01.08	Allowance for doubtful accounts	39,616	26,237
6.01.01.09	Stock option plan	1,697	5,116
6.01.01.10	Variation of IBNR	1,074	(1,633)
6.01.01.11	Income tax and social contribution	69,601	62,707
6.01.01.12	Unearned premiums	17,664	14,354
6.01.01.13	Right of use amortization (IFRS 16)	2,583	-
6.01.02	Changes in assets and liabilities	(97,733)	(163,179)
6.01.02.01	Financial instruments measured at fair value	26,610	(36,070)
6.01.02.02	Dental care receivables and operators	(60,615)	(34,745)
6.01.02.03	Taxes recoverable, other receivables and prepaid expenses	(9,241)	3,062
6.01.02.04	Inventories	(233)	(642)
6.01.02.05	Long-term receivables (Non-current assets)	(2,911)	4,219
6.01.02.06	Unsettled claims	9,966	3,826
6.01.02.09	Tax liabilities (taxes and contributions payable)	(155)	7,713
6.01.02.10	Labor charges, suppliers, advances from customers and sundry payables	1,706	(20,510)
6.01.02.11	Non-current liabilities	6,513	(1,917)
6.01.02.13	Income tax and social contribution paid	(71,672)	(92,975)
6.01.02.14	Social charges	85	(269)
6.01.02.15	Commissions payable	179	1,283
6.01.02.16	Provision for claims and insurance (other provisions)	2,035	3,846
6.02	Net cash used in investing activities	(11,536)	(10,857)
6.02.01	Purchases of property, plant and equipment	(1,664)	(933)
6.02.02	System development, software licenses and other	(9,522)	(9,594)
6.02.11	Securities held to maturity	(350)	(330)
6.03	Net cash used in financing activities	(186,748)	(79,121)
6.03.01	Dividends and interest on capital paid	(169,759)	(30,083)
6.03.02	Repurchase of shares - in treasury	(22,627)	(70,497)
6.03.04	Receipt of stock options granted	7,045	21,459
6.03.05	Lease liability (IFRS 16)	(1,407)	-
6.05	Increase (decrease) in cash and cash equivalents	4,784	4,195
6.05.01	Cash and cash equivalents at the beginning of the period	21,142	17,674
6.05.02	Cash and cash equivalents at the end of the period	25,926	21,869

Consolidated financial information/statement of changes in equity - 01/01/2019 to 06/30/2019

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Capital	Capital reserves, options granted and treasury shares	Revenue reserves	Retained earnings	Other comprehensive income	Total equity	Non-controlling shareholders	Consolidated equity
5.01	Opening balance	506,557	(7,806)	528,705	-	(2,638)	1,024,818	6,870	1,031,688
5.03	Adjusted opening balance	506,557	(7,806)	528,705	-	(2,638)	1,024,818	6,870	1,031,688
5.04	Equity transactions with owners	101,312	(14,812)	(123,330)	(84,032)	1,232	(119,630)	(1,142)	(120,772)
5.04.01	Capital increase	101,312	-	(101,312)	-	-	-	-	-
5.04.03	Stock options granted	-	1,697	-	-	-	1,697	-	1,697
5.04.04	Treasury shares acquired	-	(22,627)	-	-	-	(22,627)	-	(22,627)
5.04.05	Treasury shares sold	-	7,045	-	-	-	7,045	-	7,045
5.04.06	Dividends	-	-	(22,018)	(50,565)	-	(72,583)	-	(72,583)
5.04.07	Interest on capital	-	-	-	(33,467)	-	(33,467)	-	(33,467)
5.04.19	Put option in Subsidiary	-	(927)	-	-	-	(927)	-	(927)
5.04.20	Other	-	-	-	-	1,232	1,232	(1,142)	90
5.05	Total comprehensive income for the period	-	-	-	159,704	-	159,704	845	160,549
5.05.01	Income for the period	-	-	-	159,704	-	159,704	845	160,549
5.07	Closing balance	607,869	(22,618)	405,375	75,672	(1,406)	1,064,892	6,573	1,071,465

Consolidated financial information/statement of changes in equity - 01/01/2018 to 06/30/2018

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Capital	Capital reserves, options granted and treasury shares	Revenue reserves	Retained earnings	Other comprehensive income	Total equity	Non-controlling shareholders	Consolidated equity
5.01	Opening balance	506,557	21,432	395,253	-	(705)	922,537	4,072	926,609
5.03	Adjusted opening balance	506,557	21,432	395,253	-	(705)	922,537	4,072	926,609
5.04	Equity transactions with owners	-	(48,669)	-	(29,427)	(1,780)	(79,876)	2,221	(77,655)
5.04.03	Stock options granted	-	5,116	-	-	-	5,116	-	5,116
5.04.04	Treasury shares acquired	-	(70,497)	-	-	-	(70,497)	-	(70,497)
5.04.05	Treasury shares sold	-	21,459	-	-	-	21,459	-	21,459
5.04.07	Interest on capital	-	-	-	(29,427)	-	(29,427)	-	(29,427)
5.04.19	Put option in Subsidiary	-	(4,747)	-	-	-	(4,747)	-	(4,747)
5.04.20	Other	-	-	-	-	(1,780)	(1,780)	2,221	441
5.05	Total comprehensive income for the period	-	-	-	142,310	-	142,310	16	142,326
5.05.01	Income for the period	-	-	-	142,310	-	142,310	16	142,326
5.07	Closing balance	506,557	(27,237)	395,253	112,883	(2,485)	984,971	6,309	991,280

Consolidated financial information/statement of value added

(R\$ thousand)

(A free translation of the original in Portuguese)

Account Code	Account description	Current period from 01/01/2019 to 06/30/2019	Prior period from 01/01/2018 to 06/30/2018
7.01	Revenue	896,140	765,445
7.01.01	Net premiums with dental care plan	917,674	779,818
7.01.02	Other income	18,082	11,864
7.01.02.02	Sales and services rendered	8,320	6,910
7.01.02.03	Insurance	9,762	4,954
7.01.04	Provision for/reversal of allowance for doubtful accounts	(39,616)	(26,237)
7.02	Inputs acquired from third parties	(523,195)	(437,819)
7.02.01	Cost of sales and services	(368,215)	(312,454)
7.02.02	Materials, energy, outsourced services and other	(5,984)	(6,677)
7.02.04	Other	(148,996)	(118,688)
7.02.04.01	Other operating revenues	830	(1,823)
7.02.04.02	Selling expenses	(101,862)	(79,323)
7.02.04.03	General and administrative expenses	(46,901)	(39,208)
7.02.04.04	Variation of IBNR	(1,074)	1,633
7.02.04.05	Claims reserve	11	33
7.03	Gross value added	372,945	327,626
7.04	Retentions	(12,747)	(4,722)
7.04.01	Depreciation, amortization and depletion	(10,164)	(4,722)
7.04.02	Others	(2,583)	-
7.04.02.01	Right of use amortization (IFRS 16)	(2,583)	-
7.05	Net value added generated by the entity	360,198	322,904
7.06	Value added received through transfer	19,202	19,883
7.06.01	Earnings of equity method	2,346	2,271
7.06.02	Financial income	16,856	17,612
7.07	Total value added to distribute	379,400	342,787
7.08	Distribution of value added	379,400	342,787
7.08.01	Personnel	84,213	61,952
7.08.01.01	Direct compensation	65,039	45,719
7.08.01.02	Benefits	14,989	12,524
7.08.01.03	Severance Indemnity Fund for Employees (FGTS)	4,185	3,709
7.08.02	Taxes and contributions	125,277	125,350
7.08.02.01	Federal	120,099	103,389
7.08.02.02	State	1,522	1,175
7.08.02.03	Municipal	3,656	20,786
7.08.03	Remuneration of third-party capital	7,664	8,043
7.08.03.02	Rentals	1,253	4,358
7.08.03.03	Other	6,411	3,685
7.08.03.03.01	Financial expenses	6,411	3,685
7.08.04	Remuneration of own capital	160,549	142,326
7.08.04.01	Interest on capital	33,467	29,427
7.08.04.02	Dividends	50,565	-
7.08.04.03	Retained earnings	75,672	112,883
7.08.04.04	Non-controlling shareholders	845	16
7.08.05	Other	1,697	5,116
7.08.05.01	Stock option plan	1,697	5,116

Operational and financial performance


Operating revenue

Net operating revenue (NOR)										
	2Q19		2Q18		Δ%	6M19		6M18		Δ%
	R\$ 000	% Sales	R\$ 000	% Sales		R\$ 000	% Sales	R\$ 000	% Sales	
(+) Payments, net	460,428	102.9	390,427	104.0	17.9	917,674	103.4	779,818	104.6	17.7
(+) Sales of services and products	4,259	1.0	3,290	0.9	29.4	8,320	0.9	6,910	0.9	20.4
(+) Odontored (México)	5,000	1.1	2,776	0.7	80.1	9,762	1.1	4,954	0.7	97.1
Gross operating revenue (GOR)	469,687	105.0	396,493	105.7	18.5	935,756	105.5	791,682	106.2	18.2
(-) Direct taxes on dental care operations	18,696	4.2	18,855	5.0	(0.8)	41,889	4.7	41,330	5.5	1.4
(-) Taxes on sales of services and products	3,553	0.8	2,380	0.6	49.3	6,560	0.7	4,705	0.6	39.4
Net operating revenue (NOR)	447,438	100.0	375,258	100.0	19.2	887,307	100.0	745,647	100.0	19.0


The net operating revenue (NOR) reached R\$447,438 in 2Q19, 19.2% higher YoY. In 6M19, net revenues reached R\$887,307, 19.0% expansion YoY. Net revenues ex-Odonto System grew 12.4% in the quarter, and 12.1% in 6M19.


Net Revenue

R\$ million




Net revenue annual growth (%)






The Corporate segment incremental revenue were negative in R\$11 million in 6M17, and turning positive in \$40 million in 6M19. **The 2Q19 incremental revenue was the highest since 4Q10.**



In 4.5 years, the non-corporate segment revenues grew 146%, reaching R\$699 million in 12 months. The average ticket grew 62% in the period, from R\$22.10 to R\$35.85.



(i) Consolidated Average Ticket

Average ticket calculation	2Q19	2Q18	Δ%	6M19	6M18	Δ%
Payments, net R\$000 (A)	460,428	390,427	17.9	917,674	779,818	17.7
Average number of members (B)	7,204	6,396	12.6	7,209	6,382	13.0
Average ticket (R\$/member/month) (A/B)/# of months	21.31	20.35	4.7	21.22	20.37	4.2


The average ticket was R\$21.31 in 2Q19, 4.7% higher than 2Q18, due to corporate contracts readjustments, the sales mix of the period and the Odonto System incorporation in January/2019. **Excluding Odonto System, the 2Q19 average ticket would have been R\$21.96, 7.9% above 2Q18.**

Average ticket calculation (ex-Brasildental portfolio)	2Q19	2Q18	Δ%	6M19	6M18	Δ%
Payments, net R\$000 ex-Brasildental portfolio (A)	446,154	377,420	18.2	890,232	755,715	17.8
Average number of members ex-Brasildental portfolio (B)	6,652	5,860	13.5	6,656	5,849	13.8
Average ticket (R\$/member/month) (A/B)/# of months	22.36	21.47	4.1	22.29	21.53	3.5

Excluding the Brasildental portfolio, and the correspondent net payments, the 2Q19 average ticket would have been R\$22.36, 4.1% higher than 2Q18.

(ii) Total number of members


OdontoPrev reached 7,187,333 members in 2Q19, with a net loss of 32 thousand members in the quarter, and 103 thousand net additions in the last twelve months.



	Portfolio 2Q16	Net additions				Portfolio 2Q17	Net additions				Portfolio 2Q18	Net additions				Portfolio 2Q19
		3Q16	4Q16	1Q17	2Q17		3Q17	4Q17	1Q18	2Q18		3Q18	4Q18	1Q19	2Q19	
Corporate	4,787,359	-85,582	-5,713	-46,880	-28,144	4,621,040	48,555	34,067	8,600	98,682	4,810,944	313,344	16,043	3,844	-58,311	5,085,864
OdontoPrev ¹	4,787,359	-85,582	-5,713	-46,880	-28,144	4,621,040	48,555	34,067	8,600	98,682	4,810,944	25,053	13,809	-12,499	-36,976	4,800,331
Odonto System	0	0	0	0	0	0	0	0	0	0	0	288,291	2,234	16,343	-21,335	285,533
SME	862,619	12,689	28,243	8,208	641	912,400	30,741	20,012	11,821	-18,520	956,454	158,020	-2,571	-23,028	9,633	1,098,508
OdontoPrev	135,254	-682	-3,051	-939	-2,679	127,903	-94	1,120	-6,347	741	123,323	2,640	2,481	-1,018	8,801	136,227
Bradesco	718,189	6,922	-6,885	-2,547	5,079	720,758	11,484	-1,150	17,888	-18,781	748,980	11,086	-5,031	-6,243	7,075	737,086
BB	9,176	6,449	38,179	11,694	-1,759	63,739	19,351	20,042	280	-480	103,412	2,846	1,204	-5,356	-6,041	95,585
Odonto System	0	0	0	0	0	0	0	0	0	0	0	141,448	-1,225	-10,411	-202	129,610
Individual Plans	631,873	18,225	17,246	-15,650	5,140	656,834	6,429	-20,782	8,633	36,048	687,162	239,390	51,532	8,662	16,215	1,002,961
Retailers	352,267	2,230	8,274	-9,657	5,895	359,009	7,039	-28,102	-14,356	6,602	330,192	29,219	19,000	9,687	13,375	401,473
Bradesco	258,025	18,997	10,167	-4,102	-209	282,878	627	-7,778	12,163	23,701	311,591	6,224	27,845	4,352	4,665	354,677
BB	21,581	-3,002	-1,195	-1,891	-546	14,947	-1,237	15,098	10,826	5,745	45,379	58	2,596	-4,561	-3,165	40,307
Odonto System	0	0	0	0	0	0	0	0	0	0	0	203,889	2,091	-816	1,340	206,504
Total	6,281,851	-54,668	39,776	-54,322	-22,363	6,190,274	85,725	33,297	29,054	116,210	6,454,560	710,754	65,004	-10,522	-32,463	7,187,333

¹OdontoPrev + Bradesco + BB


Due to seasonality of the business, membership growth is higher in the 2H than 1H of the year. Since 2014, 1H net additions were, on average, negative 20 thousand members, versus net additions of 101 thousand members in 2H.



Corporate segment

Net Revenues - Corporate segment

The Corporate segment revenues totaled R\$256,002 in 2Q19, a 7.9% growth YoY. In the first semester, Corporate revenues reached R\$508,961, 8.4% higher than last year.



Corporate	2Q19	2Q18	Δ%	6M19	6M18	Δ%
(+) Payments, net	265,288	248,113	6.9	530,448	493,061	7.6
(-) Direct taxes on dental care operations	9,286	10,843	-14.4	21,487	23,648	-9.1
Net operating revenue¹ (NOR)	256,002	237,269	7.9	508,961	469,413	8.4

¹ excluding Sale of Services and Products

(i) Average Ticket - Corporate segment

The Corporate average ticket reached R\$17.29 in 2Q19 and in 6M19, in line with the same period of last year, reflecting contracts readjustments and Odonto System incorporation.


Average Ticket - Corporate	2Q19	2Q18	Δ%	6M19	6M18	Δ%
Payments, net R\$000 (A)	265,288	248,113	6.9	530,448	493,061	7.6
Average number of members (B)	5,115	4,762	7.4	5,113	4,757	7.5
Average ticket (R\$/member/month) (A/B) / # of months	17.29	17.37	-0.5	17.29	17.27	0.1

(ii) Membership - Corporate segment

	Net additions					Net additions					Net additions				
	Portfolio 2Q16	3Q16	4Q16	1Q17	2Q17	Portfolio 2Q17	3Q17	4Q17	1Q18	2Q18	Portfolio 2Q18	3Q18	4Q18	1Q19	2Q19
Corporate	4,787,359	-85,582	-5,713	-46,880	-28,144	4,621,040	48,555	34,067	8,600	98,682	4,810,944	313,344	16,043	3,844	-58,311
OdontoPrev ¹	4,787,359	-85,582	-5,713	-46,880	-28,144	4,621,040	48,555	34,067	8,600	98,682	4,810,944	25,053	13,809	-12,499	-36,976
Odonto System	0	0	0	0	0	0	0	0	0	0	0	288,291	2,234	16,343	-21,335
															285,533

¹OdontoPrev + Bradesco + BB

The Corporate segment had net loss of 58 thousand lives in the quarter, due to unemployment. Corporate portfolio reached 5,086 in 2Q19, 1.1% decrease in relation to 1Q19, and practically stable in twelve months, in organic base.



Cost of services – Corporate segment

The cost of services in the corporate segment was R\$132,536 in 2Q19, and dental care ratio stable at 51.8%. In 6M19, dental care ratio was lower, from 50.1% to 49.2%.

Selling expenses – Corporate segment

The selling expenses in the corporate segment were R\$16,666 in 2Q19, 6.5% of revenues, below previous quarters. In 2Q18, selling expenses were atypical, of 4.5% of revenues.

Corporate	1Q18	2Q18	3Q18	4Q18	1Q19	2Q19	6M18	6M19	JUL17-JUN18	JUL18-JUN19
Average ticket (R\$/member/month) (A/B) / # of months	17.34	17.37	17.47	17.30	17.19	17.29	17.27	17.29	17.24	17.80
End of period number of members (000)	4,712	4,811	5,124	5,140	5,144	5,086	4,811	5,086	4,811	5,086
Average number of members (000) (B)	4,708	4,762	4,968	5,132	5,142	5,115	4,757	5,113	4,716	4,948
(+) Payments, net (R\$ 000) (A)	244,949	248,113	260,380	266,387	265,160	265,288	493,061	530,448	975,440	1,057,215
(-) Direct taxes on dental care operations (R\$ 000)	12,805	10,843	10,898	11,658	12,201	9,286	23,648	21,487	38,675	44,042
Net operating revenue - NOR (R\$ 000)	232,144	237,269	249,482	254,729	252,959	256,002	469,413	508,961	936,765	1,013,173
Cost of services (R\$ 000)	112,386	122,989	131,099	127,376	117,864	132,536	235,375	250,400	478,282	508,875
Dental care ratio (% Sales)	48.4	51.8	52.5	50.0	46.6	51.8	50.1	49.2	51.1	50.2
Cost of Services / member / month (R\$)	8.0	8.6	8.8	8.3	7.6	8.6	8.2	8.2	8.5	8.6
Gross Profit (R\$ 000)	119,758	114,280	118,383	127,353	135,096	123,465	234,038	258,561	458,483	504,297
Selling expenses (R\$ 000)	17,742	10,655	14,771	17,738	17,866	16,666	28,397	34,532	55,060	67,041
Selling expenses (% Sales)	7.6	4.5	5.9	7.0	7.1	6.5	6.0	6.8	5.9	6.6
Contribution Margin (R\$ 000)	102,016	103,625	103,613	109,615	117,230	106,799	205,641	224,029	403,424	437,257
Contribution Margin (% Sales)	43.9	43.7	41.5	43.0	46.3	41.7	43.8	44.0	43.1	43.2

You can find the key metrics per segment, from 2015 to 2017, at Attachment V, page 37.


SME

Net Revenues - SME

The SME revenues increased **26.6% YoY**, totaling R\$72,706 in the quarter. In the first semester, SME net revenues reached R\$144,335, a 21.9% growth.

SME	2Q19	2Q18	Δ%	6M19	6M18	Δ%
(+) Payments, net	76,125	60,306	26.2	151,866	125,368	21.1
(-) Direct taxes on dental care operations	3,419	2,883	18.6	7,531	6,978	7.9
Net operating revenue¹ (NOR)	72,706	57,423	26.6	144,335	118,390	21.9

¹ excluding Sale of Services and Products



(i) Average Ticket - SME

In 2Q19, the SME average ticket reached R\$23.20, a 11.5% increase YoY. In 6M19, the SME average ticket was R\$22.90, a 5.2% increase over the previous year.

Average Ticket - SME	2Q19	2Q18	Δ%	6M19	6M18	Δ%
Payments, net R\$000 (A)	76,125	60,306	26.2	151,866	125,368	21.1
Average number of members (B)	1,094	966	13.3	1,105	960	15.1
Average ticket (R\$/member/month) (A/B) / # of months	23.20	20.82	11.5	22.90	21.77	5.2


(ii) Membership - SME

		Net additions					Net additions					Net additions				
	Portfolio 2Q16	3Q16	4Q16	1Q17	2Q17	Portfolio 2Q17	3Q17	4Q17	1Q18	2Q18	Portfolio 2Q18	3Q18	4Q18	1Q19	2Q19	Portfolio 2Q19
SME	862,619	12,689	28,243	8,208	641	912,400	30,741	20,012	11,821	-18,520	956,454	158,020	-2,571	-23,028	9,633	1,098,508
OdontoPrev	135,254	-682	-3,051	-939	-2,679	127,903	-94	1,120	-6,347	741	123,323	2,640	2,481	-1,018	8,801	136,227
Bradesco	718,189	6,922	-6,885	-2,547	5,079	720,758	11,484	-1,150	17,888	-18,781	748,980	11,086	-5,031	-6,243	7,075	737,086
BB	9,176	6,449	38,179	11,694	-1,759	63,739	19,351	20,042	280	-480	103,412	2,846	1,204	-5,356	-6,041	95,585
Odonto System	0	0	0	0	0	0	0	0	0	0	0	141,448	-1,225	-10,411	-202	129,610

SME net additions – 2Q

Thousand lives

The SME segment registered net additions of 10 thousand lives in 2Q19, compared to net loss of 23 thousand lives in 1Q19 and 19 thousand lives in 2Q18.



Cost of Services – SME


The cost of services of the SME segment was R\$29,040 in 2Q19, a decrease of 320 bps in the dental care ratio in the quarter and 190 bps in the semester.

Selling expenses – SME

The selling expenses in the SME segment were R\$9,749 in 2Q19, 13.4% of sales, versus 14.0% in 2Q18.


SME	1Q18	2Q18	3Q18	4Q18	1Q19	2Q19	6M18	6M19	JUL17-JUN18	JUL18-JUN19
Average ticket (R\$/member/month) (A/B) / # of months	22.38	20.82	22.67	22.06	22.94	23.20	21.77	22.90	21.85	24.00
End of period number of members (000)	975	956	1,114	1,112	1,089	1,099	956	1,099	956	1,099
Average number of members (000) (B)	969	966	1,035	1,113	1,100	1,094	960	1,105	934	1,027
(+) Payments, net (R\$ 000) (A)	65,062	60,306	70,416	73,679	75,741	76,125	125,368	151,866	245,061	295,961
(-) Direct taxes on dental care operations (R\$ 000)	4,095	2,883	3,698	3,826	4,112	3,419	6,978	7,531	11,555	15,055
Net operating revenue - NOR (R\$ 000)	60,967	57,423	66,718	69,853	71,629	72,706	118,390	144,335	233,506	280,905
Cost of services (R\$ 000)	22,531	24,738	27,731	27,607	25,866	29,040	47,269	54,906	95,885	110,244
Dental care ratio (% Sales)	37.0	43.1	41.6	39.5	36.1	39.9	39.9	38.0	41.1	39.2
Cost of Services / member / month (R\$)	7.8	8.5	8.9	8.3	7.8	8.9	8.2	8.3	8.6	8.9
Gross Profit (R\$ 000)	38,436	32,684	38,987	42,246	45,763	43,666	71,121	89,429	137,622	170,661
Selling expenses (R\$ 000)	6,260	8,012	8,577	8,218	8,763	9,749	14,272	18,512	28,576	35,308
Selling expenses (% Sales)	10.3	14.0	12.9	11.8	12.2	13.4	12.1	12.8	12.2	12.6
Contribution Margin (R\$ 000)	32,176	24,673	30,410	34,027	37,000	33,917	56,849	70,916	109,046	135,354
Contribution Margin (% Sales)	52.8	43.0	45.6	48.7	51.7	46.6	48.0	49.1	46.7	48.2

You can find the key metrics per segment, from 2015 to 2017, at Attachment V, page 37.

¹ excluding Sale of Services and Products

		Net additions					Net additions					Net additions				
	Portfolio 2Q16	3Q16	4Q16	1Q17	2Q17	Portfolio 2Q17	3Q17	4Q17	1Q18	2Q18	Portfolio 2Q18	3Q18	4Q18	1Q19	2Q19	Portfolio 2Q19
Individual Plans	631,873	18,225	17,246	-15,650	5,140	656,834	6,429	-20,782	8,633	36,048	687,162	239,390	51,532	8,662	16,215	1,002,961
Retailers	352,267	2,230	8,274	-9,657	5,895	359,009	7,039	-28,102	-14,356	6,602	330,192	29,219	19,000	9,687	13,375	401,473
Bradesco	258,025	18,997	10,167	-4,102	-209	282,878	627	-7,778	12,163	23,701	311,591	6,224	27,845	4,352	4,665	354,677
BB	21,581	-3,002	-1,195	-1,891	-546	14,947	-1,237	15,098	10,826	5,745	45,379	58	2,596	-4,561	-3,165	40,307
Odonto System	0	0	0	0	0	0	0	0	0	0	0	203,889	2,091	-816	1,340	206,504

The individual plans surpassed 1 million lives, with net additions of 16 thousand lives in the quarter. In the last 4 quarters, the two main individual plans channels, retailers and Bradesco, added lives.



Cost of Services – Individual Plans

The cost of services was R\$40,484 in 2Q19, with a dental care ratio of 35.8%, due to the selling mix, and the launching of new products, of higher ticket and utilization, that allows **higher net present value**.

Selling expenses – Individual Plans

The selling expenses in the quarter were 21.4% of revenues, versus 25.3% in 2Q18.

Individual Plans	1Q18	2Q18	3Q18	4Q18	1Q19	2Q19	6M18	6M19	JUL17-JUN18	JUL18-JUN19
Average ticket (R\$/member/month) (A/B) / # of months	40.91	40.85	40.72	38.60	39.48	39.88	40.46	39.60	38.79	43.80
End of period number of members (000)	651	687	927	978	987	1,003	687	1,003	687	1,003
Average number of members (000) (B)	647	669	807	952	982	995	665	991	672	845
(+) Payments, net (R\$ 000) (A)	79,380	82,009	98,570	110,269	116,345	119,015	161,389	235,360	312,839	444,199
(-) Direct taxes on dental care operations (R\$ 000)	5,575	5,129	6,229	6,645	6,880	5,991	10,704	12,871	18,307	25,746
Net operating revenue - NOR (R\$ 000)	73,805	76,880	92,341	103,624	109,465	113,024	150,685	222,489	294,532	418,453
Cost of services (R\$ 000)	20,018	22,610	29,299	32,090	33,251	40,484	42,628	73,735	85,285	135,124
Dental care ratio (% Sales)	27.1	29.4	31.7	31.0	30.4	35.8	28.3	33.1	29.0	32.3
Cost of Services / member / month (R\$)	10.3	11.3	12.1	11.2	11.3	13.6	10.7	12.4	10.6	13.3
Gross Profit (R\$ 000)	53,787	54,271	63,042	71,534	76,213	72,541	108,057	148,754	209,246	283,330
Selling expenses (R\$ 000)	17,695	19,426	21,302	21,562	24,648	24,222	37,121	48,870	71,803	91,734
Selling expenses (% Sales)	24.0	25.3	23.1	20.8	22.5	21.4	24.6	22.0	24.4	21.9
Contribution Margin (R\$ 000)	36,092	34,844	41,740	49,972	51,565	48,319	70,936	99,884	137,443	191,596
Contribution Margin (% Sales)	48.9	45.3	45.2	48.2	47.1	42.8	47.1	44.9	46.7	45.8


You can find the key metrics per segment, from 2015 to 2017, at Attachment V, page 37.

Brasildental JV

(R\$000, except otherwise specified)	2Q19	2Q18	Δ%	6M19	6M18
Net operating revenue (NOR)	29,006	27,193	6.7	58,053	52,498
Average ticket (R\$/member/month)	18.15	17.70	2.5	18.21	17.28
Number of members	550	542	1.5	550	542
Cost of services	14,306	13,058	9.6	27,506	24,241
SG&A	7,212	7,095	1.6	14,431	14,193
Selling expenses	3,226	3,535	-8.7	6,220	6,631
Administrative expenses (G&A)	3,986	3,560	12.0	8,211	7,563
Other operating revenues	-24	-13	86.8	-50	-21
Allowance for doubtful receivables	1,059	1,103	-4.0	2,040	1,758
Profit sharing	130	56	130.5	198	226
EBITDA	6,323	5,892	7.3	13,928	12,101
EBITDA margin (%)	21.8	21.7	0.6 p.p.	24.0	23.1
Net income	3,677	3,116	18.0	9,823	7,463

BRASILDENTAL Adjusted EBITDA and Net Income evolution

R\$ million and % Sales



In 2Q19, Brasildental EBITDA reached R\$6,323, 7.3% higher than 2Q18, with a 21.8% margin. Net income reached R\$3,677, 18.0% higher than 2Q18.

Odonto System

 (R\$000, except otherwise specified)	2Q19	1Q19	4Q18	3Q18 ¹
Net operating revenue (NOR)	25,783	25,843	27,072	17,278
Average ticket (R\$/member/month)	14.53	14.50	15.14	14.66
Number of members	621,647	641,844	636,728	633,622
Cost of services	7,897	7,514	7,903	5,793
Dental care ratio (%)	30.6	29.1	29.2	33.5
Selling expenses	2,211	2,145	2,068	1,393
Selling expenses (%)	8.6	8.3	7.6	8.1
Contribution Margin	15,674	16,184	17,100	10,092
Contribution Margin (%)	60.8	62.6	63.2	58.4


¹AUG-SEP18


Cost of services and dental care ratio

Cost of services (ex IBNR) and dental loss ratio (% Sales)										
	2Q19		2Q18		Δ% p.p. Sales	6M19		6M18		Δ% p.p. Sales
	R\$ 000	% Sales	R\$ 000	% Sales		R\$ 000	% Sales	R\$ 000	% Sales	
Cost of services (ex IBNR)	202,694	45.3	170,778	45.5	0.2	380,249	42.9	326,076	43.7	0.8
Indemnifiable claims, net	196,155	43.8	166,319	44.3	0.5	367,008	41.4	311,650	41.8	0.4
Payroll charges on services	(37)	(0.0)	4	0.0	-	(34)	(0.0)	7	0.0	-
Dental materials	2,091	0.5	1,764	0.5	-	4,146	0.5	3,623	0.5	-
Other operating expenses	3,851	0.9	2,250	0.6	-0.3	7,921	0.9	9,992	1.3	0.4
Odontored (México)	633	0.1	441	0.1	-	1,207	0.1	804	0.1	-

For comparison purposes, the IBNR Provision (Incurred but not Reported) and technical reserves (Odontored), approved by ANS, were excluded from the Cost of Services. In 2Q19 there was a constitution of IBNR and technical reserves of R\$9,897, as compared to a constitution of R\$9,694 in 2Q18.

In 2Q19, the cost of services represented 45.3% of revenues, the lowest 2Q since 2Q14. In the semester, the dental loss ratio was 42.9% of revenues, the lowest since 2008. The cost of services of Odonto System was 30.6% in 2Q19, and 29.9% in 6M19. Excluding Odonto System, the cost of services would have represented 46.2% of revenues in the quarter and 43.7% in 6M19.






The individual plans annualized dental care ratio was 32,3% in 2Q19 due to the selling mix, and the launching of new products, of higher ticket and utilization, through the bank channels, that allow **higher net present value**.

Gross profit

Gross profit	2Q19	2Q18	Δ%	6M19	6M18	Δ%
R\$ 000	234,848	194,786	20.6	519,796	421,237	23.4
% Sales	52.5	51.9	0.6 p.p	58.6	56.5	2.1 p.p


Gross profit reached R\$234,848 in 2Q19, 20.6% YoY. In the first semester, gross profit were R\$519,796, 23.4% higher than the previous year.




Selling expenses

(R\$000)	2Q19	2Q18	Δ%	6M19	6M18	Δ%
Selling expenses	50,775	38,133	33.2	102,221	79,960	27.8
Selling expenses (% Sales)	11.3	10.2	1.1 p.p	11.5	10.7	0.8 p.p

The selling expenses reached 11.3% of revenues in 2Q19, 110 bps higher than 2Q18. In 6M19, reached 11.5%, **given the growth of individuals portfolio, of higher acquisition cost.**



Contribution margin




Administrative expenses (G&A)

	2Q19		2Q18		Δ% p.p. Sales	6M19		6M18		Δ% p.p. Sales
	R\$ 000	% Sales	R\$ 000	% Sales		R\$ 000	% Sales	R\$ 000	% Sales	
Personnel	38,435	8.6	30,972	8.3	0.3	75,488	8.5	61,836	8.3	0.2
Third parties services	8,333	1.9	7,230	1.9	0.0	16,552	1.9	14,009	1.9	0.0
Rentals and occupancy	10,758	2.4	10,363	2.8	-0.4	20,007	2.3	17,054	2.3	0.0
Taxes and fees	3,051	0.7	2,758	0.7	0.0	6,360	0.7	5,693	0.8	-0.1
Publicity and advertising	4,483	1.0	5,998	1.6	-0.6	8,348	0.9	8,150	1.1	-0.2
Others	2,119	0.5	1,696	0.5	0.0	3,375	0.4	3,744	0.5	-0.1
G&A (not adjusted at EBITDA base)	67,179	15.0	59,017	15.7	-0.7	130,130	14.7	110,486	14.8	-0.1
Depreciation and amortization	4,998	1.1	2,284	0.6	0.5	10,164	1.1	4,722	0.6	0.5
Amortization of utilization rights	1,332	0.3	-	-	0.3	2,583	0.3	-	-	0.3
Acquisitions	-	-	62	-	-	-	-	740	0.1	-0.1
G&A (not adjusted at EBITDA base)	6,330	1.4	2,346	0.6	0.8	12,747	1.4	5,462	0.7	0.7
Total administrative expenses (G&A)	73,509	16.4	61,363	16.4	-	142,877	16.1	115,948	15.5	0.6

G&A (included in the adjusted EBITDA base)

The administrative expenses were R\$67,179 in 2Q19 (15.0% of Sales), versus R\$59,017 in 2Q18 (15.7% of Sales). In 6M19, they were R\$130,130 (14.7% of Sales), similar level as previous year.



Allowance for doubtful receivables

Allowance for doubtful receivables	2Q19	2Q18	Δ%	6M19	6M18	Δ%
R\$ 000	19,890	12,927	53.9	39,616	26,237	51.0
% Sales	4.4	3.4	1.0 p.p	4.5	3.5	1.0 p.p


The Allowance for doubtful receivables totaled R\$19,890 (4.4% of Sales) in 2Q19, versus R\$12,927 (3.4% of Sales) in 2Q18, **given the growth of individual retailers portfolio.**

The allowance for doubtful receivables is calculated based on historical losses of the Company. Each month OdontoPrev accrues over each type of accounts receivable, due or not, according to CPC 38/IAS 39.

EBITDA and Adjusted EBITDA

	2Q19		2Q18		Δ% p.p. Sales	Y/Y %	6M19		6M18		Δ% p.p. Sales	Y/Y %
	R\$ 000	% Sales	R\$ 000	% Sales			R\$ 000	% Sales	R\$ 000	% Sales		
Net Income	62,274	13.9	60,344	16.1	(2.2)	3.2	159,704	18.0	142,310	19.1	(1.1)	12.2
(+) Current income and social contribution tax	26,734	6.0	27,891	7.4	-1.4	-4.1	66,112	7.5	61,989	8.3	-0.8	6.7
(+) Deferred income and social contribution tax	-317	-0.1	-2,258	-0.6	0.5	-85.9	3,489	0.4	718	0.1	0.3	386.2
(-) Financial income	8,844	2.0	8,586	2.3	-0.3	3.0	16,856	1.9	17,612	2.4	-0.5	-4.3
(+) Financial expenses	3,255	0.7	1,791	0.5	0.2	81.7	6,411	0.7	3,685	0.5	0.2	74.0
(+) Stock option	712	0.2	2,523	0.7	-0.5	-71.8	1,697	0.2	5,116	0.7	-0.5	-66.8
(-) Participation of minority shareholders	-592	-0.1	-147	0.0	-0.1	302.9	-845	-0.1	-16	0.0	(.1)	-
(+) Depreciation and amortization	4,998	1.1	2,284	0.6	0.5	118.8	10,164	1.1	4,722	0.6	0.5	115.3
(+) Amortization of utilization rights	1,332	0.3	-	-	0.3	-	2,583	0.3	-	-	0.3	-
(-) Equity in subsidiaries	620	0.1	920	0.2	(0.1)	-32.7	2,346	0.3	2,271	0.3	-	3.3
EBITDA	90,117	20.1	83,216	22.2	(2.1)	8.3	231,802	26.1	198,673	26.6	(0.5)	16.7
Incurred But Not Reported Provision - IBNR	10,276	2.3	9,803	2.6	-0.3	4.8	1,074	0.1	-1,633	-0.2	0.3	-165.7
Odontored - Technical reserves	-379	-0.1	-109	0.0	(0.1)	247.2	-11	0.0	-33	0.0	-	-66.5
(+) Brasilental EBITDA Pro Forma	1,580	0.4	1,473	0.4	0.0	7.3	3,740	0.4	3,047	0.4	-	22.7
(-) ISS reversal	-	-	-	-	-	-	-13,568		-	-	-	-
Odonto System	-	-	62	0.0	0.0	-100.0	-	0.0	740	0.0	-	(100.0)
Adjusted EBITDA	101,593	22.7	94,444	25.2	(2.5)	7.6	223,036	25.1	200,793	26.9	(1.8)	11.1

The adjusted EBITDA reached R\$101,593 in 2Q19, 7.6% higher than 2Q18, with a margin of 22.7%. In 6M19, the adjusted EBITDA reached R\$223,036, 11.1% higher than the previous year, with margin of 25.1%.



Financial income

	2Q19		2Q18		Δ%	6M19		6M18		Δ%
	R\$ 000	% Sales	R\$ 000	% Sales		R\$ 000	% Sales	R\$ 000	% Sales	
Net financial income	5,589	1.2	6,795	1.8	-17.8	10,445	1.2	13,927	1.9	-25.0
(+) Financial income	8,844	2.0	8,586	2.3	3.0	16,856	1.9	17,612	2.4	-4.3
(-) Financial expenses	3,255	0.7	1,791	0.5	81.7	6,411	0.7	3,685	0.5	74.0
(-) Bank fees	1,115	0.2	1,053	0.3	5.9	2,312	0.3	1,907	0.3	21.2
(-) Monetary restatement of legal provisions	364	0.1	167	-	118.0	694	0.1	312	-	122.4
(-) Monetary restatement of social security reimbursement	108	-	223	0.1	(51.6)	312	-	551	0.1	(43.4)
(-) Others financials expenses	1,668	0.4	348	0.1	379.2	3,093	0.3	915	0.1	238.0

The net financial result was R\$5,589 (1.2% of Sales) in 2Q19, versus R\$6,795 (1.8% of Sales) in 2Q18.

OdontoPrev's financial assets are comprised of an exclusive mutual fund and time deposits of prime institutions, almost all of them 100% liquid.

Income and social contribution taxes

	2Q19		2Q18		Δ%	6M19		6M18		Δ%
	R\$ 000	% Sales	R\$ 000	% Sales		R\$ 000	% Sales	R\$ 000	% Sales	
Taxes	26,417	5.9	25,633	6.8	3.1	69,601	7.8	62,707	8.4	11.0
(-) Current income and social contribution taxes	26,734	6.0	27,891	7.4	-4.1	66,112	7.5	61,989	8.3	6.7
(-) Deferred income and social contribution taxes	-317	-0.1	-2,258	-0.6	-85.9	3,489	0.4	718	0.1	386.2


	Effective tax rate			
	2Q19	2Q18	6M19	6M18
Income before taxes and profit sharing	93,690	88,206	239,529	211,319
(-) Profit sharing	4,408	2,082	9,379	6,286
(=) Tax base	89,283	86,124	230,150	205,033
<u>Taxes</u>				
(-) Current income and social contribution taxes	26,734	27,891	66,112	61,989
(-) Deferred income and social contribution taxes	-317	-2,258	3,489	718
Total taxes	26,417	25,633	69,601	62,707
Current effective tax rate	29.9%	32.4%	28.7%	30.2%

Amortization schedule from 2019	
Period	Total amortization R\$000
2019	14,579
2020	29,159
2021	29,159
2022	29,159
2023	29,159
Total	131,214

Net Income

Net income reached R\$62,274 in 2Q19, 3.2% above 2Q18. In the semester, net income was R\$159,704, 12.2% above the previous year, with a 18.0% net margin.

Net income	2Q19	2Q18	Δ%	6M19	6M18	Δ%
R\$ 000	62,274	60,344	3.2	159,704	142,310	12.2
% Sales	13.9	16.1	-2.2 p.p	18.0	19.1	-1.1 p.p





Cash flow

(R\$000)	2Q19	2Q18	6M19	6M18
CASH FLOW FROM OPERATIONAL ACTIVITIES				
Net income for the period	62,866	60,491	160,549	142,326
Reconciliation of net income with the cash generated by operations	75,327	63,944	140,252	115,026
	138,193	124,435	300,801	257,352
Decrease (increase) in operational assets	-32,683	-8,804	-73,000	-28,106
Increase (decrease) in operational liabilities	-36,193	-48,033	-51,343	-99,003
NET CASH PROVIDED BY (USED IN) OPERATIONAL ACTIVITIES	69,317	67,598	176,458	130,243
CASH FLOW FROM INVESTING ACTIVITIES				
Acquisition of property and equipment	-1,289	-427	-1,664	-933
System development, software licenses and other	-6,030	-4,342	-9,522	-9,594
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	-7,319	-4,769	-11,186	-10,527
CASH FLOW FROM FINANCING ACTIVITIES				
Dividends paid	-78,324	-3,042	-136,388	-3,042
Interest on capital paid	-17,636	-15,096	-33,371	-27,041
Treasury shares	-22,627	-37,744	-22,627	-70,497
Leasing liability	-739	0	-1,407	0
Stock Options Program vesting reimbursements	2,045	19,932	7,045	21,459
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	-117,281	-35,950	-186,748	-79,121
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	-55,283	26,879	-21,476	40,595
Cash, Cash Equivalents and short-term investments				
Balance at the beginning of period	530,570	521,857	496,763	508,141
Balance at the end of period	475,287	548,736	475,287	548,736
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	-55,283	26,879	-21,476	40,595

You can find the 1Q19, 2Q19 and 6M19 consolidated cash flow at Attachment VI, page 38.

You can find the 1Q18, 2Q18 and 6M18 consolidated cash flow at Attachment VII, page 39.




Since the IPO in 2006, OdontoPrev has presented a cash generation of R\$2,727.6 million, and paid R\$2,239.5 million to shareholders. At the end of June/2019, the net cash position was of R\$475.3 million, without any leverage.

Capex

The IT platform represents, historically, the bulk of OdontoPrev's capex.

(R\$thousand)	2Q19	2Q18	6M19	6M18
IT platform, acquisition/license of software	5,815	4,342	8,219	9,594
Computer equipment	1,095	258	1,175	481
Dental plan equipment, furniture and utensils	146	41	280	65
Installations	45	24	79	64
Vehicle	130	100	130	167
Others	87	4	1,303	155
Total capex	7,319	4,769	11,186	10,527



Statement of added value

(R\$000)	2Q19	2Q18	6M19	6M18
Revenues	449,797	383,566	896,140	765,445
Inputs purchased from third parties	-284,465	-238,680	-523,195	-437,819
(=) GROSS VALUE ADDED	165,332	144,886	372,945	327,626
Retentions	-6,330	-2,284	-12,747	-4,722
(=) WEALTH CREATED BY THE COMPANY	159,002	142,602	360,198	322,904
Wealth received in transfer	9,464	9,506	19,202	19,883
(=) WEALTH CREATED	168,466	152,108	379,400	342,787

WEALTH DISTRIBUTED	168,466	100%	152,108	100.0%	379,400	100%	342,787	100.0%
Personnel and charges	41,476	24.6%	30,079	19.8%	84,213	22.2%	61,952	18.1%
Taxes, fees and contributions	59,204	35.1%	55,049	36.2%	125,277	33.0%	125,350	36.6%
Lenders and lessors	4,208	2.5%	3,966	2.6%	7,664	2.0%	8,043	2.3%
Shareholders	62,866	37.3%	60,491	39.8%	160,549	42.3%	142,326	41.5%
Stock options	712	0.4%	2,523	1.7%	1,697	0.4%	5,116	1.5%

Stock options

Since the creation of the Stock Options Plan, back in 2007, OdontoPrev has made 12 grants, demonstrated below:

June 30, 2019 (R\$/share)											
Grant date	Granted options	Canceled options	Exercised options	Number of options outstanding on 06/30/2019 *	Historical grant share price (R\$)	Δ % IGP-M since grant date	Current share price updated by inflation	Dividends per share	IOC per share	Capital Reductions per share	Current grant share price
08/02/2007	2,662,308	989,304	1,673,004	-	3.74	108.7%	7.80	0.41	0.18	0.85	6.36
02/28/2008	4,241,928	977,544	3,264,384	-	2.70	95.0%	5.27	0.42	0.14	0.85	3.85
03/25/2009	3,060,024	839,916	2,220,108	-	1.47	79.8%	2.64	0.66	0.24	0.85	0.89
08/11/2010	2,096,121	199,803	1,896,318	-	4.31	71.2%	7.38	1.65	0.49	-	5.24
09/20/2011	1,751,445	221,174	1,530,271	-	6.96	57.5%	10.96	1.90	0.42	-	8.64
09/20/2012	1,609,097	358,112	1,250,985	-	8.22	45.7%	11.98	1.75	0.39	-	9.84
08/20/2013	3,000,000	672,650	2,293,731	33,619	7.44	41.7%	10.54	1.78	0.52	-	8.24
02/25/2014	228,497	-	228,497	-	7.30	36.0%	9.93	1.41	0.31	-	8.21
05/26/2015	2,679,397	395,749	2,102,250	181,398	10.79	**	**	**	**	**	10.79
11/19/2015	2,572,186	404,111	2,100,539	67,536	9.81	**	**	**	**	**	9.81
07/01/2016	392,680	-	-	392,680	11.41	**	**	**	**	**	11.41
10/26/2016	2,889,498	549,693	-	2,339,805	13.03	**	**	**	**	**	13.03
Total	27,183,181	5,608,056	18,560,087	3,015,038							

* After the share split of 07/01/2010 and 04/02/2012

** New stock options plan approved on Shareholder's Meeting, May/2015

Shareholder remuneration

Dividends (DIV), interest on capital (IOC), capital reduction (CR) and share buyback (SB) - R\$ thousand								
Fiscal year	Payment	Approval	Shareholder position	Type	Period	Amount R\$	Total annual	Net Income
	Total paid in 2006:					8,080	16,240	16,911
	Total paid in 2007:					18,477	16,297	47,458
	Total paid in 2008:					30,436	39,958	55,153
	Total paid in 2009:					28,983	200.381 ¹	58,976
	Total paid in 2010:					523,850	352,027	121,004
	Total paid in 2011:					85,806	159,686 ²	145,311
	Total paid in 2012:					207,467	159,527 ³	145,566
	Total paid in 2013:					181,975	206,322 ⁴	188,091
	Total paid in 2014:					216,658	213,581 ⁵	194,709
	Total paid in 2015:					223,205	220,946 ⁶	220,946
2015	01/06/2016	12/14/2015	12/15/2015	IOC	4Q15	10,696	172,791	215,990
2016	04/05/2016	03/14/2016	03/14/2016	IOC	1Q16	11,902		
2015	05/04/2016	04/11/2016	04/12/2016	DIV	4Q15	49,331		
2016	06/03/2016	04/27/2016	04/27/2016	DIV	1Q16	43,115		
2016	07/05/2016	06/14/2016	06/17/2016	IOC	2Q16	11,402		
2016	09/05/2016	07/27/2016	08/01/2016	DIV	2Q16	23,779		
2016	10/05/2016	09/15/2016	09/20/2016	IOC	3Q16	11,336		
2016	12/05/2016	10/26/2016	10/31/2016	DIV	3Q16	23,998		
	Total paid in 2016:					185,559		
2016	01/04/2017	12/13/2016	12/16/2015	IOC	4Q16	11,797	246,667	502,919
2017	04/05/2017	03/15/2017	03/20/2017	IOC	1Q17	12,664		
2016	05/04/2017	03/28/2017	03/31/2017	DIV	4Q16	35,462		
2017	06/05/2017	04/24/2017	05/02/2017	DIV	1Q17	42,507		
2017	07/05/2017	06/19/2017	06/22/2017	IOC	2Q17	11,363		
2017	09/05/2017	07/26/2017	07/31/2017	DIV	2Q17	100,000		
2017	10/04/2017	09/18/2017	09/21/2017	IOC	3Q17	11,675		
2017	12/06/2017	10/25/2017	10/30/2017	DIV	3Q17	53,544		
	Total paid in 2017:					279,012		
2017	01/04/2018	12/11/2017	12/14/2017	IOC	4Q17	11,945	173,358	284,793
2018	04/04/2018	03/12/2018	03/15/2018	IOC	1Q18	15,096		
2017	05/04/2018	04/02/2018	04/05/2018	DIV	4Q17	2,970		
2018	07/04/2018	06/13/2018	06/18/2018	IOC	2Q18	14,332		
2018	09/05/2018	07/25/2018	07/30/2018	DIV	2Q18	27,909		
2018	10/05/2018	09/21/2018	09/26/2018	IOC	3Q18	14,464		
	Total paid in 2018:					86,716		
2018	01/09/2019	12/18/2018	12/21/2018	DIV	2018	58,063		
2018	01/09/2019	12/18/2018	12/21/2018	IOC	4Q18	15,735		
2018	05/03/2019	04/01/2019	04/04/2019	DIV	2018	5,741		
2018	05/03/2019	04/01/2019	04/04/2019	DIV	2018	22,018		
2019	05/03/2019	03/18/2019	03/21/2019	JCP	1Q19	17,636		
2019	05/16/2019	05/02/2019	05/07/2019	DIV	1Q19	50,565		
2019	07/03/2019	06/17/2019	06/21/2019	IOC	2Q19	15,830		
	Total paid in 2019:					185,588		
2019	09/04/2019	08/01/2019	08/06/2019	DIV	2Q19	27,761		
	Total to be paid in 2019:					27,761		
	Total since the IPO					2,289,573		

¹ R\$ 37,983 paid with statutory reserve.

² R\$ 21,641 paid with statutory reserve.

³ R\$ 21,238 paid with statutory reserve.

⁴ R\$ 27,635 paid with statutory reserve.

⁵ R\$ 28,608 paid with statutory reserve.

⁶ R\$ 11,047 paid with statutory reserve.


Capital Markets

The market cap reached R\$9.7 billion at the end of 2Q19, compared to R\$6.9 billion in 2Q18, with record number of individual shareholders, 113% higher in the last twelve months, and ADTV of R\$23 million in 2019, 39% above 6M18.


OdontoPrev in Capital Markets	JUN18	JUN19	Δ%
Total number of shareholders	6,588	14,008	113
Share price (R\$)	13.07	18.26	40
Market Cap (R\$ billion)	6.9	9.7	40

ODPV3 liquidity	6M18	6M19	Δ%
ADTV (R\$ thousand)	16,554	22,961	39
Average number of trades/day	4,931	5,390	9


Increasing number of individual investors



Total shareholder return since IPO x IBX




Global shareholder structure: investors from 32 countries



Source: OdontoPrev

Dividends and Interest on Capital are top priorities (cash disbursement)

R\$ million



Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

1. Operations and general information

Odontoprev S.A. ("Company" or "OdontoPrev"), a listed corporation headquartered at Avenida Marcos Penteado de Ulhôa Rodrigues, 939 - 14th floor, section 1401, Jatobá Building, Castelo Branco Office Park, Tamboré - Barueri, São Paulo - Brazil, started to operate on August 28, 1987. Its corporate purpose is to provide private dental care plans, the management, sale or availability of these plans to corporate entities and/or individuals, as well the participation, as partner, shareholder or quotaholder in other civil or commercial companies, in commercial enterprises of whatever nature, in Brazil and/or overseas, and the management of its own assets and/or those of third parties.

The Company is classified as a dental operator in the tertiary sector, according to Resolution 39 of the Collegiate Board (RDC) of the Brazilian Health Supplementary Agency (ANS) of October 27, 2000.

The Company holds direct and indirect interests in the following companies:

	Holding percentage (%)							
	June 30, 2019				December 31, 2018			
	Subsidiaries	Associate	Joint		Subsidiaries	Associate	Joint	
	Direct	Indirect	Indirect	Venture	Direct	Indirect	Indirect	Venture
COMPANIES:								
Clidec - Clínica Dentária Especializada Cura D'ars Ltda. (Clidec)	99.9	-	-	-	99.9	-	-	-
Odontoprev Serviços Ltda. (OdontoPrev Serviços)	99.9	-	-	-	99.9	-	-	-
Easy Software S.A. (Easy)	-	51.0	-	-	-	51.0	-	-
Dental Partner Comércio de Produtos e Equipamentos Odontológicos Ltda. (Dental Partner)	-	99.9	-	-	-	99.9	-	-
G2D Serviços Tecnológicos S.A. (G2D)	-	-	15.7	-	-	-	15.7	-
Clidec Participações S.A. (Clidec Participações)	-	90.6	-	-	-	90.6	-	-
TERTIARY SECTOR DENTAL OPERATOR - RDC 39 ANS:								
Brasilental Operadora de Planos Odontológicos S.A. (Brasilental)	-	-	-	25.0	-	-	-	25.0
Garcia Pedrosa Ltda. (Rede Dental)	99.9	-	-	-	99.9	-	-	-
Odonto System Planos Odontológicos Ltda. (Odonto System) ¹	-	-	-	-	100.0	-	-	-
INSURANCE COMPANY:								
Odontored CV Sociedad Anónima de Capital Variable (Odontored)	60.0	-	-	-	60.0	-	-	-
CHAIN OF DENTAL RADIOLOGY CLINICS:								
Clínicas Radiológicas Papaiz (Papaiz Group)	-	-	-	49.0	-	-	-	49.0

¹Subsidiary incorporated in January 02, 2019.

Clidec: established on July 02, 1970 with the purpose of providing dental care services.

OdontoPrev Serviços: established on December 03, 1999 for provision of commercial advisory, consulting and business management services and holding of interests in other companies as partner or shareholder.

Easy: established on November 03, 1993, controlled by Odontoprev Serviços, for the development and licensing of software programs and holding of interests in other companies as partner or shareholder.

Dental Partner: established on November 14, 2008, controlled by Clidec, sells, in the retail and wholesale markets of products and equipment, sanitizers, drugs, medicines, pharmaceutical inputs and related items, as well as the wholesale of medications and drugs for human consumption, provision of services of warehousing, storage, loading, organization, custody of goods of any kind, provision of services of: (i) technical and administrative programming and organizing services; (ii) general management of goods and business; (iii) collecting, sending or delivering mail, documents, objects or goods.

G2D: established on December 19, 2011, Associate of Odontoprev Serviços, owns a platform for online scheduling of appointments with health professionals. For consolidation purposes, the Company uses its financial statements with one-month gap in relation to the consolidated financial statements.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

Clidec Participações: established on June 11, 2012, Subsidiary of Clidec, its purpose is to hold interests in other companies as shareholder or quotaholder and its shareholders are Clidec and some of the sellers and current executives of the Papaiz Group.

Brasildental: established on March 12, 2014, a Joint Venture with BB Seguros Participações S.A. for operation of private dental care plans and management, sale or provision of such plans to corporate entities and/or individuals.

Rede Dental: established on August 31, 1990 for operation of private dental care plans and management, sale or provision of these plans to individuals and corporate entities.

Odonto System: established on May 09, 1989 in Fortaleza city in Ceará state, its purpose is to operate dental care plans and has all its quotas acquired by OdontoPrev in August 07, 2018. In January 02, 2019, the General Meeting (GM) approved the Odonto System's corporate incorporation by OdontoPrev, this procedure was finished in March 29, through approval of ANS by official letter 39/2019/ASSNT-DIOPE/DIRAD-DIOPE/DIOPE.

Odontored: established on August 13, 2009 in Mexico, for the development of dental care plans, including their operation, management and sale, as well as the provision of dental care services directly or indirectly through third-parties. On June 06, 2013, the company was authorized by the Health Department to operate as insurance company specialized in health and, on July 15, 2013, the National Insurance and Bond Commission (CNSF) allowed the operation of accident and health insurance in the lines of health and medical expenditures. For consolidation purposes, the Company uses its financial statements with one-month gap in relation to the consolidated financial statements.

Papaiz Group: share of dental radiology clinics acquired on January 31, 2013 through Clidec Participações, a Joint Venture with the Fleury Group.

Approval of the financial statements

The issue of the company and consolidated financial statements was authorized and approved by the Company's Board of Directors (BD) on August 01, 2019.

2. Description of significant accounting policies

2.1 Preparation and presentation

The parent company financial statements have been prepared in accordance with the accounting practices adopted in Brazil issued by the Brazilian Accounting Pronouncements Committee (CPC), and the consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), under the assumption of going concern, and disclose all (and only) the applicable significant information related to the financial statements, which is consistent with the information utilized by Management in the performance of its duties.

The financial statements have been prepared and are presented in accordance with the ANS chart of accounts and the requirements of the Brazilian Securities Commission (CVM).

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

2.2 Consolidated financial statements

(a) Subsidiaries

Subsidiaries are all entities over which the Company has direct or indirect control over the financial and operating management, generally accompanying a shareholding of more than one half of the voting rights or most of the risks and rewards originated from these investments, in accordance with IFRS. Subsidiaries are consolidated from the date on which control is transferred to OdontoPrev.

The Company applies the acquisition method to account for business combinations, which are recorded at the fair value of transferred assets, liabilities and equity calculated on the acquisition date. Acquisition-related costs are recorded in the statement of income as incurred. Non-controlling interests in Subsidiaries are recognized proportionally based on the fair value at the acquisition date.

The excess of the amount paid over the fair value of assets and liabilities assumed on the acquisition date of any equity interest is recorded as goodwill, after the allocation to tangible and/or intangible assets.

Investments in Subsidiaries and equity in the results of Subsidiaries, as well as assets, liabilities, income and expenses from intercompany transactions were eliminated in the consolidated financial statements.

(b) Associates

Associates are all entities over which the Company has significant influence and the power to take part in decisions related to financial and operating policies, without holding control. Investments in Associates are initially recognized by the cost value and after accounted for using the equity accounting method.

(c) Joint venture

Joint ventures are all entities in which there is the sharing, contractually agreed upon, of the business control, which only exists when decisions on significant activities require the unanimous consent by the parts sharing the control. Joint ventures are accounted for under the equity accounting method.

2.3 Company financial statements

In the Company financial statements, Subsidiaries are accounted for using the equity accounting method.

2.4 Operating segments

Operating segments are reported in a manner consistent with the internal reporting provided to the Company's chief operating and strategic decision-maker, i.e. the Statutory Board, which is responsible for allocating resources and assessing the performance of the operating segments (note 18).

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

2.5 Currency

(a) Functional and presentation currency

Items included in the individual and consolidated financial statements are measured using the currency of the primary economic environment in which the Company operates (the functional currency), these financial statements are presented in Brazilian Reais (R\$).

(b) Translation of transactions and balances in foreign currency

For the Odontored Subsidiary (note 1), the functional currency is the Mexican Peso, which is converted into currency of the Company for presentation purposes, using the closing exchange rate on the date of the respective balance (current assets and liabilities), the date of the transactions (non-current assets and liabilities and equity) and monthly average (revenues and expenses). Gains or losses on the conversion of balances denominated in foreign currency resulting from the settlement of such transactions and the conversion of balances at the closing date are recognized in shareholders' equity.

2.6 Current assets

2.6.1 Classification

(a) Cash and cash equivalents

Cash and cash equivalents represent funds without restriction for investment in the Company's operations and for which there is no restriction on immediate use (note 5).

Cash equivalents are highly liquid assets held to meet short-term cash commitments with original maturities of up to three months from their acquisition and insignificant risk of change in value (note 5).

(b) Financial assets at fair value through income or loss

A financial asset is stated at fair value through income or loss if the Company manages these investments and makes purchase and sale decisions based on their fair values according to the risk management and investment strategy. These financial assets correspond to financial investments accounted for in current assets (notes 4.1.1 and 6) and changes in fair value are recognized in income or loss for the year.

(c) Securities held-to-maturity

Acquired with the intention and financial ability to hold them in the portfolio to maturity classified in non-current assets when maturity is greater than 12 months and are recorded at cost at the acquisition date, including income earned (notes 4.1.1 and 6).

(d) Loans and receivables

These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are classified in current assets, except for maturities greater than 12 months after the balance sheet date (these

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

are classified in non-current assets). The loans and receivables of the Company and its Subsidiaries comprise dental care and insurance receivables (note 7).

These are reported in the balance sheet at the nominal values of the notes representing these receivables, with the corresponding entry recorded in net premiums with dental care plan or insurance in the statement of income or unearned premiums in current liabilities, according to the risk coverage period of the contracts in force at the balance sheet date, and at the amounts receivable from reimbursement of events. In Subsidiary Odontored they are reported in the balance sheet at the nominal values of the policies representing these receivables, with the corresponding entry recorded in the insurance account in the statement of income according to the risk coverage period of the contracts in force.

2.6.2 Recognition and measurement

Financial assets are recognized at fair value, and the costs, gains and losses arising from the transaction are recorded in the statement of income in a specific account. Financial assets are derecognized when the rights to receive cash flows from the investments have expired or the Company and its Subsidiaries have transferred substantially all the risks and rewards of ownership.

The Company assesses at each balance sheet date whether there is objective evidence that a financial asset or group of financial assets is impaired (note 2.6.4).

2.6.3 Fair value estimation

The Company adopted IFRS 13 - Fair Value Measurement for financial instruments that are measured in the balance sheet at fair value, which requires disclosure of this measurements by level of the hierarchy as presented below, and its financial risk management policy is to contract financial products available in the Brazilian market, whose market value can be reliably measured, seeking high liquidity to honor its future liabilities (note 4.1.1).

- Level 1: quoted prices (unadjusted) in active markets for identical assets and liabilities.
- Level 2: discounted cash flow or another methodology for pricing the asset based on observable market data.
- Level 3: inputs for the asset or liability that are not based on observable market data.

2.6.4 Impairment of financial assets measured at amortized cost

The Company and its Subsidiaries assess at the end of each reporting period whether there is evidence that the credit quality of an asset or group of assets is impaired, and impairment losses are incurred as a result of a loss event that has an impact on the estimated future cash flows of the asset or group of financial assets.

The Company and its Subsidiaries recognize allowance for doubtful accounts for invoices that are more than 60 days past due for individual contracts and 90 days for collective contracts, plus an average loss percentage determined in a portfolio behavior study. Losses on trade receivables are recorded in the account "allowance for doubtful accounts" in the statement of income.

Amounts more than 180 days past due, which Management does not expect to recover any more, are accounted for as effective loss.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

By assessing the existence of objective evidence of impairment, the Company and its Subsidiaries measure the provision, reducing the carrying amount to its recoverable amount and recognizing the amount of the provision. If, in a subsequent period, the amount of the impairment loss decreases and this decrease can be related objectively to an event occurring after the impairment was recognized, the recovery and reversal are recognized in the statement of income.

The other types of financial assets classified as loans and receivables do not include assets classified as impaired. The maximum exposure to credit risk at the balance sheet date is the carrying amount of each class of accounts receivable previously mentioned.

2.6.5 Deferred Acquisition Costs (DAC)

These are expenditures directly incremental and related to the origin or renewal of contracts, that is, the amounts paid for agency services in collective contracts and commissions paid in annual individual contracts, both recognized in the statement of income over a 12-month period. Other expenditures are recorded as selling expenses, as incurred.

2.7 Non-current assets

2.7.1 Long-term receivables

(a) Deferred income tax and social contribution (asset and liability)

Deferred tax assets with probable deductibility are recognized in respect to taxable temporary differences, that is, on those differences that will result in amounts to be excluded from the calculation of taxable income relating to income tax and social contribution of future years, when the carrying amount of the asset will be recovered (note 9.1).

Deferred tax is measured based on the rates expected to be applied to temporary differences when these are reversed.

Deferred tax assets and liabilities are offset when there is a legal right to offset current tax assets and liabilities, and when they refer to taxes charged by the same tax authorities and on the same entity subject to taxation, or on separate taxable entities but when there is the intention to liquidate the current tax assets and liabilities on a net basis or when the tax assets and liabilities will be realized simultaneously.

Deferred income tax and social contribution assets are revised at each reporting date and are reduced to the extent that realization is no longer probable.

(b) Judicial deposits

These refer to tax and civil lawsuits, monetarily restated according to the Sistema Especial de Liquidação e Custódia (SELIC) index, and labor lawsuits monetarily restated according to savings account index (notes 9.2 and 16.1).

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

2.7.2 Investments

These are represented by investments in Subsidiaries, associates and joint ventures accounted for using the equity method of accounting based on their respective balance sheets (note 10).

2.7.3 Property, plant and equipment

(a) Property, plant and equipment in use

Stated at cost of acquisition, less accumulated depreciation calculated using the straight-line method at annual rates (note 11).

Gains and losses on disposals are determined by comparing the proceeds from the sale and the carrying amount and are recognized in the statement of income.

(b) Right of use

Recognition of estimated impacts of present value adjustments of payment of lease liabilities measured according to the requirements of IFRS 16 - Leases (notes 12.2 e 26).

2.7.4 Intangible assets

(c) Goodwill on acquisition of investments

Refers to goodwill based on expected future profitability, paid on the acquisition of investments (note 12.1). Goodwill represents the excess of the amount paid for business acquisition over the net fair value of assets and liabilities of the acquired subsidiary, including the allocation of intangible assets.

Goodwill is tested for impairment at least annually (note 12.1), and it is carried at cost less accumulated impairment losses, if any, which are not reversed.

(d) System development and software licenses

Development expenditures related to software system and licenses that are directly attributable to the design and testing of identifiable and unique software products controlled by the Company are recognized as intangible assets until they are ready for use. They are amortized on a straight-line basis over 60 months (note 12.2). Since their conclusion, maintenance expenditures are recognized as expenses.

(e) Allocated intangible assets

Amounts attributable to the brand, clients portfolio and non-competition agreement by the invested OdontoServ and Odonto System which are amortized using the straight-line method according to the terms identified in the appraisal report (note 12.2).

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

2.8 Impairment of non-financial assets

In accordance with CVM Resolution 639/2010 and IAS 36 - Impairment of Assets, assets are tested for impairment in order to: (i) verify whether there is any indication of impairment of assets; and (ii) measure any impairment of existing assets to complement or reverse the provision for impairment of assets, when applicable.

Assets that are subject to depreciation/amortization are reviewed for impairment periodically or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

An impairment loss is recognized when the assets' carrying amount exceeds its recoverable amount (higher of an assets' fair value less costs to sell and its value in use).

Assets which have an indefinite useful life, for example goodwill, are not subject to amortization and are tested for impairment annually (note 12.1).

2.9 Dental care plan and insurance contracts - Liability Adequacy Test (LAT)

The Company and its Subsidiaries issue dental care and insurance contracts, in which they assume the insurance risk, which includes the frequency of use and fluctuation of dental care costs (note 4.2).

If any insufficiency is identified, the Company records the loss immediately as expense in statement of income for the year, first reducing the acquisition costs up to the limit of zero and then making additional reserves for insurance liabilities already recorded on the test date.

The last test was performed on the base date of December 31, 2018 in accordance with business segments defined by the Company (note 18) and considered technical reserves (notes 2.10 and 13.2), net premiums with dental care plan, administrative and selling expenses. To calculate the present value of projected flows, the Company used risk-free forward rates (ETTJ) published by the Brazilian Association of Financial and Capital Market Entities (ANBIMA).

LAT results did not present insufficiencies on its performing date, therefore, established reserves did not need to be adjusted. In the quarter, the recognition of an additional provision with respect to LAT was not necessary.

2.10 Technical reserves of dental care operations

In accordance with Normative Resolution (RN) 393/2015, amended by RN 442/2018, the Company and its Subsidiaries (operators) recognize monthly in current liabilities:

- (i) **Provision for "Unearned Premiums":** calculated on a "*pro rata die*" basis according to the premiums issued, and recognized in income according to the risk coverage period (note 13.2).
- (ii) **Provision for "Unsettled Claims":** classify the events to be settled with dental care operations. Costs of services rendered are recorded based on claims reported by accredited service providers regarding the analysis of events covered by the plans, with a corresponding entry to the account "indemnifiable claims, net" in the statement of income (note 13.2).

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

- (iii) **Provision for "Incurred But Not Report Claims" (IBNR):** actuarially estimated to cover payment of events that have already occurred and have not been recorded in the accounting books by the Company (notes 2.18 and 13.2) in determined occurrence period. The calculation of IBNR was prepared according to actuarial methodology based on structuring of development triangles of claim records by occurrence of events (run off triangles), which consider experience period of events reported in the last 18 months.

2.11 Taxes and contributions payable

(a) Federal tax obligations

- (i) **Income tax (IRPJ) and social contribution (CSLL):** these are calculated based on criteria established by the legislation in force. IRPJ is calculated at the rate of 15% of taxable income, plus a 10% surtax on taxable income exceeding R\$240 per year and includes the tax incentive portion (notes 14 and 24). CSLL is calculated at the rate of 9% on taxable income (notes 14 and 24).
- (ii) **Other federal tax obligations:** these comprise mainly provisions for Social Integration Program (PIS) and Contribution to Social Security Financing (COFINS) which are calculated based on the criteria established by the legislation in force, using the rate of 0.65% and 4%, respectively, both on billing less paid indemnifiable claims (note 14).

(b) Municipal tax obligations

These comprise the provision for Service Tax (ISS) calculated based on criteria established by the legislation in force. ISS is calculated at rates between 2% and 5% (note 14).

2.12 Trade and other payables

These refer to unsettled obligations for goods or services acquired in the normal course of businesses which are classified as current liabilities, except if the maturity is over 12 months after the balance sheet date, which are classified as non-current liabilities.

2.13 Commissions payable

Payables related to brokerage service provided by brokers and commissions payable, which are generally settled monthly.

2.14 Other liabilities

Labor liabilities (salaries, vacation pay and fees), dividends, sundry payables (note 15) and advances from customers.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

2.15 Contingent liabilities and legal obligations

The Company and its Subsidiaries assess their contingent based on the requirements of the accounting pronouncement IAS 37 - Provisions, Contingent Liabilities and Contingent Assets, which for the lawsuits assessed as "probable losses", based on the assessments of internal and external attorneys, the similarity of previous disputes, the complexity of the lawsuit and the opinion of the legal courts, the Company made a reserve for 100% of intended amounts (note 16.1).

For civil lawsuits, whose probability of loss is classified as "possible" and the object of which is the treatment performed to the beneficiaries of the dental plans, 25% of the intended amounts representing the expectation of loss and probable outflow of cash is provisioned. Disputes directly related to the activity of the Company and/or its Subsidiaries, depending on their outcome, may: a) demonstrate a failure in the operation; b) indicate possible deficiency in the service rendered; c) affect the image.

In addition, the Company and its Subsidiaries also perform individual analysis for the administrative lawsuits with ANS and other consumer and class protection agencies, especially those in which a pecuniary monetary penalty was applied and the judgment not yet occurred. In these cases, the Company and its Subsidiaries made individual estimates which can be changed by the lawsuit phase or decisions taken by the agencies. The lawsuits with ANS, depending on their outcome, may generate impact on the health operators' performance indicators, and the lawsuits with the consumer protection agencies may result in financial losses and image damages.

Legal, tax and social security obligations arising from lawsuits related to tax obligations, whose legality or constitutionality is being challenged are fully recognized in the financial statements, since they are considered legal obligations, and are monetarily restated in accordance with current tax legislation (SELIC interest rate).

2.16 Share capital

Common shares are classified as equity (note 17.1).

The Company buys back shares to back up the stock option plan (notes 17.4 and 17.6).

2.17 Revenue recognition

(a) Net premiums with dental care plan

Income derived from operations related to private dental care plans in the form of previously agreed prices which have to be appropriated as the amount corresponding to the daily allocation *pro rata die* during the individual coverage period of each contract, since the first day of coverage (note 19). The net premiums with dental care plan corresponding to the future coverage are recorded in "unearned premiums" (notes 2.10 and 13.2).

Contracts related to collective post-payment plans are recorded in Income under "net premiums with dental care plan", at cost.

(b) Revenue from sales and services

Revenues provided by Subsidiaries and are allocated to the statement of income on the accrual basis (notes 18 (d) and 19).

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

(c) Insurance

Corresponds to income from dental care insurance provided by Subsidiary Odontored (note 1) recognized in the statement of income according to the risk coverage (notes 18 (d) and 19).

(d) Financial income

Income arises from financial instruments and monetary restatement (note 23).

2.18 Cost of services rendered

The services provided by accredited professionals and dental clinics are recognized in the statement of income on an accrual basis, when claims covered by the plans are reported and analyzed, together with the recording of IBNR (note 20). The costs of the company-owned dental care chain are recognized in the statement of income on the accrual basis (note 20).

The claims arising from subsidiary Odontored are recognized in the statement of income on the accrual basis, according to the claim notices received, together with the respective technical claims reserve (note 20).

2.19 Employee and management benefits

Regarding the employee and management benefit program, even in the form of financial instruments, the Company and its Subsidiaries adopt the following procedures: (i) employee profit sharing expenses are classified as profit sharing results in operating expenses, according to IAS 19 - Employee Benefits; (ii) all the expenses of long-term incitement program are classified as operating expenses, according to IAS 19 - Employee Benefits; and (iii) all the estimated costs of stock options granted under share-based payment contracts are classified as operating expenses, with a corresponding entry to shareholders' equity in stock options granted, in accordance with IFRS 2 - Share-based Payment (note 17.6).

2.20 Dividends and interest on capital

The distribution of dividends and interest on capital to the OdontoPrev's shareholders is recognized as a liability in the financial statements based on the Company's Bylaws that establish a compulsory minimum dividend of 50% calculated over net income. Any amount that exceeds the minimum required is recorded in equity, in the account "additional dividend proposed", until it is approved by the shareholders at the Annual General Meeting (AGM) (note 17.5).

2.21 Earnings per share

The Company calculates basic and diluted earnings per share in accordance with IAS 33 - Earnings per Share (note 25).

2.22 New standards, amendments and interpretations

The main new standards and interpretations of standards that affect the Company and its Subsidiaries are summarized below:

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

IFRS 15 - Revenue from Contract with Customer: effective since January 01, 2018, it introduces a comprehensive framework for determining criteria of recognition and measurement, replacing the current standards for revenue recognition. Revenues from insurance contracts and dental care plans are outside the scope of IFRS 15 and will be addressed within the scope of IFRS 17 - Insurance contracts, which will enter into effect starting January 01, 2022. Management concluded that even for the Company and Consolidated there was no material impact of IFRS 15 on the financial statements.

IFRS 9 - Financial Instruments: effective since January 01, 2018, it replaces the guidance of IAS 39 - Financial Instruments: Recognition and Measurement, including new models for the classification and measurement of financial instruments and measurement of expected credit losses for financial and contractual assets, and new requirements on hedge accounting.

Management concluded that both in the Company and in Consolidated, its activities are predominantly related to insurance, therefore, the Company choose to apply the temporary exemption benefit from IFRS 15, allowed for the CPC Review from December 12, 2017, and will continue to apply IAS 39 for annual periods until December 31, 2021, adopting the related pronouncement as of January 01, 2022.

IFRS 17 - Insurance contracts: effective date is January 01, 2022, it will replace IFRS 4 – Insurance Contracts, and it aims to help investors and other stakeholders to understand better aspects inherent to the Company's operations, such as risk exposure, profitability and financial position. The Company is evaluating the full impact of its adoption.

IFRIC 23 – Uncertainty Over Income Tax Treatments: this interpretation, effective since January 01, 2019 clarifies the way to apply the recognition and measurement requirements when there is uncertainty over income tax treatments, that is, there are doubts regarding the acceptance of the treatments adopted by the tax authority applying IAS 12 – Income Taxes. Management concluded that there was no material impact of IFRIC 23 over the Company and Consolidated financial statements.

3. Accounting estimates and judgments

For the preparation of financial statements, Management used judgments, estimates and assumptions that affect the application of accounting policies of the Company and Consolidated and the reported amounts of assets, liabilities, income and expenses, however, actual results may differ from these estimates.

Estimates and assumptions are reviewed on a continuous basis and their impact are recognized on a prospective basis in accordance with IAS 8 - Accounting Policies, Changes in Accounting Estimates and Errors.

(a) Judgments

Information about judgment referring to the adoption of accounting policies which impact significantly the amounts recognized in the financial statements included: (i) evaluation of insurance liabilities (notes 2.9, 2.10 and 13) and (ii) evaluation of tax, civil and labor contingent liabilities (notes 2.15 and 16.1).

(b) Uncertainties about assumptions and estimates

Information about uncertainties related to assumptions and estimates that have a high risk of resulting in a material adjustment included: (i) calculation of impairment of financial assets (notes 2.6.4 and 7), (ii) evaluation of deferred tax

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

assets (notes 2.7.1 (a) and 9.1) and (iii) calculation of impairment of non-financial assets (notes 2.7.4 (a), 2.8 and 12.1) and (iv) measurement of right of use, lease liability and related present value adjustments (notes 2.7.3 (b) e 26).

4. Risk management

The main risks arising from the businesses of the Company and its Subsidiaries listed below are managed by different departments and comprise several fund allocation strategies and policies considered appropriate by Management.

Polices and strategies are monitored by the Audit Committee, created and installed on March 26, 2010, by determination of the Board of Directors and in accordance with the Company's Bylaws.

4.1 Financial risk factors

4.1.1 Market risk (interest rate)

Arises from the possibility that the Company and its Subsidiaries are subject to changes in interest rates that may generate impacts on the fair value of the financial investments portfolio.

The Company and its Subsidiaries adopt the policy to invest in securities issued by financial institutions (Bank Deposit Certificate - CDB) and short-term funds, complying with internal assessment criteria and limits established based on qualitative and quantitative information, including the requirement to allocate resources in compliance with RN 392/2015, amended by RN 419/2016, both from ANS, to guarantee the technical provisions. Almost all the Company's and its Subsidiaries' financial investments portfolio is exposed to fluctuations in interest rates on the domestic market.

As at June 30, 2019, 69.5% (72.0% at December 31, 2018) of the amounts in Consolidated are held in investment funds, these funds are substantially affected by variations in SELIC rate.

In compliance with CVM Resolution 475/2008 and IFRS 7 - Financial Instruments: Disclosures, the Company and its Subsidiaries performed a sensitivity analysis of their financial instruments, based on the variation in the SELIC, Broad Consumer Price Index (IPCA) and Mexican Bond rates, as shown in the table below:

											Consolidated
											June 30, 2019
	Indexed to SELIC					Indexed to IPCA			Others		
	Bank deposits SELIC (p.y) ¹	certificates (CDBs)	Investment funds (FI fixed income)	Investment funds (FI fixed income)	Financial bills (LF)	Federal public bonds (LFT)	IPCA (p.y) ¹	Federal public bonds (NTN-B)	Bond (p.y) ³	Public bonds (CETES)	Total financial investments
Hierarchical level ²	-	2	2	2	1	1	-	1	-	1	-
Investments	-	16,027	854	311,449	6,946	97,604	-	15,577	-	904	449,361
Forecast profitability for the next 12 months:											
Probable	5.80%	930	50	18,064	403	5,661	2.82%	439	8.17%	74	25,621
25% decrease	4.35%	697	37	13,548	302	4,246	2.12%	329	6.13%	55	19,214
50% decrease	2.90%	465	25	9,032	201	2,831	1.41%	220	4.09%	37	12,811
25% increase	7.25%	1,162	62	22,580	504	7,076	3.53%	549	10.21%	92	32,025
50% increase	8.70%	1,394	74	27,096	604	8,492	4.23%	659	12.26%	111	38,430

¹Based on interest rate curves informed by B3 S.A. Brasil Bolsa Balcão.

²Hierarchical level classification (note 2.6.3).

³Rates available at Bank of Mexico.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

Bank deposit certificate (CDB): distribution and classification

	Consolidated				Ratings of financial institutions					
	June 30, 2019	Average yield % of the CDI	December 31 2018	Average yield % of the CDI	Fitch		Moody's		S&P	
					ST	LT	ST	LT	ST	LT
Caixa Econômica Federal	15,934	100.8%	15,454	100.8%	F1+	AA	NP	Ba3	brA-1+	brAAA
Banco Bradesco S.A.	93	94.0%	91	94.0%	F1+	AAA	NP	Ba3	brA-1+	brAAA
China Construction Bank Brasil S.A.	-	0.0%	976	102.3%	F1+	AAA	P-1	A1	-	brAAA
Itaú Unibanco S.A.	-	0.0%	120	94.0%	F1+	AAA	NP	Ba3	brA-1+	brAAA
	16,027		16,641							

4.1.2 Credit risk

Arises from the possibility of the Company and its direct and indirect Subsidiaries not receiving the amounts arising from financial instruments, premiums with dental care plan and services (notes 6, 7 and 19). The credit policy takes into consideration the specific characteristics of dental care plan operations and is focused on maintaining the flexibility required by market conditions. The Company constantly monitors its receivables and calculates the allowance for doubtful accounts (note 2.6.4).

None of the Company's customer represents 10% of revenues or more of the total of the respective class of financial assets.

4.1.3 Liquidity risk

The liquidity risk management objective is to monitor the settlement terms of the rights and obligations of the Company and its Subsidiaries and of their financial instruments, preparing projected cash flow analysis and periodically reviewing the liabilities assumed and the financial instruments used, mainly those related to assets pledged as guarantee of technical provisions.

The receivables comprising the Company's and its Subsidiaries' cash flows arise mainly from collective and individual contracts in prepayment model, which establish the settlement of monthly payments mainly at the beginning of each month for use of benefits. On the other hand, the payments to the accredited chain, the main suppliers, occur throughout the month. These are short-term assets and liabilities, being monitored through the following indicators:

Risk	Indicator	Formula	Reference	Consolidated	
				June 30, 2019	December 31, 2018
Credit	Average receipt term (PMR)	$\frac{\text{Receivables} - \text{Unearned premiums} \times 180 \text{ days}}{\text{Net payments}}$	Days	3	6
Liquidity	Average payment term (PMP)	$\frac{\text{Unsettled claims} \times 180 \text{ days}}{\text{Indemnifiable claims, net}}$	Days	24	21
Liquidity	General liquidity index (ILG)	$\frac{\text{Current assets} + \text{Non-current assets}}{\text{Current liabilities} + \text{Non-current liabilities}}$	Proportion Assets x Liabilities	1.40	1.40

4.2 Insurance risk and dental materials cost fluctuation risk

OdontoPrev's business model is based on the customers' monthly or yearly payments and is exposed to a risk of insurance and dental materials cost fluctuation, taking into consideration that in the dental care plan sector the risk is limited to the frequency of utilization and the low cost of the treatments given.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

In the development and structuring of dental care plans the following factors are taken into consideration:

Risk model: determines who is responsible for the cost of dental treatment: (i) prepaid, which is most customers' choice due to predictability, where the customer pays a *per capita* monthly rate which includes the actuarial estimate of dental treatments, other administrative and selling expenses; and (ii) postpaid, where the customer pays this *per capita* monthly rate which includes only administrative and selling expenses and the entire cost of dental treatments when they are used.

Service model: in accordance with contract coverage, defines how the beneficiary will receive contracted dental care: (i) accredited chain; (ii) free choice; (iii) own service units; and (iv) exclusive dental offices in the client's establishment.

Enrollment model: this determines if the entire group (mandatory enrollment) or part of the group (free enrollment) of beneficiaries will be included in the plan and how the payment of the *per capita* monthly rate will be made.

Types of coverage: this describes all the dental care treatments whose costs are totally or partially covered in the dental care plan contracted, the ANS determines minimum dental care coverage.

Usage moderating factors: rules to use and access to the covered dental services that contribute to define cost and avoid predatory and abusive use, most used are as follows: (i) co-participation; and (ii) grace periods. These factors are present in several plan structures, mainly per free enrollment and individual.

Fees: different remunerations for professionals of accredited chain and several levels of free choice reimbursement.

In addition to insurance risk, the risk of dental materials cost fluctuation also has direct impact on dental care plans, as they may rise as a result of usage volume, legislation and increase in dental material values.

In order to manage them, the Company has its own system that permits individual evaluation of all treatments, monitoring dental costs and promoting clinical governance of performed events.

Collective contracts have average term of 24 or 36 months, with clause establishing fine for breach of contract and annual adjustments of rates practiced using claim rate (cost of services in the last 12 months, divided into the net premiums with dental care plan) and/or inflation adjustment at official rate established in contract. They are also traded in an average term of 12 months automatically renewable by an indeterminate period of time, with clauses establishing fine for rescission and adjustment clause using official rate established in contract as reference.

The Company constantly monitors its contracts in order to minimize risks and maintain their financial balance. In general claim ratio up to 60% allows contribution margin (gross income less selling expenses divided by gross sales and/or services revenues) able to support the Company's administrative expenses. At June 30, 2019, the consolidated claim ratio was 42.9% (43.7% at June 30, 2018) and the contribution margin was 45.6% (45.5% at June 30, 2018).

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

Consolidated: increase/decrease contribution margin						
	Period ended at		Changes in the claims ratio			
	June 30, 2019		Equal to 60%		Equal to 40%	
Sales revenue ² (notes 18 and 19)	887,307	100.0%	887,307	100.0%	887,307	100.0%
Cost of services ¹ (notes 18 and 20)	(380,248)	-42.9%	(532,384)	-60.0%	(354,923)	-40.0%
Gross income	507,059	57.1%	354,923	40.0%	532,384	60.0%
Selling expenses (notes 18 and 21)	(102,221)	-11.5%	(102,221)	-11.5%	(102,221)	-11.5%
Contribution margin	404,838	45.6%	252,702	28.5%	430,163	48.5%
(Decrease)/Increase in margin			(152,136)	-17.1 p.p	25,325	2.9 p.p

¹Do not include incurred but not reported events (IBNR) and claims reserves (note 18).

²Do not include R\$13,800 related to reversal of provision for ISS calculated over the amounts of events through favorable decision received by the Company in March 2019.

Consolidated: increase/decrease contribution margin						
	Period ended at		Changes in the claims ratio			
	June 30, 2018		Equal to 60%		Equal to 40%	
Sales revenue (notes 18 and 19)	745,647	100.0%	745,647	100.0%	745,647	100.0%
Cost of services ¹ (notes 18 and 20)	(326,076)	-43.7%	(447,388)	-60.0%	(298,259)	-40.0%
Gross income	419,571	56.3%	298,259	40.0%	447,388	60.0%
Selling expenses (notes 18 and 21)	(79,960)	-10.7%	(79,960)	-10.7%	(79,960)	-10.7%
Contribution margin	339,611	45.5%	218,299	29.3%	367,428	49.3%
(Decrease)/Increase in margin			(66,935)	-16.3 p.p	7,142	3.7 p.p

¹Do not include incurred but not reported events (IBNR) and claims reserves (note 18).

4.3 Strategy risk - market of operations (competition)

The Company operates in a competitive market, competing with operators of health insurance and dental care exclusive, hospital medical plans, dental care cooperatives and charity entities that offer dental care plans with similar benefits.

OdontoPrev sells dental care plans to companies, associations and individuals through: (i) an internal sales team; (ii) external brokers; (iii) commercial associations and new distribution ways; (iv) Bradesco and (v) Banco do Brasil.

The factors that encourage the growth in the dental care plan sector are the following: (i) structural imbalance between the supply and demand of services; (ii) lack of alternatives in the public system; (iii) inclusion of dental care plans in employee benefit programs; (iv) opportunities represented by the increasing interest of new distribution ways and (v) regulation.

4.4 Legal and regulatory risk - capital

The Company carries out its capital risk management activities based on a centralized model, with the main purpose of meeting the requirements of minimum regulatory capital for its segment, according to the capital requirements defined by ANS as well increase the return on capital to the shareholders. The strategy and model used by Management consider both "regulatory capital" and "economic capital".

The Company keeps capital levels above the regulatory requirements (note 13.1).

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

5. Cash and cash equivalents

	Company		Consolidated	
	June 30, 2019	December 31, 2018	June 30, 2019	December 31, 2018
Cash	13	10	232	69
Amounts in transit	15,615	13,701	15,622	13,707
Checking accounts	4,212	876	5,327	2,344
Financial investments (interest-bearing current account)	4,437	2,010	4,745	5,022
	24,277	16,597	25,926	21,142

6. Financial assets at fair value through income or loss and held to maturity (financial investments)

	Classification	Company		Consolidated	
		June 30, 2019	December 31, 2018	June 30, 2019	December 31, 2018
Bank deposits certificates (CDBs)	Current asset	16,027	16,430	16,027	16,641
ANS Investment funds (FI ANS)	Current asset	-	-	854	835
Investment funds (FI fixed income)	Current asset	300,016	306,043	311,449	341,647
Financial Bills (LF)	Current asset	6,946	3,963	6,946	3,963
Federal public bonds (LFT)	Current asset	97,604	96,072	97,604	96,072
Public bonds (CETES)	Current asset	-	-	904	1,236
Fair value through income or loss		420,593	422,508	433,784	460,394
Federal public bonds (NTN-B)	Non-current asset	15,577	15,227	15,577	15,227
Held to maturity		15,577	15,227	15,577	15,227
Financial investments		436,170	437,735	449,361	475,621

CDBs: floating rate securities indexed to the interbank deposit certificate daily interest rates, mostly of which have daily liquidity (note 4.1.1).

ANS investment funds (FI ANS): investment funds quotas intended to restriction on technical provisions required by ANS which are valued based on the value disclosed by the investment funds' administrators.

Investment funds (fixed income): investment funds quotas on Bradesco FI RF Bond and BRAM FI RF Referenced DI Coral which are valued based on the value disclosed by Bradesco Asset Management.

Federal public bonds - Financial Treasury Bills (LFT): acquired since March 30, 2017, refer to the assets from managed portfolio, which are managed by Bradesco Asset Management.

Financial Bills (LF): private securities acquired from Santander bank on May 30, 2018.

Public bonds - *Certificados de la Tesorería de la Federación* (CETES): fixed-income financial instruments from Odontored issued by the Mexican government.

Federal public bonds - National Treasury Notes (NTN-B): acquired since March 28, 2016, refer to the assets from managed portfolio, which are managed by Bradesco Asset Management. As at June 30, 2019 the fair value is R\$17,468 (R\$16,389 at December 31, 2018).

(A free translation of the original in Portuguese)

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

		Investment portfolio by original maturity dates - Company				
	Classification	No maturity date	01 up to 180 days	181 up to 360 days	Over 360 days	Total
Bank deposits certificates (CDBs)	Current asset	-	3,839	-	12,188	16,027
Investment funds (FI fixed income)	Current asset	300,016	-	-	-	300,016
Federal public bonds (LFT)	Current asset	-	-	-	97,604	97,604
Financial Bills (LF)	Current asset	-	-	-	6,946	6,946
Fair value through income or loss		300,016	3,839	-	116,738	420,593
Federal public bonds (NTN-B)	Non-current asset	-	-	-	15,577	15,577
Held to maturity		-	-	-	15,577	15,577
June 30, 2019		300,016	3,839	-	132,315	436,170
December 31, 2018		306,043	976	3,723	126,993	437,735

		Investment portfolio by original maturity dates - Consolidated				
	Classification	No maturity date	01 up to 180 days	181 up to 360 days	Over 360 days	Total
Bank deposits certificates (CDBs)	Current asset	-	3,839	-	12,188	16,027
ANS Investment funds (FI ANS)	Current asset	854	-	-	-	854
Investment funds (FI fixed income)	Current asset	311,449	-	-	-	311,449
Federal public bonds (LFT)	Current asset	-	-	-	97,604	97,604
Financial Bills (LF)	Current asset	-	-	-	6,946	6,946
Public bonds (CETES)	Current asset	-	904	-	-	904
Fair value through income or loss		312,303	4,743	-	116,738	433,784
Federal public bonds (NTN-B)	Non-current asset	-	-	-	15,577	15,577
Held to maturity		-	-	-	15,577	15,577
June 30, 2019		312,303	4,743	-	132,315	449,361
December 31, 2018		342,482	2,212	3,723	127,204	475,621

		Changes in the investment portfolio - Company						
		Current			Non-current			
					Fair value through income or loss		Held to maturity	
		Fair value through income or loss			Fair value through income or loss		Held to maturity	
	CDBs	FI fixed income	LFT	LF	Total	LFT	NTN-B¹	Total financial investments
December 31, 2017	19,217	358,572	27,058	-	404,847	57,049	14,636	476,532
Investments	-	783,194	74,273	3,850	861,317	-	-	861,317
(-) Withdrawals	(3,810)	(855,627)	(10,754)	-	(870,191)	(57,049)	(812)	(928,052)
Income	1,023	19,904	5,495	113	26,535	-	1,403	27,938
December 31, 2018	16,430	306,043	96,072	3,963	422,508	-	15,227	437,735
Incorporation of Odonto System²	211	23,260	-	-	23,471	-	-	23,471
Investments	-	478,345	-	2,802	481,147	-	-	481,147
(-) Withdrawals	(1,128)	(515,776)	(2,729)	(2)	(519,635)	-	(427)	(520,062)
Income	514	8,144	4,261	183	13,102	-	777	13,879
June 30, 2019	16,027	300,016	97,604	6,946	420,593	-	15,577	436,170

¹Withdrawals corresponding to interest payments.

²Subsidiary incorporated in January 02, 2019.

(A free translation of the original in Portuguese)

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

Changes in the investment portfolio - Consolidated										
	Current						Non-current			Total financial investments
	Fair value through income or loss						Fair value through income or loss		Held to maturity	
	CDBs	FI ANS	FI fixed income	LFT	LF	CETES	Total	LFT	NTN-B ¹	
December 31, 2017	19,217	1,483	369,840	27,058	-	1,184	418,782	57,049	14,836	490,467
Consolidation of Odonto System ²	865	-	9,982	-	-	-	10,847	-	-	10,847
Investments	178	800	906,525	74,273	3,850	3,917	989,543	-	-	989,543
(-) Withdrawals	(4,677)	(1,493)	(965,733)	(10,754)	-	(3,991)	(986,648)	(57,049)	(812)	(1,044,509)
Income	1,058	45	21,033	5,495	113	126	27,870	-	1,403	29,273
December 31, 2018	16,641	835	341,647	96,072	3,963	1,236	460,394	-	15,227	475,621
Investments	-	-	521,273	-	2,802	2,129	526,204	-	-	526,204
(-) Withdrawals	(1,128)	-	(559,982)	(2,729)	(2)	(2,548)	(566,389)	-	(427)	(566,816)
Income	514	19	8,511	4,261	183	87	13,575	-	777	14,352
June 30, 2019	16,027	854	311,449	97,604	6,946	904	433,784	-	15,577	449,361

¹Withdrawals corresponding to interest payments.

²Subsidiary incorporated in January 02, 2019.

Coverage of guarantee financial investments (according to RN 393/2015 amended by RN 419/2016 from ANS)					
	Classification	Company		Consolidated	
		June 30, 2019	December 31, 2018	June 30, 2019	December 31, 2018
Technical provisions					
Unsettled claims (over 30/60 days)	Current liability	3,154	494	3,155	620
IBNR	Current liability	83,594	82,403	84,147	83,073
Restriction required by ANS		86,748	82,897	87,302	83,693
Unsettled claims (total)	Current liability	49,381	38,352	49,534	39,568
IBNR	Current liability	83,594	82,403	84,147	83,073
Required guarantee by ANS		132,975	120,755	133,681	122,641
Restriction and guarantee of technical provisions					
Bank deposits certificates (CDBs)	Current asset	7,360	7,140	7,360	7,140
ANS investment funds (FI ANS)	Current asset	-	-	854	835
Federal public bonds (LFT)	Current asset	66,597	64,608	66,597	64,608
Federal public bonds (NTN-B)	Non-current asset	15,577	15,227	15,577	15,227
Restricted financial investments		89,534	86,975	90,388	87,810
Bank deposits certificates (CDBs)	Current asset	8,573	8,315	8,573	8,315
Federal public bonds (LFT)	Current asset	31,007	31,464	31,007	31,464
Financial Bills (LF)	Current asset	6,946	3,963	6,946	3,963
Investment funds (FI fixed income)	Current asset	5,648	-	5,648	5,513
Guarantee financial investments		141,708	130,717	142,562	137,065

7. Dental care receivables (loans and receivables - customers)

	Company		Consolidated	
	June 30, 2019	December 31, 2018	June 30, 2019	December 31, 2018
Receivable pecuniary compensation (invoices)	190,389	174,848	190,666	178,608
Allowance for doubtful accounts	(48,934)	(49,169)	(49,152)	(51,169)
Dental care receivables	141,455	125,679	141,514	127,439
Participation of beneficiaries in indemnifying events/claims	3,670	2,452	3,670	3,339
Allowance for doubtful accounts	(72)	(5)	(58)	(5)
Participation of beneficiaries in indemnifying events/claims, net	3,598	2,447	3,612	3,334
Operators of health care plans (invoices - operators)	8,229	7,475	9,073	8,327
Allowance for doubtful accounts	(8)	(7)	(7)	(37)
Dental care operators, net	8,221	7,468	9,066	8,290
Other healthcare plan receivables	-	-	21,504	15,634
Credits of operations with health care plans (Customers)	153,274	135,594	175,696	154,697
Invoices, debit notes, invoices - operators, insurance	202,288	184,775	224,913	205,908
Allowance for doubtful accounts	(49,014)	(49,181)	(49,217)	(51,211)
Credits of operations with health care plans (Customers)	153,274	135,594	175,696	154,697

(A free translation of the original in Portuguese)

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

Maturity	Credits for health care plans by maturity age							
	Company				Consolidated			
	Invoices, debit notes and operators invoices	Allowance for doubtful accounts	June 30, 2019	December 31, 2018	Invoices, debit notes invoices - operators and insurances	Allowance for doubtful accounts	June 30, 2019	December 31, 2018
Falling due	110,614	(1,490)	109,124	101,817	133,012	(1,495)	131,517	119,280
Up to 30 days	37,760	(5,682)	32,078	25,296	37,805	(5,687)	32,118	27,128
From 31 to 60 days	15,811	(6,947)	8,864	5,440	15,812	(6,952)	8,860	5,451
From 61 to 90 days	8,469	(6,917)	1,552	1,319	8,470	(6,923)	1,547	1,327
Over 91 days	29,634	(27,978)	1,656	1,722	29,814	(28,160)	1,654	1,511
	202,288	(49,014)	153,274	135,594	224,913	(49,217)	175,696	154,697

	Changes in allowance for doubtful accounts and customers			
	Company		Consolidated	
	June 30, 2019	December 31, 2018	June 30, 2019	December 31, 2018
Invoices	190,389	174,848	190,666	178,608
Invoices - operators	8,229	7,475	9,073	8,327
Allowance for doubtful accounts	(49,014)	(49,181)	(49,217)	(51,211)
Openning balances	(49,181)	(46,760)	(51,211)	(46,950)
Provisions (reversals) recorded in the period, net	(39,570)	(56,637)	(39,616)	(57,557)
Actual losses	39,737	54,216	41,610	53,296
Dental care receivables	149,604	133,142	150,522	135,724
Debit notes	3,670	2,452	3,670	3,339
Insurance	-	-	21,504	15,634
Other healthcare plan receivables	3,670	2,452	25,174	18,973
Customers	153,274	135,594	175,696	154,697
Advances from customers	(984)	(937)	(1,446)	(972)
Customers, net	152,290	134,657	174,250	153,725

8. Tax and social security credits (taxes recoverable)

	Company		Consolidated	
	June 30, 2019	December 31, 2018	June 30, 2019	December 31, 2018
INSS ¹	18,615	18,345	18,615	18,345
IRPJ	532	10	1,519	1,492
CSLL	109	4	1,341	1,018
IRRF	160	95	1,263	1,096
PIS and COFINS	246	210	2,445	2,449
ISS ²	8,058	1,470	8,064	1,485
Other	-	-	140	151
	27,720	20,134	33,387	26,036

¹Credits related to the 5-year collections prior to the filing of the INSS lawsuit (note 16.1 (b) (i)).

²Credits of R\$6,635 related to the payments of ISS between March and August/2018 due to inclusion of events in the calculation basis, in March 2019 the Company obtained favorable final decision (note 16.1 (a) (ii)).

(A free translation of the original in Portuguese)

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

9. Long-term receivables

9.1 Deferred income tax and social contribution

Temporary differences	Classification	Expected realization	Note	Company		Consolidated	
				December 31, 2018	Debit (credit) to income	December 31, 2018	Debit (credit) to income
Allowance for doubtful accounts	Asset	Up to 12 months	7	16,722	(57)	16,665	(678)
Non-deductible losses (recovery)	Asset	Over 12 months		2,693	(9)	2,684	(9)
Provision for contingent liabilities	Asset	Over 12 months	16.1	7,936	3,562	11,498	1,150
Other provisions	Asset	Up to 12 months	15	4,639	851	5,490	1,065
Other	Asset	Up to 12 months		9,281	(110)	9,171	(60)
Consolidation of Odonto System ¹	Asset	Up to 12 months		-	(2,938)	(2,938)	(1,229)
Incorporation of Odonto System ¹	Asset	Up to 12 months		-	-	1,229	-
Amortization of Goodwill	Liability	Over 12 months		-	(4,957)	(4,957)	(4,957)
Deferred income tax/social contribution				41,271	(3,658)	38,842	(3,489)
Consolidation of Odonto System ¹				-	-	-	-
Incorporation of Odonto System ¹				-	-	1,229	-
Deferred income tax				30,347	(2,690)	27,657	(2,565)
Deferred social contribution				10,924	(968)	9,956	(924)
Deferred income tax/social contribution				41,271	(3,658)	38,842	(3,489)

¹Subsidiary incorporated in January 02, 2019.

9.2 Judicial deposits

	Company		Consolidated	
	June 30, 2019	December 31, 2018	June 30, 2019	December 31, 2018
Tax	7,951	1,286	9,840	8,525
Social security and labor	2,037	1,054	2,038	4,315
Civil	3,784	1,405	4,333	1,405
	13,772	3,745	16,211	14,245

9.3 Other receivables

Provision for potential risks determined in the review of accounting, tax and labor procedures of acquired companies (note 12.1), which has a corresponding entry to "other payables" (note 16.3).

	Company		Consolidated	
	June 30, 2019	December 31, 2018	June 30, 2019	December 31, 2018
Prontodente ¹	126	258	126	258
DentalCorp	1,463	1,463	1,463	1,463
Papaiz Group	-	-	1,323	1,323
Odonto System	17,500	-	17,500	17,500
	19,089	1,721	20,412	20,544

¹Corresponds to installment payments of tax debts made in 2017.

According to the agreement with the former owners of acquired companies, in certain circumstances, they guarantee the reimbursement of any payments the Company and its Subsidiaries are required to make. These amounts (except for Odonto System) are deposited in investment funds and CDBs in the name of the former owners who can only use these funds with the Company's and Subsidiaries' authorization in order to avoid any credit risk. The values referring to the Odonto System are assured for the warranty insurance and letter of guarantee.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

9.4 Tax and social security credits

In the Company and in the Consolidated, these amounts correspond to credits related to the 5-year collections prior to the filing of the INSS lawsuit (note 16.1 (b) (i)) in the total amount of R\$85,320 (R\$84,080 as of December 31, 2018), monetarily restated, being R\$18,615 (R\$18,345 as of December 31, 2018) are classified in the current assets (note 8) and R\$66,705 (R\$65,735 as of December 31, 2018) in non-current assets. The compensation of the amounts began in February 2018 and will be completed within 1 year and 6 months, therefore, the compensation of credits of INSS related to the Company's part and also PIS and COFINS could be compensated with this credits.

10. Investments**10.1 Interest in Subsidiaries**

	Interest in Subsidiaries						Joint Ventures	Company
	OdontoPrev			Odonto System ²	Odontored ¹	Total	Brasilidental	Total investments
June 30, 2019	Clídec	Serviços	Rede Dental					
Share capital	12,790	9,700	1,162	-	3,128	-	9,500	-
Quotas/shares	12,790	9,700	1,162	-	3,128	-	380,000	-
Interest (%)	99.9	99.9	99.9	-	60.0	-	25.0	-
Assets	31,360	35,020	6,190	-	27,787	-	49,734	-
Liabilities	9,034	20,872	2,658	-	17,329	-	26,051	-
Equity	21,851	14,479	2,909	-	8,718	-	13,860	-
Net revenue	7,624	26,204	5,808	-	9,762	-	32,749	-
Costs and expenses	6,969	24,739	4,734	-	7,321	-	17,401	-
Taxes and profit sharing	180	1,797	451	-	701	-	5,525	-
Income (loss) for the period	475	(332)	623	-	1,740	-	9,823	-
December 31, 2018	25,512	7,446	3,318	218,684	4,468	259,428	3,465	262,893
Incorporation of Odonto System ¹	-	-	-	(218,684)	-	(218,684)	-	(218,684)
Capital increase	-	7,423	-	-	-	7,423	-	7,423
Put option in subsidiary	(47)	-	-	-	-	(47)	-	(47)
Dividends	(3,615)	-	(1,000)	-	-	(4,615)	-	(4,615)
Revenue (expense) of equity method	475	(332)	623	-	1,045	1,811	2,456	4,267
June 30, 2019	22,325	14,537	2,941	-	5,513	45,316	5,921	51,237

¹For consolidation purposes financial statements with a one-month gap are used (note 1).²Subsidiary incorporated in January 02, 2019.

As of June 30, 2019, the Consolidated investment balance is R\$10,720 (R\$8,054 as of December 31, 2018) corresponding to other investments (note 1), which generated earnings from equity method of accounting as of June 30, 2019 of R\$2,346 (R\$2,271 as of June 30, 2018).

11. Property, plant and equipment

	Company												
	Computer equipment	Vehicles	Facilities	Machinery and equipment	Furniture and fixtures	Communication equipment	Dental care equipment	Buildings	Total for own use	Fixed assets in progress	Leasehold improvements	Right of use (IFRS 16)	Total
December 31, 2018	4,289	786	1,593	327	1,839	951	17	-	9,802	7	1,365	-	11,174
Incorporation of Odonto System ¹	-	-	1,362	333	85	-	-	6,002	7,782	-	823	-	8,605
Reclassification of the effects of IFRS 16	-	-	-	-	-	-	-	-	-	-	-	22,324	22,324
Additions	1,078	130	123	-	3	9	-	-	1,343	-	41	-	1,384
Write-offs	-	(121)	-	-	(1)	-	-	-	(122)	-	-	(79)	(201)
Transfers	(9)	-	(1,416)	(167)	(42)	-	-	(5,859)	(7,493)	-	-	-	(7,493)
Depreciation	(888)	(87)	(180)	(55)	(192)	(86)	-	(143)	(1,631)	-	(656)	(673)	(2,960)
June 30, 2019	4,470	708	1,482	438	1,692	874	17	-	9,681	7	1,573	21,572	32,833
Acquisition cost	18,717	1,686	3,152	1,939	6,425	2,296	429	1,142	35,786	7	11,855	22,928	70,576
Accumulated depreciation	(14,247)	(978)	(1,670)	(1,501)	(4,733)	(1,422)	(412)	(1,142)	(26,105)	-	(10,282)	(1,356)	(37,743)
Net book value	4,470	708	1,482	438	1,692	874	17	-	9,681	7	1,573	21,572	32,833
Annual depreciation rate (%)	20	20	10	10	10	10	10	-	-	-	20	20	-

¹Subsidiary incorporated in January 02, 2019.

(A free translation of the original in Portuguese)

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

	Consolidated												
	Computer equipment	Vehicles	Facilities	Machinery and equipment	Furniture and fixtures	Communication equipment	Dental care equipment	Buildings	Total for own use	Fixed assets in progress	Leasehold improvements	Right of use (IFRS 16)	Total
December 31, 2018	5,072	922	2,973	757	2,581	1,051	611	6,002	19,969	753	3,592	-	24,314
Reclassification of the effects of CPC	-	-	-	-	-	-	-	-	-	-	-	37,465	37,465
Capital increase with assets ²	-	-	-	158	44	-	-	7,221	7,423	-	-	-	7,423
Additions	1,219	130	197	-	14	9	8	-	1,577	-	87	-	1,664
Write-offs	(26)	(97)	(8)	(2)	(39)	-	-	-	(172)	-	-	(79)	(251)
Transfers	(139)	(1)	(1,273)	(168)	114	-	-	(5,859)	(7,326)	-	-	79	(7,247)
Depreciation	(992)	(134)	(205)	(64)	(251)	(94)	(57)	(143)	(1,940)	-	(893)	(1,332)	(4,165)
June 30, 2019	5,134	820	1,684	681	2,463	966	562	7,221	19,531	753	2,786	36,133	59,203
Acquisition cost	20,692	1,853	4,982	2,380	8,208	2,480	2,763	8,363	51,721	753	14,975	38,716	106,165
Accumulated depreciation	(15,558)	(1,033)	(3,298)	(1,699)	(5,745)	(1,514)	(2,201)	(1,142)	(32,190)	-	(12,189)	(2,583)	(46,962)
Net book value	5,134	820	1,684	681	2,463	966	562	7,221	19,531	753	2,786	36,133	59,203
Annual depreciation rate (%)	20	20	10	10	10	10	10	10	-	-	20	20	-

¹Subsidiary incorporated in January 02, 2019.

²Building arising from the incorporation of Odonto System, which was used to increase the capital of OdontoPrev Serviços in June 2019.

12. Intangible assets

12.1 Goodwill on acquisition of investments

	Historical data relating to the acquisition and/or approval					June 30, 2019				December 31, 2018
	Date	Total value	Asset value	Strategic focus	CGU	Date of merger	Goodwill	Amortization ¹	Net goodwill	Net goodwill
Bradesco Dental	10/18/2009	723,392	313,752	Business and individual	Bradesco	07/01/2010	409,640	-	409,640	409,640
Biodent	06/19/2008	2,837	98	Premium segment	Care Plus	12/01/2008	2,739	(319)	2,420	2,420
Care Plus	06/19/2008	13,113	(230)	Premium segment	Care Plus	12/01/2008	13,343	(1,563)	11,780	11,780
SRJSPE	06/26/2008	13,720	(130)	Premium segment	Care Plus	12/01/2008	13,850	(1,616)	12,234	12,234
Rede Dental	10/08/2007	7,584	(119)	Regionalization	Rede Dental	Not merged	7,703	(1,544)	6,159	6,159
OdontoServ ²	02/27/2009	30,841	10,025	Regionalization	OdontoServ	12/01/2009	20,816	-	20,816	20,816
Prontodente	12/22/2008	5,445	(235)	Medium and large companies	OdontoPrev ³	12/01/2009	5,680	-	5,680	5,680
Sepao	10/24/2008	9,203	82	Medium and large companies	OdontoPrev ³	12/01/2009	9,121	(303)	8,818	8,818
DentalCorp	02/09/2007	25,244	386	Small and medium companies	OdontoPrev ³	03/03/2008	24,858	(9,529)	15,329	15,329
Odonto System ⁴	08/07/2018	203,084	4,668	Complementarity portfolio	-	01/02/2019	145,793	-	145,793	-
Company		1,034,463	328,297				653,543	(14,874)	638,669	492,876
Consolidation of Odonto System ⁴	08/07/2018	203,084	4,668	Complementarity portfolio	-	01/02/2019	(145,793)	-	(145,793)	145,793
Incorporation of Odonto System ⁴	08/07/2018	203,084	4,668	Complementarity portfolio	-	01/02/2019	145,793	-	145,793	-
Easy	07/08/2008	3,100	456	Verticalization	-	Not merged	2,644	(265)	2,379	2,379
G2D	08/09/2012	750	416	Verticalization	-	Not merged	334	-	334	334
Papaiz Group	01/31/2013	5,487	780	Verticalization	-	Not merged	6,008	-	6,008	6,008
Consolidated		1,449,968	339,285				662,529	(15,139)	647,390	647,390

¹Amortization on a straight-line basis up to December 31, 2008, after this date impairment tests are performed.

²Includes Adcon merged on May 01, 2014.

³Equivalent to the total result of the Company deducted from Bradesco, Care Plus and OdontoServ CGUs, including Prontodente, Sepao and DentalCorp. Such grouping is due to the strategic focus of these acquisitions being closely related to the commercial and retention activities of OdontoPrev, as well as to the identification of independent cash inflow.

⁴Includes the amounts referring to the brand, clients portfolio and non-competition agreement allocated in the intangible assets incorporated to the Company in January 02, 2019 and shown in Consolidated statements in December 31, 2018.

The Company evaluates its recoverability through impairment tests (note 2.7.4 (a)) for goodwill from acquisitions of investments allocated to cash generating units (CGU's).

The last impairment test was performed in December 31, 2018, in this test we used the income approach through discounted cash flow methodology (value in use) based on the nature of each CGU, existence of financial and operational control, history and availability of financial projections. During the performed tests, the Company concluded that the value in use obtained by applying these assumptions is higher than the book value.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

12.2 System development, software licenses and changes in intangible assets

	Company						
	System development and software licenses	Intangible assets OdontoServ	Intangible assets Odonto System ¹	Total	Goodwill on acquisition of investments	Right of use (IFRS 16)	Total intangible
December 31, 2018	51,080	108	-	51,188	492,876	-	544,064
Incorporation of Odonto System ¹	224	-	49,985	50,209	145,793	-	196,002
Recognition of right of use (IFRS 16)	-	-	-	-	-	23,006	23,006
Reclassification of the effects of IFRS 16	-	-	-	-	-	(22,324)	(22,324)
Additions	9,108	-	-	9,108	-	-	9,108
Transfers	(1)	-	-	(1)	-	-	(1)
Write-offs	(231)	-	-	(231)	-	-	(231)
Amortization	(2,849)	(108)	(4,236)	(7,193)	-	(682)	(7,875)
June 30, 2019	57,331	-	45,749	103,080	638,669	-	741,749
Cost	90,999	8,527	52,623	152,149	653,543	-	805,692
Accumulated amortization	(33,668)	(8,527)	(6,874)	(49,069)	(14,874)	-	(63,943)
Net book value	57,331	-	45,749	103,080	638,669	-	741,749
Amortization period	5 years	Appraisal report	Appraisal report				

¹Subsidiary incorporated in January 02, 2019.

	Consolidated						
	System development and software licenses	Intangible assets OdontoServ	Intangible assets Odonto System ¹	Total	Goodwill on acquisition of investments	Right of use (IFRS 16)	Total intangible
December 31, 2018	54,993	108	49,877	104,978	647,390	-	752,368
Recognition of right of use (IFRS 16)	-	-	-	-	-	38,795	38,795
Reclassification of the effects of IFRS 16	-	-	-	-	-	(37,544)	(37,544)
Additions	9,522	-	-	9,522	-	-	9,522
Transfers	(141)	-	-	(141)	-	-	(141)
Amortization	(3,095)	(108)	(4,128)	(7,331)	-	(1,251)	(8,582)
June 30, 2019	61,279	-	45,749	107,028	647,390	-	754,418
Cost	96,327	8,527	52,623	157,477	662,529	-	820,006
Accumulated amortization	(35,048)	(8,527)	(6,874)	(50,449)	(15,139)	-	(65,588)
Net book value	61,279	-	45,749	107,028	647,390	-	754,418
Amortization period	5 years	Appraisal report	Appraisal report				

¹Subsidiary incorporated in January 02, 2019.**13. Minimum capital and technical reserves**

ANS establishes the rules for recognizing technical provisions and minimum capital requirements, according to RN 209/2009, amended by RNs 227/2010, 243/2010, 290/2012, 313/2012, 393/2015 and Normative Instruction IN 50/2012.

13.1 Minimum capital

- Adjusted minimum equity (AME) represents the minimum amount of net assets, calculated by multiplying the K Factor by the capital base.
- The solvency margin (SM) corresponds to the amount of adjusted equity (AE) sufficient (S) to cover the higher of 0.20 times the sum of the last 12 months premium or 0.33 times the annual average of the last 36 months of indemnifiable claims, net.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

Company: calculation of AME, AE, SM and S		
	June 30, 2019	December 31, 2018
Base capital	8,503	8,503
(x) K Factor ¹	3.23%	3.23%
Adjusted minimum equity (AME)	275	275
Equity	1,066,298	1,027,456
Legal obligations ²	23	38
Equity interests in other operators	(8,862)	(225,467)
Deferred acquisition costs	(22,810)	(22,280)
Prepaid expenses	(2,439)	(1,831)
Intangible assets	(741,749)	(544,064)
Adjusted equity (AE)	290,461	233,852
(A) 0.20 times the sum of the premiums – past 12 months	349,320	311,568
(B) 0.33 times the average of the events – past 36 months	218,212	200,423
Solvency margin (SM) total = higher between (A) and (B)³	349,320	311,568
Sufficiency (insufficiency) total⁴ (AME - SM total)	(58,859)	(77,716)
SM required ⁴ (%)	74.210%	70.520%
SM required ⁴ (R\$)	259,230	219,718
Sufficiency required (AE - SM required)	31,231	14,134

¹K Factor corresponds classification: group dentistry, tertiary sector, region 1 according to annex RN 209/2009.²According to IN 50/2012, the amount of legal obligations refers to the carrying amount of tax legal provisions on December 31, 2012 net of write-offs in periods subsequent to that date (payments between 2013 and 2020).³Total solvency margin should be set up until December 31, 2022 according to RN 313/2012.⁴Required solvency margin as provided for in the scale of dilution according to RN 313/2012.**13.2 Changes in technical reserves**

According to IFRS 4, the changes in reserves related to claims/events (insurance liabilities) and the assets directly related to these contracts are as follows:

	Company				Consolidated			
	Unearned premiums	Unsettled claims	IBNR	DAC¹	Unearned premiums	Unsettled claims	IBNR	Other Provisions
December 31, 2017	136,528	33,182	81,434	15,092	136,608	33,292	82,086	4,340
Consolidation of Odonto System ²	-	-	-	-	4,565	3,944	140	-
Indemnifiable claims, net	-	669,569	-	-	-	676,247	-	-
Paid events	-	(664,399)	-	-	-	(673,915)	-	-
Variation of IBNR	-	-	969	-	-	-	847	-
Unearned premiums	1,618,916	-	-	-	1,678,224	-	-	-
Premiums recognized in income	(1,600,167)	-	-	-	(1,659,519)	-	-	-
Deferred acquisition expenses	-	-	-	24,068	-	-	-	-
Amortized acquisition expenses	-	-	-	(16,880)	-	-	-	-
Insurance recognized in income	-	-	-	-	-	-	-	13,797
Insurance ³	-	-	-	-	-	-	-	(8,273)
Occurred claims	-	-	-	-	-	-	-	2,400
Paid claims ²	-	-	-	-	-	-	-	(925)
December 31, 2018	155,277	38,352	82,403	22,280	159,878	39,568	83,073	11,339
Incorporation of Odonto System ²	4,537	1,124	85	-	-	-	-	-
Indemnifiable claims, net	-	368,058	-	-	-	367,008	-	-
Paid events	-	(358,153)	-	-	-	(357,042)	-	-
Variation of IBNR	-	-	1,106	-	-	-	1,074	-
Unearned premiums	929,313	-	-	-	935,338	-	-	-
Premiums recognized in income	(911,659)	-	-	-	(917,674)	-	-	-
Deferred acquisition expenses	-	-	-	13,524	-	-	-	-
Amortized acquisition expenses	-	-	-	(12,994)	-	-	-	-
Insurance recognized in income	-	-	-	-	-	-	-	9,762
Insurance ³	-	-	-	-	-	-	-	(7,931)
Occurred claims	-	-	-	-	-	-	-	1,196
Paid claims ²	-	-	-	-	-	-	-	(992)
June 30, 2019	177,468	49,381	83,594	22,810	177,542	49,534	84,147	13,374

¹Assets directly related to insurance contracts to Company and Consolidated²Control of Odontored assumed in April 01, 2016 (note 1).³Subsidiary incorporated in January 02, 2019.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

14. Tax obligations (taxes payable)

	Company		Consolidated	
	June 30, 2019	December 31, 2018	June 30, 2019	December 31, 2018
Income tax and social contribution payable	3,292	7,648	3,580	9,140
IRPJ	2,391	5,362	2,598	6,425
CSLL	901	2,286	982	2,715
Other federal tax liabilities	12,329	11,067	16,206	15,652
COFINS	3,147	3,344	3,565	3,519
PIS	511	543	601	580
PIS, COFINS and CSLL (PCC)	1,175	1,060	1,188	1,077
IRRF	5,456	5,369	5,645	5,594
IVA ¹	-	-	3,163	2,345
ANS Fee	860	751	861	752
Tax payments in installments ²	1,127	-	1,127	1,368
Other	53	-	56	417
State tax liabilities	-	-	166	51
Municipal tax liabilities³	8,466	9,343	8,845	9,669
	24,087	28,058	28,797	34,512

¹Tax on added value from Subsidiary Odontored.²Installments made by the Subsidiary Odonto System (note 16.2) incorporated in January 02, 2019.³In January and February 2018, the Company complied with determinations of Complementary Law (LC) 157/2016 which introduced changes in the calculation of ISS, and, since March 2018, the Company is under determination of Unconstitutionality Direct Action (ADI) number 5,835 which suspended temporarily these changes. On September 11, 2018 the Company obtained a first instance injunction to collect ISS over the effective value of the services provided and, in March 2019, the Company obtained favorable final decision (note 16.1 (a) (ii)).**15. Other payables**

	Company		Consolidated	
	June 30, 2019	December 31, 2018	June 30, 2019	December 31, 2018
Other provisions	16,147	13,643	17,234	14,103
Commissions	5,194	4,843	5,194	4,843
IT support and service	1,342	831	1,362	839
Telecommunications	938	516	941	516
Services	2,341	1,461	3,117	1,742
Lease	-	320	-	358
Travel	290	214	526	305
Indemnifiable claims and charges	5,671	4,616	5,671	4,642
Marketing	275	794	282	794
Insurance	96	48	141	64
INSS refund ¹	19,836	23,032	19,836	22,876
Unidentified credits ²	7,228	9,719	7,229	10,172
Other	298	297	977	296
	43,509	46,691	45,276	47,447

¹Refers to amounts to be reimbursed to customers for the success obtained in the lawsuit related to INSS (note 16.1 (b) (i)).²Refers to amounts received from customers and not identified, not exceeding a period of 60 days.**16. Non-current****16.1 Provisions for contingent liabilities**

	Company		Consolidated	
	June 30, 2019	December 31, 2018	June 30, 2019	December 31, 2018
Tax	25,489	17,555	26,664	24,079
Social security and labor	2,877	1,308	3,351	3,829
INSS	389	389	389	389
Other	2,488	919	2,962	3,440
Civil	5,451	4,478	5,718	4,655
	33,817	23,341	35,733	32,563

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

Changes	Company					
	June 30, 2019					
	Tax		Social security and labor			
	TPS ¹	Other	INSS	Other	Civil	Total
Opening balance	13,837	3,718	389	919	4,478	23,341
Incorporation of Odonto System ²	-	5,349	-	2,052	165	7,566
Provision	4,521	3,723	-	323	3,220	11,787
Write-offs	-	(6,195)	-	(806)	(2,569)	(9,570)
Monetary restatement	480	56	-	-	157	693
Provision	18,838	6,651	389	2,488	5,451	33,817
Judicial deposits (note 9.2)	-	(7,951)	(389)	(1,648)	(3,784)	(13,772)
Net provision	18,838	(1,300)	-	840	1,667	20,045
Number of lawsuits						270

¹Corresponds to the provision for payment of TPS as described in item (a) (i).²Subsidiary incorporated in January 02, 2019.

Changes	Consolidated					
	June 30, 2019					
	Tax		Social security and labor			
	TPS ¹	Other	INSS	Other	Civil	Total
Opening balance	13,853	10,226	389	3,440	4,655	32,563
Consolidation of Odonto System ²	-	-	-	-	-	-
Provision	4,520	3,723	-	344	3,603	12,190
Write-offs	-	(6,195)	-	(822)	(2,697)	(9,714)
Monetary restatement	481	56	-	-	157	694
Provision	18,854	7,810	389	2,962	5,718	35,733
Judicial deposits (note 9.2)	-	(9,840)	(389)	(1,649)	(4,333)	(16,211)
Net provision	18,854	(2,030)	-	1,313	1,385	19,522
Number of lawsuits						301

¹Corresponds to the provision for payment of TPS as described in item (a) (i).²Subsidiary incorporated in January 02, 2019.

The amounts related to possible losses not accrued of the Company and its Subsidiaries refers to 73 labor lawsuits, 15 tax lawsuits and 934 civil lawsuits (not related to treatments made to the dental plan beneficiaries). As of June 30, 2019 these lawsuits amounts to R\$71,738 (R\$68,257 at December 31, 2018).

(a) Tax**(i) Regulatory tax per healthcare plan (TPS)**

Through a lawsuit distributed on August 16, 2017, the Company and its Subsidiary Rede Dental filed a petition to waive the mandatory requirement of the Regulatory tax per healthcare plan ("TPS"), authorized by article 20, item I of Law 9,961/2000, as well as reimbursement of amounts paid in the last five years. A decision granting urgency protection (injunction) has already been issued, to determine the suspension of the enforceability of the TPS. Also, on May 07, 2018, a decision was issued considering the lawsuit with grounds to declare the tax to be not applicable, thus sentencing ANS to reimburse the amounts paid since August 16, 2012. ANS has filed an appeal, however, until June 30, 2019, this decision was not yet concluded.

(ii) ISS

On September 11, 2018, the Company obtained an injunction in the first instance to collect the ISS on the effective value of the services rendered, that is, on the balance of the invoiced amount less the onlendings made to the providers of dental services. However, despite the preliminary injunction, the Company chose to collect the amount

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

due as the judicial decision and continue to provision the difference of the amounts in case the final decision in the lawsuit is unfavorable. In March 2019, a favorable decision was reached by the Company, due to this fact, the Company reverted the amount of R\$7,165, plus the already paid amount of R\$6,635 (note 8), totaling R\$13,800 (notes 4.2 and 18).

In the lawsuit filed by the Subsidiary Rede Dental, on October 9, 2018, a decision was passed granting provisional emergency protection to deduct the value of onlendings paid to providers of dental services in determining the ISS calculation base, that is, to collect it on the effective value of the services provided. Despite the preliminary judicial decision, the Company has collected the full amount up to the present moment, but it is being adjusted to the City Hall for the payment under the terms of the decision. The final decision is still pending.

(iii) COFINS

The Subsidiary Clidec filed a lawsuit requesting to pay COFINS as established by Complementary Law LC7/1970 rather than in accordance with Law 9,718/1998, and to offset the difference in amounts paid at the rate of 3% against social contribution. The Company was partially successful, since the increase in the COFINS calculation basis was determined unconstitutional. Clidec awaits the granting of its claim for offsetting amounts due, as a result of the partially valid decision.

(b) Social security and labor

(i) INSS

During the year ended December 31, 2017 the Company received favorable final court decision for a lawsuit filed against the Federal Government, where the right to not pay social security contribution levied on compensations paid to accredited dentists. The amount of R\$85,320 (R\$84,090 as of December 31, 2018) regarding the payments made in the five years prior to the date of filing the lawsuit, was also recorded as a tax credit, for which the Company was successful (notes 8 and 9.4).

Bradesco Dental also has a lawsuit related to compensation paid to independent brokers, whose court decision has been unfavorable to the company, therefore, the remaining balance of R\$389 has been transferred to the Union and the lawsuit is in closing phase.

Subsidiary Rede Dental is also a part to court questioning on the payment of social security contribution levied on the compensation paid to accredited dentists, still in progress in the Judiciary, which remained valid, however, the National Treasury filed Special and Extraordinary Resources, which are pending examination of admissibility. The company regularly makes monthly payments.

(ii) Other

The Company and its Subsidiaries are parts to several labor lawsuits, most of them relating to: (i) recognition of employment relationship; (ii) equal pay; (iii) overtime; (iv) union classification and (v) indemnity.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

(c) Civil claims

The Company and its Subsidiaries are parts to civil lawsuits, mainly involving requests for indemnification for property damages and pain and suffering.

(d) Tax assessment notice on stock options

On August 31, 2015, tax authorities issued assessment notices summarized below, claiming that the Company compensated Managers and Employees who had joined the stock option programs and had exercised that option in calendar years 2010, 2011 and 2012.

(i) Tax credits consisting of social security contributions for calendar years 2010, 2011 and 2012, plus late payment interest and tax deficiency penalty in the amounts of R\$23,113 (company contribution and GILRAT/SAT) and R\$3,735 (third parties), and as of June 30, 2019, the monetarily restated amounts correspond to R\$31,767 and R\$5,133, respectively. The challenge presented was judged by the 9th Panel of DRJ/Ribeirão Preto, partially accepting the appeal to recognize the compensatory nature. The tax credit recorded was maintained, excluding the portion of the benefit corresponding to the shares subject to calculation basis lock-up (note 17.6). Amount after decision: R\$14,971. On June 07, 2016 the Company filed a spontaneous appeal to the Administrative Board of Tax Appeals (CARF). Relying on the opinion of the Company's legal counsel, Management considers that an unfavorable outcome is possible.

(ii) Isolated fine resulting from alleged non-withholding of Withholding Income Tax (IRRF) related to calendar years 2010, 2011 and 2012, in the total amount of R\$14,425. The challenge presented was judged by the 3rd Panel of DRJ/Ribeirão Preto, partially accepting the appeal to recognize the compensatory nature. The tax credit recorded was maintained, excluding the portion of the benefit corresponding to the shares subject to calculation basis lock-up. Amount after decision: R\$5,843. On December 27, 2016, the Company filed a spontaneous appeal to CARF. Relying on the opinion of the Company's legal counsel, Management considers that an unfavorable outcome is remote.

(f) Stock options court guarantee insurance

The Company, in compliance with decision made at the Board of Directors' Meeting held on March 28, 2017, contracted a court guarantee insurance in order to beneficiaries guarantee and support obligations of lawsuits of the Company and of beneficiaries of the stock option plan approved in a General Meeting of Shareholders (which have or will have seized assets or assets under restriction and/or that are required for court discussion), as a result of legal and administrative procedures started by tax authorities as a result of exercise of options by beneficiaries mentioned above. The amount insured by such policies is R\$5,243.

16.2 Other provisions - Installments of debts from taxes and social contributions

Installments of debts referring from different federal taxes and social security contributions of the Subsidiary Odonto System to be settled until September, 2024, being classifieds on current liabilities R\$1,127 (note 14) and R\$3,455 on non-current liabilities.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

16.3 Other liabilities

	Company		Consolidated	
	June 30, 2019	December 31, 2018	June 30, 2019	December 31, 2018
Prontodente ¹	123	258	123	258
DentalCorp	813	813	813	813
Papaiz Group	-	-	1,323	1,323
Odonto System	17,118	-	17,118	17,500
	18,054	1,071	19,377	19,894

¹Corresponds to installments of tax debts made in 2017.**16.4 Put option in Subsidiary**

Company and Consolidated (put option - accounting in accordance with IAS 32.23)							
Shareholders' Agreement				Accounting			
Company (note 1)	Subsidiary (note 1)	Exercise date	Assumptions	Account	Counterpart (note 17.2)	June 30, 2019	December 31, 2018
			(a) base strike price of the option: greater amount of (i) capital contributions made by minority up to option exercise date x 3; (ii) 9 x EBITDA for the 12 months preceding the date of exercise; (b) discount rate: Mexican government bonds remuneration rate used (8.01% p.y.); (c) conversion rate: equivalent to Brazilian Real x Mexican Peso; (d) prospective changes in the present value of strike price are recorded directly in equity.	Put option in Subsidiary (Non- current liabilities)	Other capital reserves (Equity)		
OdontoPrev	Odontored	04/01/2019				27,238	26,358
			(a) Price is equivalent to 4 x EBITDA for the last 12 months preceding the exercise notification plus debits and deducted from cash and cash equivalents; (b) discount rate: CDI Fixed Long Term (720 days) - (12.20% p.y.)	Put option in Subsidiary (Non- current liabilities)	Other capital reserves (Equity)		
Clidec	Clidec Participações	During the year 2021				1,088	1,041
						28,326	27,399

16.5 Investment payable

According to the Odonto System purchase agreement, OdontoPrev retained R\$17,500 (R\$17,500 as of December 31, 2018) which R\$3,500 have been classified in current liabilities and R\$14,000 in non-current liabilities (R\$3,500 and R\$14,000 as of December 31, 2018), to assure the obligation to indemnify the sellers. The amounts will be settled in 5 years corresponding to 20% on each anniversary of the contract.

17. Equity**17.1 Share capital**

	Company	
	June 30, 2019	December 31, 2018
Subscribed and paid-up capital (R\$ thousands)	607,869	506,557
Common shares with no par value (number of shares)	531,294,792	531,294,792
Article 8 of Bylaws - authorization to issue shares, with no changes in the Bylaws (number of shares)	80,000,000	80,000,000
Closing price: ODPV3 - B3 S.A. Brasil Bolsa Balcão (R\$/share)	18.26	13.75
Book value (R\$/share)	2.01	1.93

17.2 Capital reserves

	Company and Consolidated	
	June 30, 2019	December 31, 2018
Goodwill on the issue of shares	48,392	48,392
Stock option plan	(13,354)	(11,787)
Options granted	13,030	16,313
Deferral of granted stock options	(1,050)	(3,019)
Additional paid-up capital	(25,334)	(25,081)
Other capital reserves	(28,326)	(27,399)
	6,712	9,206

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

Options granted: amounts from 7th, 9th and 10th as well the amount estimated from 11th and 12th grants of options, using the Black & Scholes methodology (note 17.6).

Deferral of granted stock options: amount estimated from 11th and 12th grants of options to be appropriated to the remaining vesting period (note 17.6).

Additional paid-up capital: amount of the difference between the constitution estimated by the Black & Scholes methodology and the amount of the exercise from 1st to 10th grants of options.

Other capital reserves: counter entry of the put option recorded in non-current liabilities (note 16.4).

17.3 Retained earnings

	Company and Consolidated	
	June 30, 2019	December 31, 2018
Legal reserve	-	101,312
Statutory reserve of regulatory capital	202,623	202,623
Reserve for investments and expansion	202,623	202,623
Tax incentive reserve	129	129
	405,375	506,687

Legal reserve: this reserve must be recorded by the Company through the allocation of 5% of the income for the year, up to 20% of the share capital.

The General Meeting in April 01, 2019 approved the capitalization of the legal reserve in the amount of R\$101,312 due to the fact that the Company reached the legal limits to measure and record reserves without new stock emissions (article 169, 1^o paragraph of the Law 6,404/1976 and amendments). This procedure will assure the capital's integrity as well the Company will have new possibilities to distribute its financial resources to the legal reserve.

Statutory reserve of regulatory capital: Constituted by the Company, with the allocation of up to 50% of the net income of the year, limited to 40% of the share capital, whose purpose and objective is to meet the capital requirement regulation related to the solvency margin required by ANS.

Reserve for investment and expansion: Constituted by the Company, with the allocation of up to 50% of the net income of the year, limited to 40% of the share capital, whose purpose and objective is to finance the development, growth and expansion of the Company's business, allowing the realization of new investments, including acquisitions of software and hardware, investments in facilities and equipment, acquisition of equity interests, business units and commercial establishments.

17.4 Treasury shares

On May 29, 2019, the Board of Directors authorized the acquisition of 2,716,074 shares issued by the Company, through the use of funds recorded in a income retention reserve for the purpose of backing 100% of the stock options granted in 2016 (11th and 12th). Until June 30, 2019, 1,389,900 shares had been acquired, amounting to R\$22,627, for an average purchase price of R\$16.28 and 91,205 shares were cancelled due to terminations of employment relationships. The remaining balance of 1,234,969 will be available for repurchase until October 15, 2019.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

The balance of treasury shares at June 30, 2019 is R\$29,330 equivalent to 1,844,214 shares (R\$17,012 equivalent to 1,153,040 shares at December 31, 2018).

17.5 Deliberations

						Company	
		Ex-Date	Deliberation		Payment date	Period ended	
Approval	Type		Earnings per share (R\$)			2019	2018
BDM	Interest on capital	03/12/2018	0.02847		04/04/2018	-	15,096
BDM	Interest on capital	06/13/2018	0.02712		07/04/2018	-	14,332
BDM	Interest on capital	09/21/2018	0.02737		10/05/2018	-	14,464
BDM	Interest on capital	12/18/2018	0.02522		01/09/2019	-	15,735
BDM	Interest on capital	03/18/2019	0.03323		05/03/2019	17,636	-
BDM	Interest on capital	06/17/2019	0.02989		07/03/2019	15,831	-
Interest on capital						33,467	59,627
BDM	Dividends	07/25/2018	0.05281		09/05/2018	-	27,909
BDM	Dividends	12/18/2018	0.10952		01/09/2019	-	58,064
BDM	Dividends	05/02/2019	0.09529		05/16/2019	50,565	-
BDM	Dividends	08/01/2019	0.05243		09/04/2019	27,761	-
Interim dividends						78,326	85,973
AGOM	Additional dividend to the compulsory minimum	04/01/2019	0.01081		05/03/2019	-	5,741
Additional dividend to the compulsory minimum						-	5,741
AGOM	Additional dividend proposed	04/01/2019	0.04149		05/03/2019	-	22,018
Additional dividend proposed						-	22,018
Total deliberated						111,793	173,359

*In the AGOM occurred in April 01, 2019, the additional dividend complementary was approved, the amount is composed by R\$11,417 from income of the year ended December 31, 2018 and R\$10,601 from earnings reserve totaling R\$22,018.

BDM = Board of Directors Meeting.

AGOM = Annual General and Ordinary Meeting.

17.6 Stock option plan

At the Extraordinary General Meeting held on April 19, 2007, stockholders approved the creation of the stock option plan (the Plan) pursuant to article 19 - XVIII of the Company's Bylaws, designated for the employees and officers of the Company and its Subsidiaries, which was amended by Extraordinary General Meeting (EGM) held on May 20, 2015. The Plan is managed by the Board of Directors, with powers to take the required actions for its maintenance, according to the approved guidelines. Options granted under the Plan are limited to 5% of capital.

			Grants awarded	
Stock option plan definitions	1st to 8th		9th a 12th	
	(2007 to 2014)		(2015 onwards)	
Strike price	Monetarily restated by IGP-M of Fundação Getúlio Vargas, after deduction of remuneration paid to shareholders Its settlement will be made with the beneficiary's own resources		Monetary restatement and deductions no longer apply Its settlement will be made with the beneficiary's own resources	
Vesting period (permanence of the beneficiary in the Company)	3 years from the date of granting of the options		3 years from the date of granting of the options	
Deadline for exercising	6 years, with full or partial exercise with written communication 1 month in advance of each BDM or term communicated		5 years, with full or partial exercise with written communication 1 month in advance of each BDM or term communicated	
Lock-up (blocking period)	3 years from the exercise date of the option		2 years from the exercise date of the option	

The table below presents twelve plan grants from 2007 to 2016, as well as the fair value of established benefit, estimated based on Black & Scholes option pricing model (methodology that considers volatility, share strike prices and share market price, grace period, risk-free discount rate among others):

(A free translation of the original in Portuguese)

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

Nº	Year	Date of approval	Recommendation ¹	Approval	Original			Grants After split ²			Risk-free rate (%)	Expected annualized volatility (%)	Fair value per unit of benefit (R\$)	
					Quantity	Strike price	Market price	Quantity	Strike price	Market price			Original	After split ⁴
1st	2007	08/02/2007	P	BD	221,859	44.85	53.79	2,662,308	3.74	4.48	11.3	33.9	20.18	1.68
2nd	2008	02/28/2008	P	BD	353,494	32.42	45.85	4,241,928	2.70	3.82	11.4	24.3	19.72	1.64
3rd	2009	03/25/2009	P	BD	255,002	17.60	24.30	3,060,024	1.47	2.03	9.3	40.6	14.17	1.18
4th	2010	08/11/2010	HRC	BD	698,707	12.93	16.88	2,096,121	4.31	5.63	4.0	26.6	7.00	2.33
5th	2011	09/20/2011	HRC	BD	583,815	20.87	28.20	1,751,445	6.96	9.40	5.3	30.1	13.23	4.41
6th	2012	09/20/2012	HRC	BD	1,609,097	8.22	11.60	1,609,097	8.22	11.60	0.4	36.1	5.01	5.01
7th	2013	08/20/2013	HRC	BD	3,000,000	7.44	9.25	3,000,000	7.44	9.25	5.1	36.2	3.66	3.66
8th	2014	02/25/2014	P	BD	228,497	7.30	8.70	228,497	7.30	8.70	5.7	33.4	3.25	3.25
9th	2015	05/26/2015	HRC	BD	2,679,397	10.79	11.31	2,679,397	10.79	11.31	12.9	28.2	4.43	4.43
10th	2015	11/19/2015	HRC	BD	2,572,186	9.81	10.18	2,572,186	9.81	10.18	15.4	27.3	4.29	4.29
11th	2016	07/01/2016	HRC	BD	392,680	11.41	13.55	392,680	11.41	13.55	12.2	29.5	6.03	6.03
12th	2016	10/26/2016	P/HRC	BD	2,889,498	13.03	12.35	2,889,498	13.03	12.35	11.4	29.2	4.04	4.04
								27,183,181						

P = President / BD = Board of Directors / HRC = Human Resources Committee.

¹In the first seven grants Randal Luiz Zanetti (former President since April 01, 2014 and President of the Board of Directors until April 02, 2019) was voluntarily a non-beneficiary.

²Splitting of shares of July 01, 2010 and April 02, 2012.

An expense was recognized on stock option plans due to the end of the vesting period, with the corresponding entry made to equity in a specific capital reserve account, for the amount of R\$1,697 as of June 30, 2019 (R\$5,116 as of June 30, 2018).

Year	Beginning of the period				Cancellations		Options exercised		End of period	
	Eligible	Options	Options 'fair value	Maximum cost(R\$ mil)	Eligible terminated	Canceled Options ¹	Eligible	Exercised Options ²	Eligible	Existing Options
2007	31	2,662,308	1.68	4,477	10	989,304	21	1,673,004	-	-
2008	46	4,241,928	1.64	6,970	9	977,544	37	3,264,384	-	-
2009	51	3,060,024	1.18	3,614	10	839,916	41	2,220,108	-	-
2010	47	2,096,121	2.33	4,894	8	199,803	39	1,896,318	-	-
2011	45	1,751,445	4.41	7,726	7	221,174	38	1,530,271	-	-
2012	51	1,609,097	5.01	8,055	12	358,112	39	1,250,985	-	-
2013 ³	52	3,000,000	3.66	10,994	12	672,650	39	2,293,731	1	33,619
2014	1	228,497	3.25	742	-	-	1	228,497	-	-
2015	47	2,679,397	4.43	11,858	7	395,749	35	2,102,250	5	181,398
2015	57	2,572,186	4.29	11,030	10	404,111	46	2,100,539	1	67,536
2016	1	392,680	6.03	2,367	-	-	-	-	1	392,680
2016	59	2,889,498	4.04	11,674	12	549,693	-	-	47	2,339,805
						5,608,056		18,560,087		3,015,038

¹The total amount of grants deducted from cancellations is 21,730,515 shares representing 4.1% of the total capital of 531,294,792 shares.

²Disposal approved by BD.

³Option partially exercised by the beneficiary.

18. Operating segments

The activities of the Company and its Subsidiaries are organized in the following business segments:

- (a) **Corporate:** include customers over 200 beneficiaries;
- (b) **Small and Medium Sizes (SMS):** customers sized between 3 and 199 beneficiaries;
- (c) **Individual:** monthly and annual plans sold to individuals;
- (d) **Others:** several less significant segments to the Company's total revenue: (i) dental care service in the Company's dental clinics (Clidec); (ii) management and advisory services provided (Odontoprev Serviços); (iii) acquisition and distribution of dental care materials for the accredited network (Dental Partner); (iv) software development (Easy); and (v) dental insurance (Odontored).

(A free translation of the original in Portuguese)

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

	Contribution margin by operating segment - Consolidated									
	CORPORATE		SMS		INDIVIDUAL		OTHERS		TOTAL	
	Period ended June 30,		Period ended June 30,		Period ended June 30,		Period ended June 30,		Period ended June 30,	
	2019	2018	2019	2018	2019	2018	2019	2018	2019	2018
Net premiums with dental care plan	530,448	493,061	151,866	125,368	235,360	161,389	-	-	917,674	779,818
Taxes on dental care plan operations ²	(21,487)	(23,648)	(7,531)	(6,978)	(12,871)	(10,704)	-	-	(41,889)	(41,330)
Revenue from sales and services	-	-	-	-	-	-	8,320	6,910	8,320	6,910
Taxes on sales of good and services	-	-	-	-	-	-	(6,560)	(4,705)	(6,560)	(4,705)
Insurance	-	-	-	-	-	-	9,762	4,954	9,762	4,954
SALES REVENUE	508,961	469,413	144,335	118,390	222,489	150,685	11,522	7,159	887,307	745,647
Cost of services ¹	(250,400)	(235,375)	(54,906)	(47,269)	(73,735)	(42,628)	(1,207)	(804)	(380,248)	(326,076)
OPERATING RESULT	258,561	234,038	89,429	71,121	148,754	108,057	10,315	6,355	507,059	419,571
Selling expenses	(34,532)	(28,397)	(18,512)	(14,272)	(48,870)	(37,121)	(307)	(170)	(102,221)	(79,960)
CONTRIBUTION MARGIN	224,029	205,641	70,917	56,849	99,884	70,936	10,008	6,185	404,838	339,611
Sales revenue (%)	57.4	63.0	16.3	15.9	25.1	20.2	1.3	1.0	100.0	100.0
Margin x sales revenue (%)	44.0	43.8	49.1	48.0	44.9	47.1	86.9	86.4	45.6	45.5
Margin x total (%)	55.3	60.6	17.5	16.7	24.7	20.9	2.5	1.8	100.0	100.0

¹Do not include incurred but not reported events (IBNR) and claims reserves (note 18).

²Do not include R\$13,800 related to reversion of provision for ISS calculated over the amounts of events through favorable decision received by the Company in March, 2019.

19. Sales revenue

	Company		Consolidated	
	Period ended June 30,		Period ended June 30,	
	2019	2018	2019	2018
Net premiums with dental care plan	911,659	773,861	917,674	779,818
Taxes on dental care plan operations ¹	(27,731)	(40,989)	(28,089)	(41,330)
Net premiums with dental care plan	883,928	732,872	889,585	738,488
Sales of goods and services	-	-	8,320	6,910
Taxes on sales of good and services	-	-	9,762	4,954
Insurance	-	-	(6,560)	(4,705)
	883,928	732,872	901,107	745,647

In March, 2019 the Company reverted R\$13,800 related to provision for ISS calculated over the amounts of events through favorable decision received.

20. Cost of services

	Company		Consolidated	
	Period ended June 30,		Period ended June 30,	
	2019	2018	2019	2018
Indemnifiable claims, net	(368,058)	(313,376)	(367,008)	(311,650)
Social charges on services	40	-	34	(7)
Dental care materials	(8,411)	(6,540)	(4,146)	(3,623)
Other operating costs	(3,062)	(4,908)	(7,921)	(9,992)
Operating materials	(1,837)	(3,023)	(1,838)	(3,054)
Own units	-	-	(4,885)	(5,034)
(Provisions)/reversals	(1,225)	(1,885)	(1,198)	(1,904)
Variation in IBNR	(1,106)	1,604	(1,074)	1,633
Claims and technical reserve	-	-	(1,196)	(771)
	(380,597)	(323,220)	(381,311)	(324,410)

21. Selling expenses

Refer to commissions paid to independent brokers and other distribution channels. As of June 30, 2019, these expenses totaled R\$101,200 and R\$102,221 (R\$79,773 and R\$79,960 as of June 30, 2018) in the Company and Consolidated.

(A free translation of the original in Portuguese)

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

22. Administrative expenses (AE)

	Company		Consolidated	
	Period ended June 30,		Period ended June 30,	
	2019	2018	2019	2018
Personnel and third-part services	(90,324)	(72,545)	(92,040)	(76,585)
Rentals and occupancy	(16,615)	(13,757)	(20,007)	(17,054)
Publicity and advertising	(7,893)	(7,838)	(8,348)	(8,150)
Taxes	(6,162)	(5,484)	(6,360)	(5,693)
Depreciation and amortization	(9,479)	(3,966)	(10,164)	(4,722)
Amortization of right of use - IFRS 16	(1,356)	-	(2,583)	-
Other	(2,723)	(3,248)	(3,375)	(3,744)
	(134,552)	(106,838)	(142,877)	(115,948)

23. Financial results, net

	Company		Consolidated	
	Period ended June 30,		Period ended June 30,	
	2019	2018	2019	2018
Income from financial investments	13,879	15,032	14,352	15,414
Monetary restatement of INSS 5 previous years	44	1,359	54	1,359
Monetary restatement of judicial deposits	1,240	107	1,240	107
Other	1,005	604	1,210	732
Financial income	16,168	17,102	16,856	17,612
Bank fees	(2,298)	(1,897)	(2,312)	(1,907)
Present value adjustments (PVA) of IFRS 16	(1,280)	-	(2,039)	-
Monetary restatement of provision of contingent liabilities	(693)	(297)	(694)	(312)
Monetary restatement over INSS reimbursement	(312)	(551)	(312)	(551)
Other	(979)	(857)	(1,054)	(915)
Financial expenses	(5,562)	(3,602)	(6,411)	(3,685)
	10,606	13,500	10,445	13,927

24. Income tax and social contribution calculation

	Company		Consolidated	
	Period ended June 30,		Period ended June 30,	
	2019	2018	2019	2018
IRPJ and CSLL calculation basis	228,030	204,028	230,150	205,033
(x) Current rate (%)	34	34	34	34
Expected income tax and social contribution expenses at the effective rate	(77,530)	(69,370)	(78,251)	(69,711)
Effect of income tax and social contribution on permanent/temporary differences:				
Earnings of equity method	1,364	1,170	764	772
Contingent liabilities (tax, social security, labor and civil) (note 9)	(727)	(1,811)	(817)	(1,801)
Allowance for doubtful accounts (note 9)	693	(346)	688	(344)
Other provisions (note 9)	(3,302)	340	(3,619)	304
Amortization of Goodwill (note 9)	4,957	-	4,957	-
Interest on capital	11,379	10,005	11,379	10,005
Stock option plan	(577)	(1,739)	(577)	(1,739)
Other	(925)	133	(636)	525
Current IRPJ and CSLL	(64,668)	(61,618)	(66,112)	(61,989)
Deferred IRPJ and CSLL	(3,658)	(100)	(3,489)	(718)
IRPJ and CSLL total expenses	(68,326)	(61,718)	(69,601)	(62,707)
Effective rate	-30.0%	-30.2%	-30.2%	-30.6%

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

25. Earnings per share

(a) Basic

	April to June		Period ended at	
	2019	2018	2019	2018
Profit assigned to the Company's shareholders (R\$ thousand)				
Weighted average number of common shares outstanding (thousands)	62,274	60,344	159,704	142,310
Basic earnings per share (R\$)	530,442	527,929	530,442	528,469
	0.11740	0.11430	0.30108	0.26929

(b) Diluted

	April to June		Period ended at	
	2019	2018	2019	2018
Profit assigned to the Company's shareholders (R\$ thousands)	62,274	60,344	159,704	142,310
Common shares (thousands)				
Weighted average number of outstanding shares	530,442	527,929	530,442	528,469
Adjustment of stock option plan	3,015	5,858	3,015	5,858
Weighted average number of shares for the diluted earnings per share	533,457	533,787	533,457	534,327
Diluted earnings per share (R\$)	0.11674	0.11305	0.29938	0.26634

26. Right of use and lease liability – adoption of IFRS16

The Company and its Subsidiaries adopted the IFRS 16 – Leases and recorded its effects since January 01, 2019, however, the comparative position was not presented for the year 2018 as allowed by the IFRS transition rules.

The Company and its Subsidiaries recorded lease liabilities related to the property rentals formerly classified as operational leases according to assumptions of IAS 17 – Leases. These liabilities were measured considering the present value of future leases payments, discounted used the average rate of 9.4%, which refers to the rate used by the Company in its projections, and the counterpart was recorded as right of use in asset. The measured impacts of the adoption are presented below:

	Classification	Company	Consolidated
		June 30, 2019	June 30, 2019
Right of use	Non current asset	22,928	38,716
Accumulated amortization	Non current asset	(1,356)	(2,583)
		21,572	36,133
Lease liability	Current liability	2,742	5,769
Present value adjustments (PVA)	Current liability	(2,364)	(3,874)
		378	1,895
Lease liability	Non current liability	29,150	47,520
Present value adjustments (PVA)	Non current liability	(7,705)	(12,106)
		21,445	35,414

(A free translation of the original in Portuguese)

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

27. Related parties

		Transactions with Subsidiaries and Associates (note 1)						
Assets/(Liabilities)	Nature	OdontoPrev	Cildec	OdontoPrev Serviços	Easy	Dental Partner	Rede Dental	Brasilidental
Other receivables	Administrative services	5,341	-	859	-	1,273	-	-
Suppliers of goods and services	Administrative services	(1,273)	-	-	-	-	(341)	(5,859)
Revenue/(Expenses)								
Net premiums with dental care plan	Dental care plans	59	-	-	-	-	-	-
Net premiums with dental care plan	Assumed/transferred co-responsibility	29,304	-	-	-	-	-	(27,442)
Cost of services	Dental care services and materials	-	(14)	-	-	-	-	-
Revenue from sales and services	Administrative services	-	6,505	24,842	-	9,011	-	-
Indemnifiable claims, net	Dental care services	(3,450)	-	-	-	-	(1,862)	-
Dental care materials	Dental care materials	(8,762)	(249)	-	-	-	-	-
Administrative expenses	Administrative services	(27,870)	-	(44)	(28)	-	-	-
June 30, 2019		(10,719)	6,242	24,798	(28)	9,011	(1,862)	(27,442)
June 30, 2018		15,076	6,431	15,685	(33)	(7,009)	(1,980)	(28,170)

The Company and its Subsidiaries conduct transactions with companies of the Bradesco Group, of which Bradesco Saúde, shareholder of OdontoPrev, is part.

			Consolidated	
			June 30,	
Transaction	Companies related with the Bradesco Group	Nature	2019	2018
Assets/(Liabilities)				
Cash and cash equivalents	Banco Bradesco S.A.	Cash account	5,184	5,493
Financial investments	Banco Bradesco S.A.	Financial investments	431,805	507,889
Considerations receivable	Banco Bradesco S.A.	Considerations receivable	4,765	5,172
Trade receivables	Bradesco Capitalização S.A.	Capitalization certificates	-	85
Suppliers of goods and services	Bradesco Vida e Previdência S.A.	Life insurance for employees	(141)	(51)
Suppliers of goods and services	Bradesco Cartões S.A.	Travel expenses	(526)	(273)
Suppliers of goods and services	Bradesco Saúde S.A.	Medical care - employees	(1,103)	-
Revenue/(Expenses)				
Net premiums with dental care plan	Banco Bradesco S.A.	Revenue from sales	29,687	31,398
Other operating revenue	Mediservice	Administration fees	283	352
Selling expenses	Bradseg Promotora de Vendas S.A.	Commissions	(8,418)	(7,677)
AE - Personnel and third-part services	Banco Bradesco S.A.	Bookkeeping expenses	(53)	(35)
AE - Personnel and third-part services	Bradesco Saúde S.A.	Medical assistance for employees	(5,124)	(4,838)
AE - Personnel and third-part services	Bradesco Vida e Previdência S.A.	Life insurance for employees	(181)	(156)
AE - Rentals and occupancy	Banco Bradesco S.A.	Rental expenses	(41)	(314)
AE - Other	Banco Bradesco Cartões S.A.	Travel expenses	(931)	(1,938)
AE - Other	Bradesco Auto Re Cia de Seguros	Insurance expenses	(104)	(74)
Financial expenses	Banco Bradesco S.A.	Financial investments management	(61)	(113)
Financial expenses	Banco Bradesco S.A.	Banking expenses	(1,229)	(1,208)
Financial income	Banco Bradesco S.A.	Financial investments income	13,647	14,509
Donation	Fundação Bradesco	Donation	(266)	(175)
			27,209	29,731

As mentioned in note 16.1 (e), the Company contracted a court guarantee related to the tax assessment notices on stock options, the insurance policies were hired together with Swiss Re Corporate Solutions Brasil Seguros S/A ("Swiss Re Brasil"), which has a Joint Venture with Bradesco Seguros S/A ("Bradesco Seguros").

The Company and its Subsidiaries pay profit sharing to their employees and Administrators, subject to the achievement of operational goals and specific objectives, established and approved at the beginning of each year. As of June 30, 2019, the profit sharing was recognized in the amounts of R\$7,120 (R\$5,517 as of June 30, 2018) and R\$9,379 (R\$6,286 as of June 30, 2018), for the Company and Consolidated.

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

In 2019, the Company implemented a long-term incitement program (ILP Program), which establishes the criteria for payment of cash bonuses, corresponding to salary multiples, to be made by the Company and its Subsidiaries to the eligible beneficiaries after the measurement period, since the goals and conditions established in the terms are met. The stock option program remains in effect, as approved by the Shareholders' Meeting, with the last granting being made in 2016.

The measurement period corresponds to 3 years and the payment is conditioned to the achievement of corporate performance goals established by the Board of Directors and the service condition.

On an exceptional basis, for the first and second concessions of the ILP Program, the year of 2019 and the years of 2019 and 2020 will be considered as cumulative period, with the remaining conditions established.

As of June 30, 2019, the long-term incitement program was recognized in the amounts R\$7,356 and R\$,144 for the Company and Consolidated.

The annual fixed compensation attributed to the Board of Directors and the Fiscal Council and the fixed/variable attributed to Board of Directors are as follows:

	Period ended June 30,	
	2019	2018
Statutory Board	5,597	5,505
Pro-labore	2,383	2,523
Benefits	232	243
Bonuses	2,982	2,739
Board of Directors	713	795
Pro-labore	713	795
Supervisory Board	166	166
Pro-labore	166	166
	6,476	6,466

The members of the Statutory Board hold stock options in accordance with the stock option plan (note 17.6):

Year	Beginning of the period		Cancellations		Options exercised		End of the period	
	Eligible	Options	Eligible terminated	Canceled Options	Eligible	Exercised Options	Eligible	Existing Options
2007	6	1,285,488	3	584,424	3	701,064	-	-
2008	5	1,397,592	2	488,916	3	908,676	-	-
2009	7	1,378,356	3	678,084	4	700,272	-	-
2010	5	787,521	-	-	5	787,521	-	-
2011	5	533,829	1	126,934	4	406,895	-	-
2012	7	617,288	1	100,000	6	517,288	-	-
2013	7	1,202,331	1	212,264	6	990,067	-	-
2014	1	228,497	-	-	1	228,497	-	-
2015 ¹	7	1,160,215	1	94,057	5	1,019,024	1	47,134
2015	8	1,128,360	1	89,658	7	1,038,702	-	-
2016	1	392,680	-	-	-	-	1	392,680
2016	7	1,029,342	1	130,677	-	-	6	898,665
		11,141,499		2,505,014		7,298,006		1,338,479

¹Option partially exercised by the beneficiary.

(A free translation of the original in Portuguese)

Odontoprev S.A.

Notes to the interim financial statements (Company and Consolidated)

As of June 30, 2019 and 2018 and December 31, 2018

(All amounts in thousands of Brazilian Reais unless otherwise stated)

The Board of Directors and Fiscal Council, as well the Audit Committee and the Human Management Committee include members of the Directory of Bradesco Seguros.

The Company does not sponsor a supplementary pension plan or any other post-employment benefit or termination of employment contract.

28. Insurance

The policy of the Company and of its Subsidiaries is to maintain sufficient insurance coverage to cover the risks involved, as follows:

	Consolidated	
	Period ended June 30,	
	2019	2018
Building	50,956	50,956
Machinery, furniture and fixtures	29,255	29,255
Property damages	80,211	80,211
Loss of profits	137,504	137,504
Directors & Management liability insurance	60,000	60,000
	277,715	277,715

29. Subsequent events

The Board of Directors' Meeting held at August 01, 2019 has approved the distribution of R\$27,761 as interim dividends of the year 2019 to be paid at September 04, 2019.

Comments on the Behavior of Business Projections

The Company has no practice to disclose financial projections.

(A free translation of the original in Portuguese)

Interim Financial Statements - 06/30/2019 - ODONTOPREV S.A.

Other relevant information

Shareholders with more than 5%

SHAREHOLDERS HOLDING MORE THAN 5% OF THE COMPANY'S SHARES						
Position at 06/30/2019						
Shareholder	Common shares		Preferred shares		Total	
	Number	%	Number	%	Number	%
Bradesco Saúde S.A.	265,648,397	50.01	-	-	265,648,397	50.01
Treasury shares	1,844,214	0.35	-	-	1,844,214	0.35
Outstanding shares	263,802,181	49.64	-	-	263,802,181	49.64
Total	531,294,792	100.00	-	-	531,294,792	100.00

DISTRIBUTION OF THE COMPANY'S CAPITAL (COMPANY SHAREHOLDERS) DOWN TO THE INDIVIDUAL HOLDINGS						
Name: Bradesco Saúde S.A.						
Position at 06/30/2019						
Shareholder	Common shares		Preferred shares		Total	
	Number	%	Number	%	Number	%
Bradesco Seguros S.A.	20,870,945	100.00	-	-	20,870,945	100.00

DISTRIBUTION OF THE COMPANY'S CAPITAL (COMPANY SHAREHOLDERS) DOWN TO THE INDIVIDUAL HOLDINGS						
Name: Bradesco Seguros S.A.						
Position at 06/30/2019						
Shareholder	Common shares		Preferred shares		Total	
	Number	%	Number	%	Number	%
Bradseg Participações S.A.	724,802	93.59	-	-	724,802	93.59
Others	49,612	6.41	-	-	49,612	6.41
Total	774,414	100.00	-	-	774,414	100.00

DISTRIBUTION OF THE COMPANY'S CAPITAL (COMPANY SHAREHOLDERS) DOWN TO THE INDIVIDUAL HOLDINGS						
Name: Bradseg Participações S.A.						
Position at 06/30/2019						
Shareholder	Common shares		Preferred shares		Total	
	Number	%	Number	%	Number	%
Banco Bradesco S.A.	7,766	97.20	-	-	7,766	97.20
Tapajós Holding Ltda	224	2.80	-	-	224	2.80
Total	7,990	100.00	-	-	7,990	100.00

*According to the Reference Form of May, 2019 available in Bradesco's Bank Investors Relationship website.

DISTRIBUTION OF THE COMPANY'S CAPITAL (COMPANY SHAREHOLDERS) DOWN TO THE INDIVIDUAL HOLDINGS						
Name: Banco Bradesco S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Number	%	Number	%	Number	%
Cidade de Deus Cia Cial Participações	1,837,129,968	45.56	970,801	0.02	1,838,100,769	22.79
Fundação Bradesco	687,056,074	17.04	-	-	687,056,074	8.52
NCF participações S.A.	339,512,264	8.42	89,988,708	2.23	429,500,972	5.33
Others	1,161,573,799	28.81	3,916,065,553	97.13	5,077,639,352	62.97
Treasury shares	6,692,963	0.17	24,889,584.00	0.62	31,582,547	0.39
Total	4,031,965,068	100.00	4,031,914,646	100.00	8,063,879,714	100.00

DISTRIBUTION OF THE COMPANY'S CAPITAL (COMPANY SHAREHOLDERS) DOWN TO THE INDIVIDUAL HOLDINGS						
Name: Cidade de Deus Cia Cial Participações						
Shareholder	Common shares		Preferred shares		Total	
	Number	%	Number	%	Number	%
Fundação Bradesco	2,776,765,252	35.41	-	-	2,776,765,252	35.41
Nova Cidade de Deus Participações S.A.	3,755,570,498	47.89	-	-	3,755,570,498	47.89
Others	1,309,623,774	16.70	-	-	1,309,623,774	16.70
Total	7,841,959,524	100.00	-	-	7,841,959,524	100.00

DISTRIBUTION OF THE COMPANY'S CAPITAL (COMPANY SHAREHOLDERS) DOWN TO THE INDIVIDUAL HOLDINGS						
Name: NCF participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Number	%	Number	%	Number	%
Cidade de Deus Cia Cial Participações	893,190,142	74.72	-	-	893,190,142	39.51
Fundação Bradesco	300,379,172	25.13	1,065,350,875	100.00	1,365,730,047	60.41
Nova Cidade de Deus Participações S.A.	1,788,311	0.15	-	-	1,788,311	0.08
Total	1,195,357,625	100.00	1,065,350,875	100.00	2,260,708,500	100.00

DISTRIBUTION OF THE COMPANY'S CAPITAL (COMPANY SHAREHOLDERS) DOWN TO THE INDIVIDUAL HOLDINGS						
Name: Nova Cidade de Deus Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Number	%	Number	%	Number	%
BBD Participações S.A	182,904,922	53.70	-	-	182,904,922	26.07
Fundação Bradesco	157,710,559	46.30	360,928,543	100.00	518,639,102	73.93
Total	340,615,481	100.00	360,928,543	100.00	701,544,024	100.00

DISTRIBUTION OF THE COMPANY'S CAPITAL (COMPANY SHAREHOLDERS) DOWN TO THE INDIVIDUAL HOLDINGS						
Name: BBD Participações S.A						
Shareholder	Common shares		Preferred shares		Total	
	Number	%	Number	%	Number	%
Treasury Shares	57,870,816	36.71	21,580,974	14.25	79,451,790	25.71
NCD Participação Ltda	-	-	74,784,306	49.38	74,784,306	24.20
Others	99,759,961	63.29	55,080,853	36.37	154,840,814	50.10
Total	157,630,777	100.00	151,446,133	100.00	309,076,910	100.00

DISTRIBUTION OF THE COMPANY'S CAPITAL (COMPANY SHAREHOLDERS) DOWN TO THE INDIVIDUAL HOLDINGS						
Name: NCD Participação Ltda						
Shareholder	Common shares		Preferred shares		Total	
	Number	%	Number	%	Number	%
Fundação Bradesco	773,303,109	-	-	-	773,303,109	100.00
Others	-	-	1	0.00	1	0.00
Total	773,303,109	-	1	0.00	773,303,110	100.00

(A free translation of the original in Portuguese)

Interim Financial Statements - 06/30/2019 - ODONTOPREV S.A.

Other relevant information

Shareholders' positions


CONSOLIDATED SHAREHOLDING POSITION OF CONTROLLING SHAREHOLDERS AND MANAGEMENT AND OUTSTANDING SHARES						
Position at 06/30/19						
Shareholder	Amount of common shares (in units)	%	Amount of preferred shares (in units)	%	Total amount of shares (in units)	%
Controlling Shareholders	265,648,397	50.01	-	-	265,648,397	50.01
Management	1,100,226	0.21	-	-	1,100,226	0.21
Treasury Shares	1,844,214	0.35	-	-	1,844,214	0.35
Others	262,701,955	49.44	-	-	262,701,955	49.44
Total	531,294,792	100.00	-	-	531,294,792	100.00
Outstanding Shares	262,701,955	49.44	-	-	262,701,955	49.44

CONSOLIDATED SHAREHOLDING POSITION OF CONTROLLING SHAREHOLDERS AND MANAGEMENT AND OUTSTANDING SHARES						
Position at 06/30/18						
Shareholder	Amount of common shares (in units)	%	Amount of preferred shares	%	Total amount of shares (in units)	%
Controlling Shareholders	265,648,397	50.01	-	-	265,648,397	50.01
Management	7,778,936	1.46	-	-	7,778,936	1.46
Treasury shares	2,868,345	0.54	-	-	2,868,345	0.54
Others	254,999,114	47.99	-	-	254,999,114	47.99
Total	531,294,792	100.00	-	-	531,294,792	100.00
Outstanding Shares	254,999,114	47.99	-	-	254,999,114	47.99

(A free translation of the original in Portuguese)

Interim Financial Statements - 06/30/2019 - ODONTOPREV S.A.

Other relevant information/Shareholdings



V – Commitment Clause

The Arbitration Commitment Clause is mentioned in chapter VI – Arbitration, contained in the Bylaws (approved in the AGOM of 04/01/2019).

Article 36 – The Company, its shareholders, management and the members of the Fiscal Council, effective and substitutes, if any, are commitment to resolve, through arbitration, face to Market Arbitration Chamber, according to this rules, any and all disputes that may arise between them, related or deriving of their conditions issuer, shareholders, managers and members of the Fiscal Council, mainly related to the provisions comprised in Law 6,385/1976 and Law 6,404/1976, in these Bylaws, in the regulations issued by the National Monetary Council, Brazilian Central Bank and Brazilian Securities Commission, as well as other regulations applicable to the functioning of capital markets in general, besides those comprised in the Regulations of the New Market Listing, the B3 rules and to the contract of participation in the New Market.

(A free translation of the original in Portuguese)

Odontoprev S.A.
Quarterly Information (ITR) at
June 30, 2019
and Report on Review of
Quarterly Information

Report on Review of Quarterly Information

To the Board of Directors and Shareholders
Odontoprev S.A.

Introduction

We have reviewed the accompanying parent company and consolidated interim accounting information of Odontoprev S.A. ("Company"), included in the Quarterly Information Form (ITR) for the quarter ended June 30, 2019, comprising the balance sheet as at that date and the statements of income, comprehensive income, changes in equity and cash flows for the quarter then ended, and a summary of significant accounting policies and other explanatory information.

Management is responsible for the preparation of the parent company interim accounting information in accordance with the accounting standard CPC 21, Interim Financial Reporting, of the Brazilian Accounting Pronouncements Committee (CPC), and of the consolidated interim accounting information in accordance with CPC 21 and International Accounting Standard (IAS) 34 - Interim Financial Reporting issued by the International Accounting Standards Board (IASB), as well as the presentation of this information in accordance with the standards issued by the Brazilian Securities Commission (CVM), applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim accounting information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and International Standards on Reviews of Interim Financial Information (NBC TR 2410 – Review of Interim Financial Information Performed by the Independent Auditor of the Entity and ISRE 2410 – Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion on the parent company interim information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying parent company interim accounting information included in the quarterly information referred to above has not been prepared, in all material respects, in accordance with CPC 21 applicable to the preparation of the Quarterly Information, and presented in accordance with the standards issued by the CVM.

Conclusion on the consolidated interim information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim accounting information included in the quarterly information referred to above has not been prepared, in all material respects, in accordance with CPC 21 and IAS 34 applicable to the preparation of the Quarterly Information, and presented in accordance with the standards issued by the CVM.

Other matters**Statements of value added**

We have also reviewed the parent company and consolidated statements of value added for the quarter ended June 30, 2019. These statements are the responsibility of the Company's management, and are required to be presented in accordance with standards issued by the CVM applicable to the preparation of Quarterly Information (ITR) and are considered supplementary information under IFRS, which do not require the presentation of the statement of value added. These statements have been submitted to the same review procedures described above and, based on our review, nothing has come to our attention that causes us to believe that they have not been prepared, in all material respects, in a manner consistent with the parent company and consolidated interim accounting information taken as a whole.

São Paulo, August 01, 2019.

PricewaterhouseCoopers
Auditores Independentes
CRC 2SP000160/O-5

Edison Arisa Pereira
Contador CRC 1SP127241/O-0

Statement of directors about the financial statements

ODONTOPREV S.A.

(article 29, subsection II of CVM Instruction number 480/09)

STATEMENT

We declare, as the Statutory Directors of Odontoprev S.A., a listed company, with its head office located in the city of Barueri, State of São Paulo, at Marcos Penteado de Ulhôa Rodrigues Avenue, 939 – 14^º Floor, registered with CNPJ/MF number 58.119.199/0001-51 (Company) in accordance with the terms of:

- (i) Subsection VI of paragraph 1 of article 25 of Instruction ICVM 480, that we have reviewed, discussed and agreed with the Company's interim financial statements for the period ended June 30, 2019.

Barueri, August 01, 2019.

Statement of directors about the independent auditor's review report

ODONTOPREV S.A.

(article 29, subsection II of CVM Instruction 480/09)

STATEMENT

We declare, as the Statutory Directors of Odontoprev S.A., a listed company, with its head office located in the city of Barueri, State of São Paulo, at Marcos Penteado de Ulhôa Rodrigues Avenue, 939 – 14º Floor, registered with CNPJ/MF number 58.119.199/0001-51 (Company) in accordance with the terms of:

- (i) Subsection V of paragraph 1 of article 25 of Instruction ICVM 480 of December 07th, 2009, as amended, that we have reviewed, discussed and agreed with the opinions expressed in the report issue by the Company's independent auditors, PricewaterhouseCoopers Auditores Independentes, with respect to the Company's interim financial statements for the period ended June 30, 2019.

Barueri, August 01, 2019.